#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Distress Tolerance among Substance Users is Associated with Functional Connectivity between Prefrontal Regions during a Distress Tolerance Task
#Text=Distress tolerance (DT), defined as the ability to persist in goal directed behavior while experiencing affective distress, is implicated in the development and maintenance of substance use disorders.
1-1	0-8	Distress	_	
1-2	9-18	Tolerance	_	
1-3	19-24	among	_	
1-4	25-34	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-5	35-40	Users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-6	41-43	is	_	
1-7	44-54	Associated	_	
1-8	55-59	with	_	
1-9	60-70	Functional	_	
1-10	71-83	Connectivity	_	
1-11	84-91	between	_	
1-12	92-102	Prefrontal	_	
1-13	103-110	Regions	_	
1-14	111-117	during	_	
1-15	118-119	a	_	
1-16	120-128	Distress	_	
1-17	129-138	Tolerance	_	
1-18	139-143	Task	_	
1-19	144-152	Distress	_	
1-20	153-162	tolerance	_	
1-21	163-164	(	_	
1-22	164-166	DT	_	
1-23	166-167	)	_	
1-24	167-168	,	_	
1-25	169-176	defined	_	
1-26	177-179	as	_	
1-27	180-183	the	_	
1-28	184-191	ability	_	
1-29	192-194	to	_	
1-30	195-202	persist	_	
1-31	203-205	in	_	
1-32	206-210	goal	_	
1-33	211-219	directed	_	
1-34	220-228	behavior	_	
1-35	229-234	while	_	
1-36	235-247	experiencing	_	
1-37	248-257	affective	_	
1-38	258-266	distress	_	
1-39	266-267	,	_	
1-40	268-270	is	_	
1-41	271-281	implicated	_	
1-42	282-284	in	_	
1-43	285-288	the	_	
1-44	289-300	development	_	
1-45	301-304	and	_	
1-46	305-316	maintenance	_	
1-47	317-319	of	_	
1-48	320-329	substance	_	
1-49	330-333	use	_	
1-50	334-343	disorders	_	
1-51	343-344	.	_	

#Text=While theory and evidence indicate that cortico-limbic neural dysfunction may account for deficits in goal directed behavior while experiencing distress, the neurobiological mechanisms of DT have yet to be examined.
2-1	345-350	While	_	
2-2	351-357	theory	_	
2-3	358-361	and	_	
2-4	362-370	evidence	_	
2-5	371-379	indicate	_	
2-6	380-384	that	_	
2-7	385-399	cortico-limbic	_	
2-8	400-406	neural	_	
2-9	407-418	dysfunction	_	
2-10	419-422	may	_	
2-11	423-430	account	_	
2-12	431-434	for	_	
2-13	435-443	deficits	_	
2-14	444-446	in	_	
2-15	447-451	goal	_	
2-16	452-460	directed	_	
2-17	461-469	behavior	_	
2-18	470-475	while	_	
2-19	476-488	experiencing	_	
2-20	489-497	distress	_	
2-21	497-498	,	_	
2-22	499-502	the	_	
2-23	503-518	neurobiological	_	
2-24	519-529	mechanisms	_	
2-25	530-532	of	_	
2-26	533-535	DT	_	
2-27	536-540	have	_	
2-28	541-544	yet	_	
2-29	545-547	to	_	
2-30	548-550	be	_	
2-31	551-559	examined	_	
2-32	559-560	.	_	

#Text=We modified a computerized DT task for use in functional magnetic resonance imaging (fMRI), the Paced Auditory Serial Addition Task (PASAT-M), and examined the neural correlates and functional connectivity of DT among a cohort of substance users (n=21; regular cocaine and nicotine users) and healthy controls (n=25).
3-1	561-563	We	_	
3-2	564-572	modified	_	
3-3	573-574	a	_	
3-4	575-587	computerized	_	
3-5	588-590	DT	_	
3-6	591-595	task	_	
3-7	596-599	for	_	
3-8	600-603	use	_	
3-9	604-606	in	_	
3-10	607-617	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-11	618-626	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-12	627-636	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-13	637-644	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-14	645-646	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-15	646-650	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-16	650-651	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-17	651-652	,	_	
3-18	653-656	the	_	
3-19	657-662	Paced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-20	663-671	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-21	672-678	Serial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-22	679-687	Addition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-23	688-692	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-24	693-694	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-25	694-701	PASAT-M	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-26	701-702	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-27	702-703	,	_	
3-28	704-707	and	_	
3-29	708-716	examined	_	
3-30	717-720	the	_	
3-31	721-727	neural	_	
3-32	728-738	correlates	_	
3-33	739-742	and	_	
3-34	743-753	functional	_	
3-35	754-766	connectivity	_	
3-36	767-769	of	_	
3-37	770-772	DT	_	
3-38	773-778	among	_	
3-39	779-780	a	_	
3-40	781-787	cohort	_	
3-41	788-790	of	_	
3-42	791-800	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
3-43	801-806	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
3-44	807-808	(	_	
3-45	808-809	n	_	
3-46	809-810	=	_	
3-47	810-812	21	_	
3-48	812-813	;	_	
3-49	814-821	regular	_	
3-50	822-829	cocaine	_	
3-51	830-833	and	_	
3-52	834-842	nicotine	_	
3-53	843-848	users	_	
3-54	848-849	)	_	
3-55	850-853	and	_	
3-56	854-861	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
3-57	862-870	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
3-58	871-872	(	_	
3-59	872-873	n	_	
3-60	873-874	=	_	
3-61	874-876	25	_	
3-62	876-877	)	_	
3-63	877-878	.	_	

#Text=In response to distress during the PASAT-M, we found greater activation in a priori cortico-limbic network ROIs, namely the right insula, anterior cingulate cortex (ACC), bilateral medial frontal gyrus (MFG), right inferior frontal gyrus (IFG), and right ventromedial prefrontal cortex (vmPFC) significantly predicted higher DT among substance users, but not healthy controls.
4-1	879-881	In	_	
4-2	882-890	response	_	
4-3	891-893	to	_	
4-4	894-902	distress	_	
4-5	903-909	during	_	
4-6	910-913	the	_	
4-7	914-921	PASAT-M	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
4-8	921-922	,	_	
4-9	923-925	we	_	
4-10	926-931	found	_	
4-11	932-939	greater	_	
4-12	940-950	activation	_	
4-13	951-953	in	_	
4-14	954-955	a	_	
4-15	956-962	priori	_	
4-16	963-977	cortico-limbic	_	
4-17	978-985	network	_	
4-18	986-990	ROIs	_	
4-19	990-991	,	_	
4-20	992-998	namely	_	
4-21	999-1002	the	_	
4-22	1003-1008	right	_	
4-23	1009-1015	insula	_	
4-24	1015-1016	,	_	
4-25	1017-1025	anterior	_	
4-26	1026-1035	cingulate	_	
4-27	1036-1042	cortex	_	
4-28	1043-1044	(	_	
4-29	1044-1047	ACC	_	
4-30	1047-1048	)	_	
4-31	1048-1049	,	_	
4-32	1050-1059	bilateral	_	
4-33	1060-1066	medial	_	
4-34	1067-1074	frontal	_	
4-35	1075-1080	gyrus	_	
4-36	1081-1082	(	_	
4-37	1082-1085	MFG	_	
4-38	1085-1086	)	_	
4-39	1086-1087	,	_	
4-40	1088-1093	right	_	
4-41	1094-1102	inferior	_	
4-42	1103-1110	frontal	_	
4-43	1111-1116	gyrus	_	
4-44	1117-1118	(	_	
4-45	1118-1121	IFG	_	
4-46	1121-1122	)	_	
4-47	1122-1123	,	_	
4-48	1124-1127	and	_	
4-49	1128-1133	right	_	
4-50	1134-1146	ventromedial	_	
4-51	1147-1157	prefrontal	_	
4-52	1158-1164	cortex	_	
4-53	1165-1166	(	_	
4-54	1166-1171	vmPFC	_	
4-55	1171-1172	)	_	
4-56	1173-1186	significantly	_	
4-57	1187-1196	predicted	_	
4-58	1197-1203	higher	_	
4-59	1204-1206	DT	_	
4-60	1207-1212	among	_	
4-61	1213-1222	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
4-62	1223-1228	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
4-63	1228-1229	,	_	
4-64	1230-1233	but	_	
4-65	1234-1237	not	_	
4-66	1238-1245	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
4-67	1246-1254	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
4-68	1254-1255	.	_	

#Text=In addition, greater task-specific functional connectivity during distress between the right MFG and bilateral vmPFC/sgACC was associated with higher DT among substance users, but not healthy controls.
5-1	1256-1258	In	_	
5-2	1259-1267	addition	_	
5-3	1267-1268	,	_	
5-4	1269-1276	greater	_	
5-5	1277-1290	task-specific	_	
5-6	1291-1301	functional	_	
5-7	1302-1314	connectivity	_	
5-8	1315-1321	during	_	
5-9	1322-1330	distress	_	
5-10	1331-1338	between	_	
5-11	1339-1342	the	_	
5-12	1343-1348	right	_	
5-13	1349-1352	MFG	_	
5-14	1353-1356	and	_	
5-15	1357-1366	bilateral	_	
5-16	1367-1372	vmPFC	_	
5-17	1372-1373	/	_	
5-18	1373-1378	sgACC	_	
5-19	1379-1382	was	_	
5-20	1383-1393	associated	_	
5-21	1394-1398	with	_	
5-22	1399-1405	higher	_	
5-23	1406-1408	DT	_	
5-24	1409-1414	among	_	
5-25	1415-1424	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
5-26	1425-1430	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
5-27	1430-1431	,	_	
5-28	1432-1435	but	_	
5-29	1436-1439	not	_	
5-30	1440-1447	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
5-31	1448-1456	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
5-32	1456-1457	.	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	

#Text=The observed positive relationship between DT and neural activation in cortico-limbic structures, as well as functional connectivity between the rMFG and vmPFC/sgACC is in line with theory and research suggesting the importance of these structures for persisting in goal directed behavior while experiencing affective distress.
6-1	1458-1461	The	_	
6-2	1462-1470	observed	_	
6-3	1471-1479	positive	_	
6-4	1480-1492	relationship	_	
6-5	1493-1500	between	_	
6-6	1501-1503	DT	_	
6-7	1504-1507	and	_	
6-8	1508-1514	neural	_	
6-9	1515-1525	activation	_	
6-10	1526-1528	in	_	
6-11	1529-1543	cortico-limbic	_	
6-12	1544-1554	structures	_	
6-13	1554-1555	,	_	
6-14	1556-1558	as	_	
6-15	1559-1563	well	_	
6-16	1564-1566	as	_	
6-17	1567-1577	functional	_	
6-18	1578-1590	connectivity	_	
6-19	1591-1598	between	_	
6-20	1599-1602	the	_	
6-21	1603-1607	rMFG	_	
6-22	1608-1611	and	_	
6-23	1612-1617	vmPFC	_	
6-24	1617-1618	/	_	
6-25	1618-1623	sgACC	_	
6-26	1624-1626	is	_	
6-27	1627-1629	in	_	
6-28	1630-1634	line	_	
6-29	1635-1639	with	_	
6-30	1640-1646	theory	_	
6-31	1647-1650	and	_	
6-32	1651-1659	research	_	
6-33	1660-1670	suggesting	_	
6-34	1671-1674	the	_	
6-35	1675-1685	importance	_	
6-36	1686-1688	of	_	
6-37	1689-1694	these	_	
6-38	1695-1705	structures	_	
6-39	1706-1709	for	_	
6-40	1710-1720	persisting	_	
6-41	1721-1723	in	_	
6-42	1724-1728	goal	_	
6-43	1729-1737	directed	_	
6-44	1738-1746	behavior	_	
6-45	1747-1752	while	_	
6-46	1753-1765	experiencing	_	
6-47	1766-1775	affective	_	
6-48	1776-1784	distress	_	
6-49	1784-1785	.	_	

#Text=INTRODUCTION
#Text=Affective distress, which includes feelings such as anxiety, stress, and irritability, is often present in addicted individuals during an abstinence attempt, with the severity of these symptoms reported to predict treatment outcome and relapse across drug classes.
7-1	1786-1798	INTRODUCTION	_	
7-2	1799-1808	Affective	_	
7-3	1809-1817	distress	_	
7-4	1817-1818	,	_	
7-5	1819-1824	which	_	
7-6	1825-1833	includes	_	
7-7	1834-1842	feelings	_	
7-8	1843-1847	such	_	
7-9	1848-1850	as	_	
7-10	1851-1858	anxiety	_	
7-11	1858-1859	,	_	
7-12	1860-1866	stress	_	
7-13	1866-1867	,	_	
7-14	1868-1871	and	_	
7-15	1872-1884	irritability	_	
7-16	1884-1885	,	_	
7-17	1886-1888	is	_	
7-18	1889-1894	often	_	
7-19	1895-1902	present	_	
7-20	1903-1905	in	_	
7-21	1906-1914	addicted	_	
7-22	1915-1926	individuals	_	
7-23	1927-1933	during	_	
7-24	1934-1936	an	_	
7-25	1937-1947	abstinence	_	
7-26	1948-1955	attempt	_	
7-27	1955-1956	,	_	
7-28	1957-1961	with	_	
7-29	1962-1965	the	_	
7-30	1966-1974	severity	_	
7-31	1975-1977	of	_	
7-32	1978-1983	these	_	
7-33	1984-1992	symptoms	_	
7-34	1993-2001	reported	_	
7-35	2002-2004	to	_	
7-36	2005-2012	predict	_	
7-37	2013-2022	treatment	_	
7-38	2023-2030	outcome	_	
7-39	2031-2034	and	_	
7-40	2035-2042	relapse	_	
7-41	2043-2049	across	_	
7-42	2050-2054	drug	_	
7-43	2055-2062	classes	_	
7-44	2062-2063	.	_	

#Text=Accordingly, negative reinforcement models of addiction collectively emphasize that the motivational basis of addictive drug use is the reduction or avoidance of aversive internal states.
8-1	2064-2075	Accordingly	_	
8-2	2075-2076	,	_	
8-3	2077-2085	negative	_	
8-4	2086-2099	reinforcement	_	
8-5	2100-2106	models	_	
8-6	2107-2109	of	_	
8-7	2110-2119	addiction	_	
8-8	2120-2132	collectively	_	
8-9	2133-2142	emphasize	_	
8-10	2143-2147	that	_	
8-11	2148-2151	the	_	
8-12	2152-2164	motivational	_	
8-13	2165-2170	basis	_	
8-14	2171-2173	of	_	
8-15	2174-2183	addictive	_	
8-16	2184-2188	drug	_	
8-17	2189-2192	use	_	
8-18	2193-2195	is	_	
8-19	2196-2199	the	_	
8-20	2200-2209	reduction	_	
8-21	2210-2212	or	_	
8-22	2213-2222	avoidance	_	
8-23	2223-2225	of	_	
8-24	2226-2234	aversive	_	
8-25	2235-2243	internal	_	
8-26	2244-2250	states	_	
8-27	2250-2251	.	_	

#Text=Behavioral laboratory paradigms that specifically capture the real-time avoidance of affective distress have been developed to test the theory that negative reinforcement mechanisms are associated with substance use frequency and relapse.
9-1	2252-2262	Behavioral	_	
9-2	2263-2273	laboratory	_	
9-3	2274-2283	paradigms	_	
9-4	2284-2288	that	_	
9-5	2289-2301	specifically	_	
9-6	2302-2309	capture	_	
9-7	2310-2313	the	_	
9-8	2314-2323	real-time	_	
9-9	2324-2333	avoidance	_	
9-10	2334-2336	of	_	
9-11	2337-2346	affective	_	
9-12	2347-2355	distress	_	
9-13	2356-2360	have	_	
9-14	2361-2365	been	_	
9-15	2366-2375	developed	_	
9-16	2376-2378	to	_	
9-17	2379-2383	test	_	
9-18	2384-2387	the	_	
9-19	2388-2394	theory	_	
9-20	2395-2399	that	_	
9-21	2400-2408	negative	_	
9-22	2409-2422	reinforcement	_	
9-23	2423-2433	mechanisms	_	
9-24	2434-2437	are	_	
9-25	2438-2448	associated	_	
9-26	2449-2453	with	_	
9-27	2454-2463	substance	_	
9-28	2464-2467	use	_	
9-29	2468-2477	frequency	_	
9-30	2478-2481	and	_	
9-31	2482-2489	relapse	_	
9-32	2489-2490	.	_	

#Text=These paradigms measure distress tolerance, defined as the ability to persist in goal directed behavior while experiencing affective distress.
10-1	2491-2496	These	_	
10-2	2497-2506	paradigms	_	
10-3	2507-2514	measure	_	
10-4	2515-2523	distress	_	
10-5	2524-2533	tolerance	_	
10-6	2533-2534	,	_	
10-7	2535-2542	defined	_	
10-8	2543-2545	as	_	
10-9	2546-2549	the	_	
10-10	2550-2557	ability	_	
10-11	2558-2560	to	_	
10-12	2561-2568	persist	_	
10-13	2569-2571	in	_	
10-14	2572-2576	goal	_	
10-15	2577-2585	directed	_	
10-16	2586-2594	behavior	_	
10-17	2595-2600	while	_	
10-18	2601-2613	experiencing	_	
10-19	2614-2623	affective	_	
10-20	2624-2632	distress	_	
10-21	2632-2633	.	_	

#Text=The distress tolerance laboratory paradigm involves participant engagement in and persistence on a task that gradually increases in difficulty, thereby increasing affective distress.
11-1	2634-2637	The	_	
11-2	2638-2646	distress	_	
11-3	2647-2656	tolerance	_	
11-4	2657-2667	laboratory	_	
11-5	2668-2676	paradigm	_	
11-6	2677-2685	involves	_	
11-7	2686-2697	participant	_	
11-8	2698-2708	engagement	_	
11-9	2709-2711	in	_	
11-10	2712-2715	and	_	
11-11	2716-2727	persistence	_	
11-12	2728-2730	on	_	
11-13	2731-2732	a	_	
11-14	2733-2737	task	_	
11-15	2738-2742	that	_	
11-16	2743-2752	gradually	_	
11-17	2753-2762	increases	_	
11-18	2763-2765	in	_	
11-19	2766-2776	difficulty	_	
11-20	2776-2777	,	_	
11-21	2778-2785	thereby	_	
11-22	2786-2796	increasing	_	
11-23	2797-2806	affective	_	
11-24	2807-2815	distress	_	
11-25	2815-2816	.	_	

#Text=The participant has the option to persist (for a mild incentive) or in contrast, to terminate the task, thereby escaping affective distress in the short-term but losing out on the reward in the long-term.
12-1	2817-2820	The	_	
12-2	2821-2832	participant	_	
12-3	2833-2836	has	_	
12-4	2837-2840	the	_	
12-5	2841-2847	option	_	
12-6	2848-2850	to	_	
12-7	2851-2858	persist	_	
12-8	2859-2860	(	_	
12-9	2860-2863	for	_	
12-10	2864-2865	a	_	
12-11	2866-2870	mild	_	
12-12	2871-2880	incentive	_	
12-13	2880-2881	)	_	
12-14	2882-2884	or	_	
12-15	2885-2887	in	_	
12-16	2888-2896	contrast	_	
12-17	2896-2897	,	_	
12-18	2898-2900	to	_	
12-19	2901-2910	terminate	_	
12-20	2911-2914	the	_	
12-21	2915-2919	task	_	
12-22	2919-2920	,	_	
12-23	2921-2928	thereby	_	
12-24	2929-2937	escaping	_	
12-25	2938-2947	affective	_	
12-26	2948-2956	distress	_	
12-27	2957-2959	in	_	
12-28	2960-2963	the	_	
12-29	2964-2974	short-term	_	
12-30	2975-2978	but	_	
12-31	2979-2985	losing	_	
12-32	2986-2989	out	_	
12-33	2990-2992	on	_	
12-34	2993-2996	the	_	
12-35	2997-3003	reward	_	
12-36	3004-3006	in	_	
12-37	3007-3010	the	_	
12-38	3011-3020	long-term	_	
12-39	3020-3021	.	_	

#Text=In line with negative reinforcement models of drug use, low distress tolerance would be associated with a more rapid return to substance use in response to abstinence distress (i.e., to temporarily ameliorate the emotional discomfort).
13-1	3022-3024	In	_	
13-2	3025-3029	line	_	
13-3	3030-3034	with	_	
13-4	3035-3043	negative	_	
13-5	3044-3057	reinforcement	_	
13-6	3058-3064	models	_	
13-7	3065-3067	of	_	
13-8	3068-3072	drug	_	
13-9	3073-3076	use	_	
13-10	3076-3077	,	_	
13-11	3078-3081	low	_	
13-12	3082-3090	distress	_	
13-13	3091-3100	tolerance	_	
13-14	3101-3106	would	_	
13-15	3107-3109	be	_	
13-16	3110-3120	associated	_	
13-17	3121-3125	with	_	
13-18	3126-3127	a	_	
13-19	3128-3132	more	_	
13-20	3133-3138	rapid	_	
13-21	3139-3145	return	_	
13-22	3146-3148	to	_	
13-23	3149-3158	substance	_	
13-24	3159-3162	use	_	
13-25	3163-3165	in	_	
13-26	3166-3174	response	_	
13-27	3175-3177	to	_	
13-28	3178-3188	abstinence	_	
13-29	3189-3197	distress	_	
13-30	3198-3199	(	_	
13-31	3199-3202	i.e	_	
13-32	3202-3203	.	_	
13-33	3203-3204	,	_	
13-34	3205-3207	to	_	
13-35	3208-3219	temporarily	_	
13-36	3220-3230	ameliorate	_	
13-37	3231-3234	the	_	
13-38	3235-3244	emotional	_	
13-39	3245-3255	discomfort	_	
13-40	3255-3256	)	_	
13-41	3256-3257	.	_	

#Text=From this perspective, distress tolerance tasks effectively create a laboratory paradigm with high internal validity while creating a situation where affective distress during goal directed behavior and an opportunity for avoidance interact, allowing the participant to make the decision of persisting or terminating the task.
14-1	3258-3262	From	_	
14-2	3263-3267	this	_	
14-3	3268-3279	perspective	_	
14-4	3279-3280	,	_	
14-5	3281-3289	distress	_	
14-6	3290-3299	tolerance	_	
14-7	3300-3305	tasks	_	
14-8	3306-3317	effectively	_	
14-9	3318-3324	create	_	
14-10	3325-3326	a	_	
14-11	3327-3337	laboratory	_	
14-12	3338-3346	paradigm	_	
14-13	3347-3351	with	_	
14-14	3352-3356	high	_	
14-15	3357-3365	internal	_	
14-16	3366-3374	validity	_	
14-17	3375-3380	while	_	
14-18	3381-3389	creating	_	
14-19	3390-3391	a	_	
14-20	3392-3401	situation	_	
14-21	3402-3407	where	_	
14-22	3408-3417	affective	_	
14-23	3418-3426	distress	_	
14-24	3427-3433	during	_	
14-25	3434-3438	goal	_	
14-26	3439-3447	directed	_	
14-27	3448-3456	behavior	_	
14-28	3457-3460	and	_	
14-29	3461-3463	an	_	
14-30	3464-3475	opportunity	_	
14-31	3476-3479	for	_	
14-32	3480-3489	avoidance	_	
14-33	3490-3498	interact	_	
14-34	3498-3499	,	_	
14-35	3500-3508	allowing	_	
14-36	3509-3512	the	_	
14-37	3513-3524	participant	_	
14-38	3525-3527	to	_	
14-39	3528-3532	make	_	
14-40	3533-3536	the	_	
14-41	3537-3545	decision	_	
14-42	3546-3548	of	_	
14-43	3549-3559	persisting	_	
14-44	3560-3562	or	_	
14-45	3563-3574	terminating	_	
14-46	3575-3578	the	_	
14-47	3579-3583	task	_	
14-48	3583-3584	.	_	

#Text=Indeed, several findings converge to provide evidence of the utility of the distress tolerance paradigm in predicting substance use outcomes.
15-1	3585-3591	Indeed	_	
15-2	3591-3592	,	_	
15-3	3593-3600	several	_	
15-4	3601-3609	findings	_	
15-5	3610-3618	converge	_	
15-6	3619-3621	to	_	
15-7	3622-3629	provide	_	
15-8	3630-3638	evidence	_	
15-9	3639-3641	of	_	
15-10	3642-3645	the	_	
15-11	3646-3653	utility	_	
15-12	3654-3656	of	_	
15-13	3657-3660	the	_	
15-14	3661-3669	distress	_	
15-15	3670-3679	tolerance	_	
15-16	3680-3688	paradigm	_	
15-17	3689-3691	in	_	
15-18	3692-3702	predicting	_	
15-19	3703-3712	substance	_	
15-20	3713-3716	use	_	
15-21	3717-3725	outcomes	_	
15-22	3725-3726	.	_	

#Text=Low distress tolerance, as measured with these paradigms, is associated with greater substance use frequency, shorter abstinence duration, treatment dropout, and relapse.
16-1	3727-3730	Low	_	
16-2	3731-3739	distress	_	
16-3	3740-3749	tolerance	_	
16-4	3749-3750	,	_	
16-5	3751-3753	as	_	
16-6	3754-3762	measured	_	
16-7	3763-3767	with	_	
16-8	3768-3773	these	_	
16-9	3774-3783	paradigms	_	
16-10	3783-3784	,	_	
16-11	3785-3787	is	_	
16-12	3788-3798	associated	_	
16-13	3799-3803	with	_	
16-14	3804-3811	greater	_	
16-15	3812-3821	substance	_	
16-16	3822-3825	use	_	
16-17	3826-3835	frequency	_	
16-18	3835-3836	,	_	
16-19	3837-3844	shorter	_	
16-20	3845-3855	abstinence	_	
16-21	3856-3864	duration	_	
16-22	3864-3865	,	_	
16-23	3866-3875	treatment	_	
16-24	3876-3883	dropout	_	
16-25	3883-3884	,	_	
16-26	3885-3888	and	_	
16-27	3889-3896	relapse	_	
16-28	3896-3897	.	_	

#Text=The negative reinforcement model is in line with neurobiological conceptualizations of substance use disorder (SUD), such that chronic substance use leads to neuroadaptations and a chronic “negative affect” or psychologically distressed state during abstinence.
17-1	3898-3901	The	_	
17-2	3902-3910	negative	_	
17-3	3911-3924	reinforcement	_	
17-4	3925-3930	model	_	
17-5	3931-3933	is	_	
17-6	3934-3936	in	_	
17-7	3937-3941	line	_	
17-8	3942-3946	with	_	
17-9	3947-3962	neurobiological	_	
17-10	3963-3981	conceptualizations	_	
17-11	3982-3984	of	_	
17-12	3985-3994	substance	_	
17-13	3995-3998	use	_	
17-14	3999-4007	disorder	_	
17-15	4008-4009	(	_	
17-16	4009-4012	SUD	_	
17-17	4012-4013	)	_	
17-18	4013-4014	,	_	
17-19	4015-4019	such	_	
17-20	4020-4024	that	_	
17-21	4025-4032	chronic	_	
17-22	4033-4042	substance	_	
17-23	4043-4046	use	_	
17-24	4047-4052	leads	_	
17-25	4053-4055	to	_	
17-26	4056-4072	neuroadaptations	_	
17-27	4073-4076	and	_	
17-28	4077-4078	a	_	
17-29	4079-4086	chronic	_	
17-30	4087-4088	“	_	
17-31	4088-4096	negative	_	
17-32	4097-4103	affect	_	
17-33	4103-4104	”	_	
17-34	4105-4107	or	_	
17-35	4108-4123	psychologically	_	
17-36	4124-4134	distressed	_	
17-37	4135-4140	state	_	
17-38	4141-4147	during	_	
17-39	4148-4158	abstinence	_	
17-40	4158-4159	.	_	

#Text=Regulation of behavior in response to distress is theorized to be achieved in a top-down manner in which emotional salience is provided to prefrontal regions to ultimately guide and initiate appropriate goal-oriented behavior.
18-1	4160-4170	Regulation	_	
18-2	4171-4173	of	_	
18-3	4174-4182	behavior	_	
18-4	4183-4185	in	_	
18-5	4186-4194	response	_	
18-6	4195-4197	to	_	
18-7	4198-4206	distress	_	
18-8	4207-4209	is	_	
18-9	4210-4219	theorized	_	
18-10	4220-4222	to	_	
18-11	4223-4225	be	_	
18-12	4226-4234	achieved	_	
18-13	4235-4237	in	_	
18-14	4238-4239	a	_	
18-15	4240-4248	top-down	_	
18-16	4249-4255	manner	_	
18-17	4256-4258	in	_	
18-18	4259-4264	which	_	
18-19	4265-4274	emotional	_	
18-20	4275-4283	salience	_	
18-21	4284-4286	is	_	
18-22	4287-4295	provided	_	
18-23	4296-4298	to	_	
18-24	4299-4309	prefrontal	_	
18-25	4310-4317	regions	_	
18-26	4318-4320	to	_	
18-27	4321-4331	ultimately	_	
18-28	4332-4337	guide	_	
18-29	4338-4341	and	_	
18-30	4342-4350	initiate	_	
18-31	4351-4362	appropriate	_	
18-32	4363-4376	goal-oriented	_	
18-33	4377-4385	behavior	_	
18-34	4385-4386	.	_	

#Text=In particular, the anterior cingulate cortex (ACC) and areas of the prefrontal cortex (PFC) are associated with cognitive control and evaluating and manipulating emotional information to guide planning and decision making.
19-1	4387-4389	In	_	
19-2	4390-4400	particular	_	
19-3	4400-4401	,	_	
19-4	4402-4405	the	_	
19-5	4406-4414	anterior	_	
19-6	4415-4424	cingulate	_	
19-7	4425-4431	cortex	_	
19-8	4432-4433	(	_	
19-9	4433-4436	ACC	_	
19-10	4436-4437	)	_	
19-11	4438-4441	and	_	
19-12	4442-4447	areas	_	
19-13	4448-4450	of	_	
19-14	4451-4454	the	_	
19-15	4455-4465	prefrontal	_	
19-16	4466-4472	cortex	_	
19-17	4473-4474	(	_	
19-18	4474-4477	PFC	_	
19-19	4477-4478	)	_	
19-20	4479-4482	are	_	
19-21	4483-4493	associated	_	
19-22	4494-4498	with	_	
19-23	4499-4508	cognitive	_	
19-24	4509-4516	control	_	
19-25	4517-4520	and	_	
19-26	4521-4531	evaluating	_	
19-27	4532-4535	and	_	
19-28	4536-4548	manipulating	_	
19-29	4549-4558	emotional	_	
19-30	4559-4570	information	_	
19-31	4571-4573	to	_	
19-32	4574-4579	guide	_	
19-33	4580-4588	planning	_	
19-34	4589-4592	and	_	
19-35	4593-4601	decision	_	
19-36	4602-4608	making	_	
19-37	4608-4609	.	_	

#Text=Indeed, chronic substance users evidence impaired functioning and hypoactivation in prefrontal regions, including impaired response inhibition, working memory capacity, and cognitive control.
20-1	4610-4616	Indeed	_	
20-2	4616-4617	,	_	
20-3	4618-4625	chronic	_	
20-4	4626-4635	substance	_	
20-5	4636-4641	users	_	
20-6	4642-4650	evidence	_	
20-7	4651-4659	impaired	_	
20-8	4660-4671	functioning	_	
20-9	4672-4675	and	_	
20-10	4676-4690	hypoactivation	_	
20-11	4691-4693	in	_	
20-12	4694-4704	prefrontal	_	
20-13	4705-4712	regions	_	
20-14	4712-4713	,	_	
20-15	4714-4723	including	_	
20-16	4724-4732	impaired	_	
20-17	4733-4741	response	_	
20-18	4742-4752	inhibition	_	
20-19	4752-4753	,	_	
20-20	4754-4761	working	_	
20-21	4762-4768	memory	_	
20-22	4769-4777	capacity	_	
20-23	4777-4778	,	_	
20-24	4779-4782	and	_	
20-25	4783-4792	cognitive	_	
20-26	4793-4800	control	_	
20-27	4800-4801	.	_	

#Text=Given the importance of inhibiting emotionally driven impulses and determining an appropriate behavioral response during successful abstinence, it is hypothesized that neural deficits may underlie low distress tolerance among substance users.
21-1	4802-4807	Given	_	
21-2	4808-4811	the	_	
21-3	4812-4822	importance	_	
21-4	4823-4825	of	_	
21-5	4826-4836	inhibiting	_	
21-6	4837-4848	emotionally	_	
21-7	4849-4855	driven	_	
21-8	4856-4864	impulses	_	
21-9	4865-4868	and	_	
21-10	4869-4880	determining	_	
21-11	4881-4883	an	_	
21-12	4884-4895	appropriate	_	
21-13	4896-4906	behavioral	_	
21-14	4907-4915	response	_	
21-15	4916-4922	during	_	
21-16	4923-4933	successful	_	
21-17	4934-4944	abstinence	_	
21-18	4944-4945	,	_	
21-19	4946-4948	it	_	
21-20	4949-4951	is	_	
21-21	4952-4964	hypothesized	_	
21-22	4965-4969	that	_	
21-23	4970-4976	neural	_	
21-24	4977-4985	deficits	_	
21-25	4986-4989	may	_	
21-26	4990-4998	underlie	_	
21-27	4999-5002	low	_	
21-28	5003-5011	distress	_	
21-29	5012-5021	tolerance	_	
21-30	5022-5027	among	_	
21-31	5028-5037	substance	_	
21-32	5038-5043	users	_	
21-33	5043-5044	.	_	

#Text=To test this, we first validated a computerized distress tolerance paradigm modified for use in functional magnetic resonance imaging (fMRI).
22-1	5045-5047	To	_	
22-2	5048-5052	test	_	
22-3	5053-5057	this	_	
22-4	5057-5058	,	_	
22-5	5059-5061	we	_	
22-6	5062-5067	first	_	
22-7	5068-5077	validated	_	
22-8	5078-5079	a	_	
22-9	5080-5092	computerized	_	
22-10	5093-5101	distress	_	
22-11	5102-5111	tolerance	_	
22-12	5112-5120	paradigm	_	
22-13	5121-5129	modified	_	
22-14	5130-5133	for	_	
22-15	5134-5137	use	_	
22-16	5138-5140	in	_	
22-17	5141-5151	functional	_	
22-18	5152-5160	magnetic	_	
22-19	5161-5170	resonance	_	
22-20	5171-5178	imaging	_	
22-21	5179-5180	(	_	
22-22	5180-5184	fMRI	_	
22-23	5184-5185	)	_	
22-24	5185-5186	.	_	

#Text=We then examined the neural mechanisms associated with distress tolerance among chronic substance users and healthy controls.
23-1	5187-5189	We	_	
23-2	5190-5194	then	_	
23-3	5195-5203	examined	_	
23-4	5204-5207	the	_	
23-5	5208-5214	neural	_	
23-6	5215-5225	mechanisms	_	
23-7	5226-5236	associated	_	
23-8	5237-5241	with	_	
23-9	5242-5250	distress	_	
23-10	5251-5260	tolerance	_	
23-11	5261-5266	among	_	
23-12	5267-5274	chronic	_	
23-13	5275-5284	substance	_	
23-14	5285-5290	users	_	
23-15	5291-5294	and	_	
23-16	5295-5302	healthy	_	
23-17	5303-5311	controls	_	
23-18	5311-5312	.	_	

#Text=It was hypothesized that reduced neural activation during the task within corticolimbic regions would uniquely predict distress tolerance among substance users.
24-1	5313-5315	It	_	
24-2	5316-5319	was	_	
24-3	5320-5332	hypothesized	_	
24-4	5333-5337	that	_	
24-5	5338-5345	reduced	_	
24-6	5346-5352	neural	_	
24-7	5353-5363	activation	_	
24-8	5364-5370	during	_	
24-9	5371-5374	the	_	
24-10	5375-5379	task	_	
24-11	5380-5386	within	_	
24-12	5387-5400	corticolimbic	_	
24-13	5401-5408	regions	_	
24-14	5409-5414	would	_	
24-15	5415-5423	uniquely	_	
24-16	5424-5431	predict	_	
24-17	5432-5440	distress	_	
24-18	5441-5450	tolerance	_	
24-19	5451-5456	among	_	
24-20	5457-5466	substance	_	
24-21	5467-5472	users	_	
24-22	5472-5473	.	_	

#Text=We also sought to determine the relationship between task-specific neural activity and distress tolerance.
25-1	5474-5476	We	_	
25-2	5477-5481	also	_	
25-3	5482-5488	sought	_	
25-4	5489-5491	to	_	
25-5	5492-5501	determine	_	
25-6	5502-5505	the	_	
25-7	5506-5518	relationship	_	
25-8	5519-5526	between	_	
25-9	5527-5540	task-specific	_	
25-10	5541-5547	neural	_	
25-11	5548-5556	activity	_	
25-12	5557-5560	and	_	
25-13	5561-5569	distress	_	
25-14	5570-5579	tolerance	_	
25-15	5579-5580	.	_	

#Text=We hypothesized that increased functional connectivity between cortical and limbic regions would be associated with greater distress tolerance.
26-1	5581-5583	We	_	
26-2	5584-5596	hypothesized	_	
26-3	5597-5601	that	_	
26-4	5602-5611	increased	_	
26-5	5612-5622	functional	_	
26-6	5623-5635	connectivity	_	
26-7	5636-5643	between	_	
26-8	5644-5652	cortical	_	
26-9	5653-5656	and	_	
26-10	5657-5663	limbic	_	
26-11	5664-5671	regions	_	
26-12	5672-5677	would	_	
26-13	5678-5680	be	_	
26-14	5681-5691	associated	_	
26-15	5692-5696	with	_	
26-16	5697-5704	greater	_	
26-17	5705-5713	distress	_	
26-18	5714-5723	tolerance	_	
26-19	5723-5724	.	_	

#Text=MATERIALS AND METHODS
#Text=Participants
#Text=Twenty-nine substance users (SU) and twenty-nine healthy control (HC) participants were recruited, provided IRB approved written informed consent, and participated in study procedures.
27-1	5725-5734	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
27-2	5735-5738	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
27-3	5739-5746	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
27-4	5747-5759	Participants	_	
27-5	5760-5771	Twenty-nine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-6	5772-5781	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
27-7	5782-5787	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
27-8	5788-5789	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
27-9	5789-5791	SU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
27-10	5791-5792	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
27-11	5793-5796	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-12	5797-5808	twenty-nine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-13	5809-5816	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
27-14	5817-5824	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
27-15	5825-5826	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
27-16	5826-5828	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
27-17	5828-5829	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
27-18	5830-5842	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-19	5843-5847	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-20	5848-5857	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-21	5857-5858	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-22	5859-5867	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-23	5868-5871	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-24	5872-5880	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-25	5881-5888	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-26	5889-5897	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-27	5898-5905	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-28	5905-5906	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-29	5907-5910	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-30	5911-5923	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-31	5924-5926	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-32	5927-5932	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-33	5933-5943	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
27-34	5943-5944	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Of these, 12 were excluded from analyses due to excessive head motion (SU n=4; HC n=1), behavioral noncompliance (SU n=2; HC n=1), and technical problems associated with the fMRI task (SU n=2; HC n=2).
28-1	5945-5947	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-2	5948-5953	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-3	5953-5954	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-4	5955-5957	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-5	5958-5962	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-6	5963-5971	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-7	5972-5976	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-8	5977-5985	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-9	5986-5989	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-10	5990-5992	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-11	5993-6002	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-12	6003-6007	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-13	6008-6014	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-14	6015-6016	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-15	6016-6018	SU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
28-16	6019-6020	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-17	6020-6021	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-18	6021-6022	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-19	6022-6023	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-20	6024-6026	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
28-21	6027-6028	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-22	6028-6029	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-23	6029-6030	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-24	6030-6031	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-25	6031-6032	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-26	6033-6043	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-27	6044-6057	noncompliance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-28	6058-6059	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-29	6059-6061	SU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[17]	
28-30	6062-6063	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-31	6063-6064	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-32	6064-6065	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-33	6065-6066	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-34	6067-6069	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
28-35	6070-6071	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-36	6071-6072	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-37	6072-6073	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-38	6073-6074	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-39	6074-6075	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-40	6076-6079	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-41	6080-6089	technical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-42	6090-6098	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-43	6099-6109	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-44	6110-6114	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-45	6115-6118	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-46	6119-6123	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
28-47	6124-6128	task	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-48	6129-6130	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-49	6130-6132	SU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[20]	
28-50	6133-6134	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-51	6134-6135	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-52	6135-6136	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-53	6136-6137	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-54	6138-6140	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
28-55	6141-6142	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-56	6142-6143	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-57	6143-6144	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-58	6144-6145	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
28-59	6145-6146	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=The final sample included 21 substance users (mean±SD age=41.9±6.9; 19 males; 19 African Americans, 1 Caucasian; IQ=101.8±12.5) and 25 healthy controls (mean age=39.7±8.2; 16 males; 21 African Americans, 4 White Caucasians; IQ=107.4±13.1).
29-1	6147-6150	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-2	6151-6156	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-3	6157-6163	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-4	6164-6172	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-5	6173-6175	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-6	6176-6185	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[23]	
29-7	6186-6191	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[23]	
29-8	6192-6193	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-9	6193-6197	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-10	6197-6198	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-11	6198-6200	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-12	6201-6204	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-13	6204-6205	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-14	6205-6209	41.9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-15	6209-6210	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-16	6210-6213	6.9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-17	6213-6214	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-18	6215-6217	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-19	6218-6223	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-20	6223-6224	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-21	6225-6227	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-22	6228-6235	African	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-23	6236-6245	Americans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-24	6245-6246	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-25	6247-6248	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-26	6249-6258	Caucasian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-27	6258-6259	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-28	6260-6262	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-29	6262-6263	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-30	6263-6268	101.8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-31	6268-6269	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-32	6269-6273	12.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-33	6273-6274	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-34	6275-6278	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-35	6279-6281	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-36	6282-6289	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
29-37	6290-6298	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
29-38	6299-6300	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-39	6300-6304	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-40	6305-6308	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-41	6308-6309	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-42	6309-6313	39.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-43	6313-6314	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-44	6314-6317	8.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-45	6317-6318	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-46	6319-6321	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-47	6322-6327	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-48	6327-6328	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-49	6329-6331	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-50	6332-6339	African	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-51	6340-6349	Americans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-52	6349-6350	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-53	6351-6352	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-54	6353-6358	White	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-55	6359-6369	Caucasians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-56	6369-6370	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-57	6371-6373	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-58	6373-6374	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-59	6374-6379	107.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-60	6379-6380	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-61	6380-6384	13.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-62	6384-6385	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
29-63	6385-6386	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=All participants were right-handed, aged 18-55 years and recruited from the general population of Baltimore City and surrounding areas.
30-1	6387-6390	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-2	6391-6403	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-3	6404-6408	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-4	6409-6421	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-5	6421-6422	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-6	6423-6427	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-7	6428-6430	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-8	6430-6431	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-9	6431-6433	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-10	6434-6439	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-11	6440-6443	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-12	6444-6453	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-13	6454-6458	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-14	6459-6462	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-15	6463-6470	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-16	6471-6481	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-17	6482-6484	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-18	6485-6494	Baltimore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-19	6495-6499	City	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-20	6500-6503	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-21	6504-6515	surrounding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-22	6516-6521	areas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
30-23	6521-6522	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Substance users were included if they reported regular cocaine (i.e., ≥ 2 times per week) and nicotine (i.e., daily smoker) use during the past year prior to participation, and did not meet DSM-IV criteria for current substance dependence on any other substance other than cocaine or nicotine.
31-1	6523-6532	Substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]	
31-2	6533-6538	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[27]	
31-3	6539-6543	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-4	6544-6552	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-5	6553-6555	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-6	6556-6560	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-7	6561-6569	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-8	6570-6577	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-9	6578-6585	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-10	6586-6587	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-11	6587-6590	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-12	6590-6591	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-13	6591-6592	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-14	6593-6594	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-15	6595-6596	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-16	6597-6602	times	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-17	6603-6606	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-18	6607-6611	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-19	6611-6612	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-20	6613-6616	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-21	6617-6625	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-22	6626-6627	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-23	6627-6630	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-24	6630-6631	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-25	6631-6632	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-26	6633-6638	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-27	6639-6645	smoker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-28	6645-6646	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-29	6647-6650	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-30	6651-6657	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-31	6658-6661	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-32	6662-6666	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-33	6667-6671	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-34	6672-6677	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-35	6678-6680	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-36	6681-6694	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-37	6694-6695	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-38	6696-6699	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-39	6700-6703	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-40	6704-6707	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-41	6708-6712	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-42	6713-6719	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-43	6720-6728	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-44	6729-6732	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-45	6733-6740	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-46	6741-6750	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-47	6751-6761	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-48	6762-6764	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-49	6765-6768	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-50	6769-6774	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-51	6775-6784	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-52	6785-6790	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-53	6791-6795	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-54	6796-6803	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-55	6804-6806	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-56	6807-6815	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
31-57	6815-6816	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Healthy non-drug using participants did not meet DSM-IV criteria for any past or current substance abuse or dependence, nor any use of illicit substances in the past 30 days.
32-1	6817-6824	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
32-2	6825-6833	non-drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
32-3	6834-6839	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
32-4	6840-6852	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]	
32-5	6853-6856	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-6	6857-6860	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-7	6861-6865	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-8	6866-6872	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-9	6873-6881	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-10	6882-6885	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-11	6886-6889	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-12	6890-6894	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-13	6895-6897	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-14	6898-6905	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-15	6906-6915	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-16	6916-6921	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-17	6922-6924	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-18	6925-6935	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-19	6935-6936	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-20	6937-6940	nor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-21	6941-6944	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-22	6945-6948	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-23	6949-6951	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-24	6952-6959	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-25	6960-6970	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-26	6971-6973	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-27	6974-6977	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-28	6978-6982	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-29	6983-6985	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-30	6986-6990	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
32-31	6990-6991	.	_	

#Text=General procedure
#Text=The current report includes data that was part of a larger assessment battery.
33-1	6992-6999	General	_	
33-2	7000-7009	procedure	_	
33-3	7010-7013	The	_	
33-4	7014-7021	current	_	
33-5	7022-7028	report	_	
33-6	7029-7037	includes	_	
33-7	7038-7042	data	_	
33-8	7043-7047	that	_	
33-9	7048-7051	was	_	
33-10	7052-7056	part	_	
33-11	7057-7059	of	_	
33-12	7060-7061	a	_	
33-13	7062-7068	larger	_	
33-14	7069-7079	assessment	_	
33-15	7080-7087	battery	_	
33-16	7087-7088	.	_	

#Text=A pre-scan assessment included a test for current drug use (Triage®), alcohol use (breathalyzer), and pregnancy, the vocabulary portion of the Wechsler Abbreviated Scale of Intelligence (WASI-VIQ), Fagerstrom Test for Nicotine Dependence (FTND) and a questionnaire assessing frequency of use in the past year across 11 drug classes.
34-1	7089-7090	A	_	
34-2	7091-7099	pre-scan	_	
34-3	7100-7110	assessment	_	
34-4	7111-7119	included	_	
34-5	7120-7121	a	_	
34-6	7122-7126	test	_	
34-7	7127-7130	for	_	
34-8	7131-7138	current	_	
34-9	7139-7143	drug	_	
34-10	7144-7147	use	_	
34-11	7148-7149	(	_	
34-12	7149-7155	Triage	_	
34-13	7155-7156	®	_	
34-14	7156-7157	)	_	
34-15	7157-7158	,	_	
34-16	7159-7166	alcohol	_	
34-17	7167-7170	use	_	
34-18	7171-7172	(	_	
34-19	7172-7184	breathalyzer	_	
34-20	7184-7185	)	_	
34-21	7185-7186	,	_	
34-22	7187-7190	and	_	
34-23	7191-7200	pregnancy	_	
34-24	7200-7201	,	_	
34-25	7202-7205	the	_	
34-26	7206-7216	vocabulary	_	
34-27	7217-7224	portion	_	
34-28	7225-7227	of	_	
34-29	7228-7231	the	_	
34-30	7232-7240	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-31	7241-7252	Abbreviated	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-32	7253-7258	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-33	7259-7261	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-34	7262-7274	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-35	7275-7276	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-36	7276-7284	WASI-VIQ	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]	
34-37	7284-7285	)	_	
34-38	7285-7286	,	_	
34-39	7287-7297	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-40	7298-7302	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-41	7303-7306	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-42	7307-7315	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-43	7316-7326	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-44	7327-7328	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-45	7328-7332	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[31]	
34-46	7332-7333	)	_	
34-47	7334-7337	and	_	
34-48	7338-7339	a	_	
34-49	7340-7353	questionnaire	_	
34-50	7354-7363	assessing	_	
34-51	7364-7373	frequency	_	
34-52	7374-7376	of	_	
34-53	7377-7380	use	_	
34-54	7381-7383	in	_	
34-55	7384-7387	the	_	
34-56	7388-7392	past	_	
34-57	7393-7397	year	_	
34-58	7398-7404	across	_	
34-59	7405-7407	11	_	
34-60	7408-7412	drug	_	
34-61	7413-7420	classes	_	
34-62	7420-7421	.	_	

#Text=All substance users smoked a cigarette 60 minutes prior to entering the MRI.
35-1	7422-7425	All	_	
35-2	7426-7435	substance	_	
35-3	7436-7441	users	_	
35-4	7442-7448	smoked	_	
35-5	7449-7450	a	_	
35-6	7451-7460	cigarette	_	
35-7	7461-7463	60	_	
35-8	7464-7471	minutes	_	
35-9	7472-7477	prior	_	
35-10	7478-7480	to	_	
35-11	7481-7489	entering	_	
35-12	7490-7493	the	_	
35-13	7494-7497	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
35-14	7497-7498	.	_	

#Text=Distress tolerance task
#Text=All participants completed the Paced Auditory Serial Attention Task for fMRI (PASAT-M), which was modified from the Computerized Paced Auditory Serial Addition Task (PASAT-C).
36-1	7499-7507	Distress	_	
36-2	7508-7517	tolerance	_	
36-3	7518-7522	task	_	
36-4	7523-7526	All	_	
36-5	7527-7539	participants	_	
36-6	7540-7549	completed	_	
36-7	7550-7553	the	_	
36-8	7554-7559	Paced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-9	7560-7568	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-10	7569-7575	Serial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-11	7576-7585	Attention	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-12	7586-7590	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-13	7591-7594	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-14	7595-7599	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-15	7600-7601	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-16	7601-7608	PASAT-M	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-17	7608-7609	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[32]	
36-18	7609-7610	,	_	
36-19	7611-7616	which	_	
36-20	7617-7620	was	_	
36-21	7621-7629	modified	_	
36-22	7630-7634	from	_	
36-23	7635-7638	the	_	
36-24	7639-7651	Computerized	_	
36-25	7652-7657	Paced	_	
36-26	7658-7666	Auditory	_	
36-27	7667-7673	Serial	_	
36-28	7674-7682	Addition	_	
36-29	7683-7687	Task	_	
36-30	7688-7689	(	_	
36-31	7689-7696	PASAT-C	_	
36-32	7696-7697	)	_	
36-33	7697-7698	.	_	

#Text=A series of numbers flash on the screen one at a time and the participant must add the current number on the screen to the previously presented number, and then use an MRI compatible joystick to indicate the correct answer before the subsequent number appears.
37-1	7699-7700	A	_	
37-2	7701-7707	series	_	
37-3	7708-7710	of	_	
37-4	7711-7718	numbers	_	
37-5	7719-7724	flash	_	
37-6	7725-7727	on	_	
37-7	7728-7731	the	_	
37-8	7732-7738	screen	_	
37-9	7739-7742	one	_	
37-10	7743-7745	at	_	
37-11	7746-7747	a	_	
37-12	7748-7752	time	_	
37-13	7753-7756	and	_	
37-14	7757-7760	the	_	
37-15	7761-7772	participant	_	
37-16	7773-7777	must	_	
37-17	7778-7781	add	_	
37-18	7782-7785	the	_	
37-19	7786-7793	current	_	
37-20	7794-7800	number	_	
37-21	7801-7803	on	_	
37-22	7804-7807	the	_	
37-23	7808-7814	screen	_	
37-24	7815-7817	to	_	
37-25	7818-7821	the	_	
37-26	7822-7832	previously	_	
37-27	7833-7842	presented	_	
37-28	7843-7849	number	_	
37-29	7849-7850	,	_	
37-30	7851-7854	and	_	
37-31	7855-7859	then	_	
37-32	7860-7863	use	_	
37-33	7864-7866	an	_	
37-34	7867-7870	MRI	_	
37-35	7871-7881	compatible	_	
37-36	7882-7890	joystick	_	
37-37	7891-7893	to	_	
37-38	7894-7902	indicate	_	
37-39	7903-7906	the	_	
37-40	7907-7914	correct	_	
37-41	7915-7921	answer	_	
37-42	7922-7928	before	_	
37-43	7929-7932	the	_	
37-44	7933-7943	subsequent	_	
37-45	7944-7950	number	_	
37-46	7951-7958	appears	_	
37-47	7958-7959	.	_	

#Text=Correct responses result in a pleasant bell sound and an increase in the participants’ score, while incorrect and/or slow responses result in an explosion noise and a decrease in points.
38-1	7960-7967	Correct	_	
38-2	7968-7977	responses	_	
38-3	7978-7984	result	_	
38-4	7985-7987	in	_	
38-5	7988-7989	a	_	
38-6	7990-7998	pleasant	_	
38-7	7999-8003	bell	_	
38-8	8004-8009	sound	_	
38-9	8010-8013	and	_	
38-10	8014-8016	an	_	
38-11	8017-8025	increase	_	
38-12	8026-8028	in	_	
38-13	8029-8032	the	_	
38-14	8033-8045	participants	_	
38-15	8045-8046	’	_	
38-16	8047-8052	score	_	
38-17	8052-8053	,	_	
38-18	8054-8059	while	_	
38-19	8060-8069	incorrect	_	
38-20	8070-8073	and	_	
38-21	8073-8074	/	_	
38-22	8074-8076	or	_	
38-23	8077-8081	slow	_	
38-24	8082-8091	responses	_	
38-25	8092-8098	result	_	
38-26	8099-8101	in	_	
38-27	8102-8104	an	_	
38-28	8105-8114	explosion	_	
38-29	8115-8120	noise	_	
38-30	8121-8124	and	_	
38-31	8125-8126	a	_	
38-32	8127-8135	decrease	_	
38-33	8136-8138	in	_	
38-34	8139-8145	points	_	
38-35	8145-8146	.	_	

#Text=The volume is set at a constant level that was determined during pilot testing to be sufficiently loud to allow for participants to hear the task noises over the noise of the MRI scanner.
39-1	8147-8150	The	_	
39-2	8151-8157	volume	_	
39-3	8158-8160	is	_	
39-4	8161-8164	set	_	
39-5	8165-8167	at	_	
39-6	8168-8169	a	_	
39-7	8170-8178	constant	_	
39-8	8179-8184	level	_	
39-9	8185-8189	that	_	
39-10	8190-8193	was	_	
39-11	8194-8204	determined	_	
39-12	8205-8211	during	_	
39-13	8212-8217	pilot	_	
39-14	8218-8225	testing	_	
39-15	8226-8228	to	_	
39-16	8229-8231	be	_	
39-17	8232-8244	sufficiently	_	
39-18	8245-8249	loud	_	
39-19	8250-8252	to	_	
39-20	8253-8258	allow	_	
39-21	8259-8262	for	_	
39-22	8263-8275	participants	_	
39-23	8276-8278	to	_	
39-24	8279-8283	hear	_	
39-25	8284-8287	the	_	
39-26	8288-8292	task	_	
39-27	8293-8299	noises	_	
39-28	8300-8304	over	_	
39-29	8305-8308	the	_	
39-30	8309-8314	noise	_	
39-31	8315-8317	of	_	
39-32	8318-8321	the	_	
39-33	8322-8325	MRI	_	
39-34	8326-8333	scanner	_	
39-35	8333-8334	.	_	

#Text=The block design of the PASAT-M task consisted of four phases (Figure 1): an easy phase, designed to control for cognitive and motor functioning, a latency test phase to determine skill level, a distress phase, designed to elicit affective distress, and a distress tolerance (DT) phase to measure DT (i.e., latency, in seconds, to task termination).
40-1	8335-8338	The	_	
40-2	8339-8344	block	_	
40-3	8345-8351	design	_	
40-4	8352-8354	of	_	
40-5	8355-8358	the	_	
40-6	8359-8366	PASAT-M	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
40-7	8367-8371	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
40-8	8372-8381	consisted	_	
40-9	8382-8384	of	_	
40-10	8385-8389	four	_	
40-11	8390-8396	phases	_	
40-12	8397-8398	(	_	
40-13	8398-8404	Figure	_	
40-14	8405-8406	1	_	
40-15	8406-8407	)	_	
40-16	8407-8408	:	_	
40-17	8409-8411	an	_	
40-18	8412-8416	easy	_	
40-19	8417-8422	phase	_	
40-20	8422-8423	,	_	
40-21	8424-8432	designed	_	
40-22	8433-8435	to	_	
40-23	8436-8443	control	_	
40-24	8444-8447	for	_	
40-25	8448-8457	cognitive	_	
40-26	8458-8461	and	_	
40-27	8462-8467	motor	_	
40-28	8468-8479	functioning	_	
40-29	8479-8480	,	_	
40-30	8481-8482	a	_	
40-31	8483-8490	latency	_	
40-32	8491-8495	test	_	
40-33	8496-8501	phase	_	
40-34	8502-8504	to	_	
40-35	8505-8514	determine	_	
40-36	8515-8520	skill	_	
40-37	8521-8526	level	_	
40-38	8526-8527	,	_	
40-39	8528-8529	a	_	
40-40	8530-8538	distress	_	
40-41	8539-8544	phase	_	
40-42	8544-8545	,	_	
40-43	8546-8554	designed	_	
40-44	8555-8557	to	_	
40-45	8558-8564	elicit	_	
40-46	8565-8574	affective	_	
40-47	8575-8583	distress	_	
40-48	8583-8584	,	_	
40-49	8585-8588	and	_	
40-50	8589-8590	a	_	
40-51	8591-8599	distress	_	
40-52	8600-8609	tolerance	_	
40-53	8610-8611	(	_	
40-54	8611-8613	DT	_	
40-55	8613-8614	)	_	
40-56	8615-8620	phase	_	
40-57	8621-8623	to	_	
40-58	8624-8631	measure	_	
40-59	8632-8634	DT	_	
40-60	8635-8636	(	_	
40-61	8636-8639	i.e	_	
40-62	8639-8640	.	_	
40-63	8640-8641	,	_	
40-64	8642-8649	latency	_	
40-65	8649-8650	,	_	
40-66	8651-8653	in	_	
40-67	8654-8661	seconds	_	
40-68	8661-8662	,	_	
40-69	8663-8665	to	_	
40-70	8666-8670	task	_	
40-71	8671-8682	termination	_	
40-72	8682-8683	)	_	
40-73	8683-8684	.	_	

#Text=For both the easy and distress phases there are a total of six 60-second activity blocks, beginning, ending and alternating with 35-second rest blocks, for a total of about 10 minutes.
41-1	8685-8688	For	_	
41-2	8689-8693	both	_	
41-3	8694-8697	the	_	
41-4	8698-8702	easy	_	
41-5	8703-8706	and	_	
41-6	8707-8715	distress	_	
41-7	8716-8722	phases	_	
41-8	8723-8728	there	_	
41-9	8729-8732	are	_	
41-10	8733-8734	a	_	
41-11	8735-8740	total	_	
41-12	8741-8743	of	_	
41-13	8744-8747	six	_	
41-14	8748-8750	60	_	
41-15	8750-8751	-	_	
41-16	8751-8757	second	_	
41-17	8758-8766	activity	_	
41-18	8767-8773	blocks	_	
41-19	8773-8774	,	_	
41-20	8775-8784	beginning	_	
41-21	8784-8785	,	_	
41-22	8786-8792	ending	_	
41-23	8793-8796	and	_	
41-24	8797-8808	alternating	_	
41-25	8809-8813	with	_	
41-26	8814-8816	35	_	
41-27	8816-8817	-	_	
41-28	8817-8823	second	_	
41-29	8824-8828	rest	_	
41-30	8829-8835	blocks	_	
41-31	8835-8836	,	_	
41-32	8837-8840	for	_	
41-33	8841-8842	a	_	
41-34	8843-8848	total	_	
41-35	8849-8851	of	_	
41-36	8852-8857	about	_	
41-37	8858-8860	10	_	
41-38	8861-8868	minutes	_	
41-39	8868-8869	.	_	

#Text=Following the easy phase, a five-minute latency test phase begins in order to determine each participant's individual skill level.
42-1	8870-8879	Following	_	
42-2	8880-8883	the	_	
42-3	8884-8888	easy	_	
42-4	8889-8894	phase	_	
42-5	8894-8895	,	_	
42-6	8896-8897	a	_	
42-7	8898-8909	five-minute	_	
42-8	8910-8917	latency	_	
42-9	8918-8922	test	_	
42-10	8923-8928	phase	_	
42-11	8929-8935	begins	_	
42-12	8936-8938	in	_	
42-13	8939-8944	order	_	
42-14	8945-8947	to	_	
42-15	8948-8957	determine	_	
42-16	8958-8962	each	_	
42-17	8963-8976	participant's	_	
42-18	8977-8987	individual	_	
42-19	8988-8993	skill	_	
42-20	8994-8999	level	_	
42-21	8999-9000	.	_	

#Text=Each time a participant responds correctly, the subsequent number appears 500 milliseconds faster.
43-1	9001-9005	Each	_	
43-2	9006-9010	time	_	
43-3	9011-9012	a	_	
43-4	9013-9024	participant	_	
43-5	9025-9033	responds	_	
43-6	9034-9043	correctly	_	
43-7	9043-9044	,	_	
43-8	9045-9048	the	_	
43-9	9049-9059	subsequent	_	
43-10	9060-9066	number	_	
43-11	9067-9074	appears	_	
43-12	9075-9078	500	_	
43-13	9079-9091	milliseconds	_	
43-14	9092-9098	faster	_	
43-15	9098-9099	.	_	

#Text=Conversely, each time a participant is too slow or chooses an incorrect response, the subsequent number appears 250 milliseconds slower.
44-1	9100-9110	Conversely	_	
44-2	9110-9111	,	_	
44-3	9112-9116	each	_	
44-4	9117-9121	time	_	
44-5	9122-9123	a	_	
44-6	9124-9135	participant	_	
44-7	9136-9138	is	_	
44-8	9139-9142	too	_	
44-9	9143-9147	slow	_	
44-10	9148-9150	or	_	
44-11	9151-9158	chooses	_	
44-12	9159-9161	an	_	
44-13	9162-9171	incorrect	_	
44-14	9172-9180	response	_	
44-15	9180-9181	,	_	
44-16	9182-9185	the	_	
44-17	9186-9196	subsequent	_	
44-18	9197-9203	number	_	
44-19	9204-9211	appears	_	
44-20	9212-9215	250	_	
44-21	9216-9228	milliseconds	_	
44-22	9229-9235	slower	_	
44-23	9235-9236	.	_	

#Text=Skill level is calculated as the mean latency during this phase of the task.
45-1	9237-9242	Skill	_	
45-2	9243-9248	level	_	
45-3	9249-9251	is	_	
45-4	9252-9262	calculated	_	
45-5	9263-9265	as	_	
45-6	9266-9269	the	_	
45-7	9270-9274	mean	_	
45-8	9275-9282	latency	_	
45-9	9283-9289	during	_	
45-10	9290-9294	this	_	
45-11	9295-9300	phase	_	
45-12	9301-9303	of	_	
45-13	9304-9307	the	_	
45-14	9308-9312	task	_	
45-15	9312-9313	.	_	

#Text=During the distress phase, the response time allotted for each number presentation is 2.5× faster than their skill level as determined during the latency phase.
46-1	9314-9320	During	_	
46-2	9321-9324	the	_	
46-3	9325-9333	distress	_	
46-4	9334-9339	phase	_	
46-5	9339-9340	,	_	
46-6	9341-9344	the	_	
46-7	9345-9353	response	_	
46-8	9354-9358	time	_	
46-9	9359-9367	allotted	_	
46-10	9368-9371	for	_	
46-11	9372-9376	each	_	
46-12	9377-9383	number	_	
46-13	9384-9396	presentation	_	
46-14	9397-9399	is	_	
46-15	9400-9403	2.5	_	
46-16	9403-9404	×	_	
46-17	9405-9411	faster	_	
46-18	9412-9416	than	_	
46-19	9417-9422	their	_	
46-20	9423-9428	skill	_	
46-21	9429-9434	level	_	
46-22	9435-9437	as	_	
46-23	9438-9448	determined	_	
46-24	9449-9455	during	_	
46-25	9456-9459	the	_	
46-26	9460-9467	latency	_	
46-27	9468-9473	phase	_	
46-28	9473-9474	.	_	

#Text=Participants are told that their performance during this phase will influence how much money they will receive at the end of the testing session.
47-1	9475-9487	Participants	_	
47-2	9488-9491	are	_	
47-3	9492-9496	told	_	
47-4	9497-9501	that	_	
47-5	9502-9507	their	_	
47-6	9508-9519	performance	_	
47-7	9520-9526	during	_	
47-8	9527-9531	this	_	
47-9	9532-9537	phase	_	
47-10	9538-9542	will	_	
47-11	9543-9552	influence	_	
47-12	9553-9556	how	_	
47-13	9557-9561	much	_	
47-14	9562-9567	money	_	
47-15	9568-9572	they	_	
47-16	9573-9577	will	_	
47-17	9578-9585	receive	_	
47-18	9586-9588	at	_	
47-19	9589-9592	the	_	
47-20	9593-9596	end	_	
47-21	9597-9599	of	_	
47-22	9600-9603	the	_	
47-23	9604-9611	testing	_	
47-24	9612-9619	session	_	
47-25	9619-9620	.	_	

#Text=The task parameters and procedures in the distress phase are intended to maximize loss, repeated forced failure, and aversive negative performance feedback (i.e., constant explosion noises signaling failure, as well as a decreasing point meter).
48-1	9621-9624	The	_	
48-2	9625-9629	task	_	
48-3	9630-9640	parameters	_	
48-4	9641-9644	and	_	
48-5	9645-9655	procedures	_	
48-6	9656-9658	in	_	
48-7	9659-9662	the	_	
48-8	9663-9671	distress	_	
48-9	9672-9677	phase	_	
48-10	9678-9681	are	_	
48-11	9682-9690	intended	_	
48-12	9691-9693	to	_	
48-13	9694-9702	maximize	_	
48-14	9703-9707	loss	_	
48-15	9707-9708	,	_	
48-16	9709-9717	repeated	_	
48-17	9718-9724	forced	_	
48-18	9725-9732	failure	_	
48-19	9732-9733	,	_	
48-20	9734-9737	and	_	
48-21	9738-9746	aversive	_	
48-22	9747-9755	negative	_	
48-23	9756-9767	performance	_	
48-24	9768-9776	feedback	_	
48-25	9777-9778	(	_	
48-26	9778-9781	i.e	_	
48-27	9781-9782	.	_	
48-28	9782-9783	,	_	
48-29	9784-9792	constant	_	
48-30	9793-9802	explosion	_	
48-31	9803-9809	noises	_	
48-32	9810-9819	signaling	_	
48-33	9820-9827	failure	_	
48-34	9827-9828	,	_	
48-35	9829-9831	as	_	
48-36	9832-9836	well	_	
48-37	9837-9839	as	_	
48-38	9840-9841	a	_	
48-39	9842-9852	decreasing	_	
48-40	9853-9858	point	_	
48-41	9859-9864	meter	_	
48-42	9864-9865	)	_	
48-43	9865-9866	.	_	

#Text=During the DT phase, the rate of number presentations is equal to the distress phase for a maximum of 10 minutes.
49-1	9867-9873	During	_	
49-2	9874-9877	the	_	
49-3	9878-9880	DT	_	
49-4	9881-9886	phase	_	
49-5	9886-9887	,	_	
49-6	9888-9891	the	_	
49-7	9892-9896	rate	_	
49-8	9897-9899	of	_	
49-9	9900-9906	number	_	
49-10	9907-9920	presentations	_	
49-11	9921-9923	is	_	
49-12	9924-9929	equal	_	
49-13	9930-9932	to	_	
49-14	9933-9936	the	_	
49-15	9937-9945	distress	_	
49-16	9946-9951	phase	_	
49-17	9952-9955	for	_	
49-18	9956-9957	a	_	
49-19	9958-9965	maximum	_	
49-20	9966-9968	of	_	
49-21	9969-9971	10	_	
49-22	9972-9979	minutes	_	
49-23	9979-9980	.	_	

#Text=Participants are instructed that they have the opportunity to win back points they may have lost during the distress phase, but that they will no longer lose points for ‘incorrect’ or ‘too slow’ responses, although the negative auditory feedback will still be presented.
50-1	9981-9993	Participants	_	
50-2	9994-9997	are	_	
50-3	9998-10008	instructed	_	
50-4	10009-10013	that	_	
50-5	10014-10018	they	_	
50-6	10019-10023	have	_	
50-7	10024-10027	the	_	
50-8	10028-10039	opportunity	_	
50-9	10040-10042	to	_	
50-10	10043-10046	win	_	
50-11	10047-10051	back	_	
50-12	10052-10058	points	_	
50-13	10059-10063	they	_	
50-14	10064-10067	may	_	
50-15	10068-10072	have	_	
50-16	10073-10077	lost	_	
50-17	10078-10084	during	_	
50-18	10085-10088	the	_	
50-19	10089-10097	distress	_	
50-20	10098-10103	phase	_	
50-21	10103-10104	,	_	
50-22	10105-10108	but	_	
50-23	10109-10113	that	_	
50-24	10114-10118	they	_	
50-25	10119-10123	will	_	
50-26	10124-10126	no	_	
50-27	10127-10133	longer	_	
50-28	10134-10138	lose	_	
50-29	10139-10145	points	_	
50-30	10146-10149	for	_	
50-31	10150-10151	‘	_	
50-32	10151-10160	incorrect	_	
50-33	10160-10161	’	_	
50-34	10162-10164	or	_	
50-35	10165-10166	‘	_	
50-36	10166-10169	too	_	
50-37	10170-10174	slow	_	
50-38	10174-10175	’	_	
50-39	10176-10185	responses	_	
50-40	10185-10186	,	_	
50-41	10187-10195	although	_	
50-42	10196-10199	the	_	
50-43	10200-10208	negative	_	
50-44	10209-10217	auditory	_	
50-45	10218-10226	feedback	_	
50-46	10227-10231	will	_	
50-47	10232-10237	still	_	
50-48	10238-10240	be	_	
50-49	10241-10250	presented	_	
50-50	10250-10251	.	_	

#Text=The removal of loss in this phase is designed to prevent participants from choosing to quit the task because it is an adaptive response to prevent further loss.
51-1	10252-10255	The	_	
51-2	10256-10263	removal	_	
51-3	10264-10266	of	_	
51-4	10267-10271	loss	_	
51-5	10272-10274	in	_	
51-6	10275-10279	this	_	
51-7	10280-10285	phase	_	
51-8	10286-10288	is	_	
51-9	10289-10297	designed	_	
51-10	10298-10300	to	_	
51-11	10301-10308	prevent	_	
51-12	10309-10321	participants	_	
51-13	10322-10326	from	_	
51-14	10327-10335	choosing	_	
51-15	10336-10338	to	_	
51-16	10339-10343	quit	_	
51-17	10344-10347	the	_	
51-18	10348-10352	task	_	
51-19	10353-10360	because	_	
51-20	10361-10363	it	_	
51-21	10364-10366	is	_	
51-22	10367-10369	an	_	
51-23	10370-10378	adaptive	_	
51-24	10379-10387	response	_	
51-25	10388-10390	to	_	
51-26	10391-10398	prevent	_	
51-27	10399-10406	further	_	
51-28	10407-10411	loss	_	
51-29	10411-10412	.	_	

#Text=Participants are again told that their performance will determine how much money they receive at the end of the session, but that they can press a button on the joystick at any time to end the task.
52-1	10413-10425	Participants	_	
52-2	10426-10429	are	_	
52-3	10430-10435	again	_	
52-4	10436-10440	told	_	
52-5	10441-10445	that	_	
52-6	10446-10451	their	_	
52-7	10452-10463	performance	_	
52-8	10464-10468	will	_	
52-9	10469-10478	determine	_	
52-10	10479-10482	how	_	
52-11	10483-10487	much	_	
52-12	10488-10493	money	_	
52-13	10494-10498	they	_	
52-14	10499-10506	receive	_	
52-15	10507-10509	at	_	
52-16	10510-10513	the	_	
52-17	10514-10517	end	_	
52-18	10518-10520	of	_	
52-19	10521-10524	the	_	
52-20	10525-10532	session	_	
52-21	10532-10533	,	_	
52-22	10534-10537	but	_	
52-23	10538-10542	that	_	
52-24	10543-10547	they	_	
52-25	10548-10551	can	_	
52-26	10552-10557	press	_	
52-27	10558-10559	a	_	
52-28	10560-10566	button	_	
52-29	10567-10569	on	_	
52-30	10570-10573	the	_	
52-31	10574-10582	joystick	_	
52-32	10583-10585	at	_	
52-33	10586-10589	any	_	
52-34	10590-10594	time	_	
52-35	10595-10597	to	_	
52-36	10598-10601	end	_	
52-37	10602-10605	the	_	
52-38	10606-10610	task	_	
52-39	10610-10611	.	_	

#Text=Although there are a total of four phases of the PASAT-M, the final phase (i.e., the DT phase) is intended as a behavioral measure of DT, measured as time in seconds to task termination.
53-1	10612-10620	Although	_	
53-2	10621-10626	there	_	
53-3	10627-10630	are	_	
53-4	10631-10632	a	_	
53-5	10633-10638	total	_	
53-6	10639-10641	of	_	
53-7	10642-10646	four	_	
53-8	10647-10653	phases	_	
53-9	10654-10656	of	_	
53-10	10657-10660	the	_	
53-11	10661-10668	PASAT-M	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	
53-12	10668-10669	,	_	
53-13	10670-10673	the	_	
53-14	10674-10679	final	_	
53-15	10680-10685	phase	_	
53-16	10686-10687	(	_	
53-17	10687-10690	i.e	_	
53-18	10690-10691	.	_	
53-19	10691-10692	,	_	
53-20	10693-10696	the	_	
53-21	10697-10699	DT	_	
53-22	10700-10705	phase	_	
53-23	10705-10706	)	_	
53-24	10707-10709	is	_	
53-25	10710-10718	intended	_	
53-26	10719-10721	as	_	
53-27	10722-10723	a	_	
53-28	10724-10734	behavioral	_	
53-29	10735-10742	measure	_	
53-30	10743-10745	of	_	
53-31	10746-10748	DT	_	
53-32	10748-10749	,	_	
53-33	10750-10758	measured	_	
53-34	10759-10761	as	_	
53-35	10762-10766	time	_	
53-36	10767-10769	in	_	
53-37	10770-10777	seconds	_	
53-38	10778-10780	to	_	
53-39	10781-10785	task	_	
53-40	10786-10797	termination	_	
53-41	10797-10798	.	_	

#Text=Self-report mood ratings are collected prior to the easy phase (Time 1), and post-easy phase (Time 2), latency test phase (Time 3), distress phase (Time 4), and DT phase (Time 5).
54-1	10799-10810	Self-report	_	
54-2	10811-10815	mood	_	
54-3	10816-10823	ratings	_	
54-4	10824-10827	are	_	
54-5	10828-10837	collected	_	
54-6	10838-10843	prior	_	
54-7	10844-10846	to	_	
54-8	10847-10850	the	_	
54-9	10851-10855	easy	_	
54-10	10856-10861	phase	_	
54-11	10862-10863	(	_	
54-12	10863-10867	Time	_	
54-13	10868-10869	1	_	
54-14	10869-10870	)	_	
54-15	10870-10871	,	_	
54-16	10872-10875	and	_	
54-17	10876-10885	post-easy	_	
54-18	10886-10891	phase	_	
54-19	10892-10893	(	_	
54-20	10893-10897	Time	_	
54-21	10898-10899	2	_	
54-22	10899-10900	)	_	
54-23	10900-10901	,	_	
54-24	10902-10909	latency	_	
54-25	10910-10914	test	_	
54-26	10915-10920	phase	_	
54-27	10921-10922	(	_	
54-28	10922-10926	Time	_	
54-29	10927-10928	3	_	
54-30	10928-10929	)	_	
54-31	10929-10930	,	_	
54-32	10931-10939	distress	_	
54-33	10940-10945	phase	_	
54-34	10946-10947	(	_	
54-35	10947-10951	Time	_	
54-36	10952-10953	4	_	
54-37	10953-10954	)	_	
54-38	10954-10955	,	_	
54-39	10956-10959	and	_	
54-40	10960-10962	DT	_	
54-41	10963-10968	phase	_	
54-42	10969-10970	(	_	
54-43	10970-10974	Time	_	
54-44	10975-10976	5	_	
54-45	10976-10977	)	_	
54-46	10977-10978	.	_	

#Text=Distress is calculated as the mean ratings of anxiety, frustration, irritability, and stress at each time point.
55-1	10979-10987	Distress	_	
55-2	10988-10990	is	_	
55-3	10991-11001	calculated	_	
55-4	11002-11004	as	_	
55-5	11005-11008	the	_	
55-6	11009-11013	mean	_	
55-7	11014-11021	ratings	_	
55-8	11022-11024	of	_	
55-9	11025-11032	anxiety	_	
55-10	11032-11033	,	_	
55-11	11034-11045	frustration	_	
55-12	11045-11046	,	_	
55-13	11047-11059	irritability	_	
55-14	11059-11060	,	_	
55-15	11061-11064	and	_	
55-16	11065-11071	stress	_	
55-17	11072-11074	at	_	
55-18	11075-11079	each	_	
55-19	11080-11084	time	_	
55-20	11085-11090	point	_	
55-21	11090-11091	.	_	

#Text=Following the task, motivation to perform well during the task was assessed using a 10-point Likert scale ranging from “not at all motivated” to “extremely motivated”.
56-1	11092-11101	Following	_	
56-2	11102-11105	the	_	
56-3	11106-11110	task	_	
56-4	11110-11111	,	_	
56-5	11112-11122	motivation	_	
56-6	11123-11125	to	_	
56-7	11126-11133	perform	_	
56-8	11134-11138	well	_	
56-9	11139-11145	during	_	
56-10	11146-11149	the	_	
56-11	11150-11154	task	_	
56-12	11155-11158	was	_	
56-13	11159-11167	assessed	_	
56-14	11168-11173	using	_	
56-15	11174-11175	a	_	
56-16	11176-11178	10	_	
56-17	11178-11179	-	_	
56-18	11179-11184	point	_	
56-19	11185-11191	Likert	_	
56-20	11192-11197	scale	_	
56-21	11198-11205	ranging	_	
56-22	11206-11210	from	_	
56-23	11211-11212	“	_	
56-24	11212-11215	not	_	
56-25	11216-11218	at	_	
56-26	11219-11222	all	_	
56-27	11223-11232	motivated	_	
56-28	11232-11233	”	_	
56-29	11234-11236	to	_	
56-30	11237-11238	“	_	
56-31	11238-11247	extremely	_	
56-32	11248-11257	motivated	_	
56-33	11257-11258	”	_	
56-34	11258-11259	.	_	

#Text=Physiological data acquisition and analysis
#Text=Skin conductance response (SCR) and heart rate (HR) were recorded on a BIOPAC data acquisition system operating AcqKnowledge 4.1 at a sampling rate of 1 kHz/channel (BIOPAC Systems, Inc., Goleta, CA).
57-1	11260-11273	Physiological	_	
57-2	11274-11278	data	_	
57-3	11279-11290	acquisition	_	
57-4	11291-11294	and	_	
57-5	11295-11303	analysis	_	
57-6	11304-11308	Skin	_	
57-7	11309-11320	conductance	_	
57-8	11321-11329	response	_	
57-9	11330-11331	(	_	
57-10	11331-11334	SCR	_	
57-11	11334-11335	)	_	
57-12	11336-11339	and	_	
57-13	11340-11345	heart	_	
57-14	11346-11350	rate	_	
57-15	11351-11352	(	_	
57-16	11352-11354	HR	_	
57-17	11354-11355	)	_	
57-18	11356-11360	were	_	
57-19	11361-11369	recorded	_	
57-20	11370-11372	on	_	
57-21	11373-11374	a	_	
57-22	11375-11381	BIOPAC	_	
57-23	11382-11386	data	_	
57-24	11387-11398	acquisition	_	
57-25	11399-11405	system	_	
57-26	11406-11415	operating	_	
57-27	11416-11428	AcqKnowledge	_	
57-28	11429-11432	4.1	_	
57-29	11433-11435	at	_	
57-30	11436-11437	a	_	
57-31	11438-11446	sampling	_	
57-32	11447-11451	rate	_	
57-33	11452-11454	of	_	
57-34	11455-11456	1	_	
57-35	11457-11460	kHz	_	
57-36	11460-11461	/	_	
57-37	11461-11468	channel	_	
57-38	11469-11470	(	_	
57-39	11470-11476	BIOPAC	_	
57-40	11477-11484	Systems	_	
57-41	11484-11485	,	_	
57-42	11486-11489	Inc	_	
57-43	11489-11490	.	_	
57-44	11490-11491	,	_	
57-45	11492-11498	Goleta	_	
57-46	11498-11499	,	_	
57-47	11500-11502	CA	_	
57-48	11502-11503	)	_	
57-49	11503-11504	.	_	

#Text=HR data was recorded using four Ag-AgCl electrodes placed in the chest area and SCR was recorded from the non-dominant index and middle fingers using two Ag-AgCl electrodes.
58-1	11505-11507	HR	_	
58-2	11508-11512	data	_	
58-3	11513-11516	was	_	
58-4	11517-11525	recorded	_	
58-5	11526-11531	using	_	
58-6	11532-11536	four	_	
58-7	11537-11544	Ag-AgCl	_	
58-8	11545-11555	electrodes	_	
58-9	11556-11562	placed	_	
58-10	11563-11565	in	_	
58-11	11566-11569	the	_	
58-12	11570-11575	chest	_	
58-13	11576-11580	area	_	
58-14	11581-11584	and	_	
58-15	11585-11588	SCR	_	
58-16	11589-11592	was	_	
58-17	11593-11601	recorded	_	
58-18	11602-11606	from	_	
58-19	11607-11610	the	_	
58-20	11611-11623	non-dominant	_	
58-21	11624-11629	index	_	
58-22	11630-11633	and	_	
58-23	11634-11640	middle	_	
58-24	11641-11648	fingers	_	
58-25	11649-11654	using	_	
58-26	11655-11658	two	_	
58-27	11659-11666	Ag-AgCl	_	
58-28	11667-11677	electrodes	_	
58-29	11677-11678	.	_	

#Text=HR and SCR (μmho) data were recorded continuously throughout the scan and analyzed as average values over the course of both the easy and distress blocks.
#Text=fMRI data acquisition and analysis
#Text=Whole-brain blood oxygenation level-dependent (BOLD) echo-planar imaging (EPI) data were acquired on a Siemens 3-T Magnetom Trio MR Scanner (Siemens, Erlangen, Germany) equipped with a 12-channel head coil.
59-1	11679-11681	HR	_	
59-2	11682-11685	and	_	
59-3	11686-11689	SCR	_	
59-4	11690-11691	(	_	
59-5	11691-11695	μmho	_	
59-6	11695-11696	)	_	
59-7	11697-11701	data	_	
59-8	11702-11706	were	_	
59-9	11707-11715	recorded	_	
59-10	11716-11728	continuously	_	
59-11	11729-11739	throughout	_	
59-12	11740-11743	the	_	
59-13	11744-11748	scan	_	
59-14	11749-11752	and	_	
59-15	11753-11761	analyzed	_	
59-16	11762-11764	as	_	
59-17	11765-11772	average	_	
59-18	11773-11779	values	_	
59-19	11780-11784	over	_	
59-20	11785-11788	the	_	
59-21	11789-11795	course	_	
59-22	11796-11798	of	_	
59-23	11799-11803	both	_	
59-24	11804-11807	the	_	
59-25	11808-11812	easy	_	
59-26	11813-11816	and	_	
59-27	11817-11825	distress	_	
59-28	11826-11832	blocks	_	
59-29	11832-11833	.	_	
59-30	11834-11838	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]	
59-31	11839-11843	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]	
59-32	11844-11855	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]	
59-33	11856-11859	and	_	
59-34	11860-11868	analysis	_	
59-35	11869-11880	Whole-brain	_	
59-36	11881-11886	blood	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-37	11887-11898	oxygenation	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-38	11899-11914	level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-39	11915-11916	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-40	11916-11920	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-41	11920-11921	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-42	11922-11933	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-43	11934-11941	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-44	11942-11943	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-45	11943-11946	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-46	11946-11947	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-47	11948-11952	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
59-48	11953-11957	were	_	
59-49	11958-11966	acquired	_	
59-50	11967-11969	on	_	
59-51	11970-11971	a	_	
59-52	11972-11979	Siemens	_	
59-53	11980-11981	3	_	
59-54	11981-11982	-	_	
59-55	11982-11983	T	_	
59-56	11984-11992	Magnetom	_	
59-57	11993-11997	Trio	_	
59-58	11998-12000	MR	_	
59-59	12001-12008	Scanner	_	
59-60	12009-12010	(	_	
59-61	12010-12017	Siemens	_	
59-62	12017-12018	,	_	
59-63	12019-12027	Erlangen	_	
59-64	12027-12028	,	_	
59-65	12029-12036	Germany	_	
59-66	12036-12037	)	_	
59-67	12038-12046	equipped	_	
59-68	12047-12051	with	_	
59-69	12052-12053	a	_	
59-70	12054-12056	12	_	
59-71	12056-12057	-	_	
59-72	12057-12064	channel	_	
59-73	12065-12069	head	_	
59-74	12070-12074	coil	_	
59-75	12074-12075	.	_	

#Text=Thirty-nine 4 mm thick slices were obtained covering the whole brain using an acquisition plane approximately 30° axial-to-coronal from AC-PC.
60-1	12076-12087	Thirty-nine	_	
60-2	12088-12089	4	_	
60-3	12090-12092	mm	_	
60-4	12093-12098	thick	_	
60-5	12099-12105	slices	_	
60-6	12106-12110	were	_	
60-7	12111-12119	obtained	_	
60-8	12120-12128	covering	_	
60-9	12129-12132	the	_	
60-10	12133-12138	whole	_	
60-11	12139-12144	brain	_	
60-12	12145-12150	using	_	
60-13	12151-12153	an	_	
60-14	12154-12165	acquisition	_	
60-15	12166-12171	plane	_	
60-16	12172-12185	approximately	_	
60-17	12186-12188	30	_	
60-18	12188-12189	°	_	
60-19	12190-12206	axial-to-coronal	_	
60-20	12207-12211	from	_	
60-21	12212-12217	AC-PC	_	
60-22	12217-12218	.	_	

#Text=Imaging parameters were: repetition time (TR) of 2 s, echo time (TE) of 27 ms, field of view (FOV) of 220×220 mm, flip angle (FA) of 78°, and an in-plane resolution of 3.44×3.44 mm.
61-1	12219-12226	Imaging	_	
61-2	12227-12237	parameters	_	
61-3	12238-12242	were	_	
61-4	12242-12243	:	_	
61-5	12244-12254	repetition	_	
61-6	12255-12259	time	_	
61-7	12260-12261	(	_	
61-8	12261-12263	TR	_	
61-9	12263-12264	)	_	
61-10	12265-12267	of	_	
61-11	12268-12269	2	_	
61-12	12270-12271	s	_	
61-13	12271-12272	,	_	
61-14	12273-12277	echo	_	
61-15	12278-12282	time	_	
61-16	12283-12284	(	_	
61-17	12284-12286	TE	_	
61-18	12286-12287	)	_	
61-19	12288-12290	of	_	
61-20	12291-12293	27	_	
61-21	12294-12296	ms	_	
61-22	12296-12297	,	_	
61-23	12298-12303	field	_	
61-24	12304-12306	of	_	
61-25	12307-12311	view	_	
61-26	12312-12313	(	_	
61-27	12313-12316	FOV	_	
61-28	12316-12317	)	_	
61-29	12318-12320	of	_	
61-30	12321-12324	220	_	
61-31	12324-12325	×	_	
61-32	12325-12328	220	_	
61-33	12329-12331	mm	_	
61-34	12331-12332	,	_	
61-35	12333-12337	flip	_	
61-36	12338-12343	angle	_	
61-37	12344-12345	(	_	
61-38	12345-12347	FA	_	
61-39	12347-12348	)	_	
61-40	12349-12351	of	_	
61-41	12352-12354	78	_	
61-42	12354-12355	°	_	
61-43	12355-12356	,	_	
61-44	12357-12360	and	_	
61-45	12361-12363	an	_	
61-46	12364-12372	in-plane	_	
61-47	12373-12383	resolution	_	
61-48	12384-12386	of	_	
61-49	12387-12391	3.44	_	
61-50	12391-12392	×	_	
61-51	12392-12396	3.44	_	
61-52	12397-12399	mm	_	
61-53	12399-12400	.	_	

#Text=In each scanning session, a whole-brain T1-weighted structural image (MPRAGE) was acquired for anatomical reference (1mm3 isotropic voxels, TR of 1.9 s, TE of 3.51 ms, FA of 9°).
62-1	12401-12403	In	_	
62-2	12404-12408	each	_	
62-3	12409-12417	scanning	_	
62-4	12418-12425	session	_	
62-5	12425-12426	,	_	
62-6	12427-12428	a	_	
62-7	12429-12440	whole-brain	_	
62-8	12441-12443	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-9	12443-12444	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-10	12444-12452	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-11	12453-12463	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-12	12464-12469	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-13	12470-12471	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-14	12471-12477	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-15	12477-12478	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[36]	
62-16	12479-12482	was	_	
62-17	12483-12491	acquired	_	
62-18	12492-12495	for	_	
62-19	12496-12506	anatomical	_	
62-20	12507-12516	reference	_	
62-21	12517-12518	(	_	
62-22	12518-12522	1mm3	_	
62-23	12523-12532	isotropic	_	
62-24	12533-12539	voxels	_	
62-25	12539-12540	,	_	
62-26	12541-12543	TR	_	
62-27	12544-12546	of	_	
62-28	12547-12550	1.9	_	
62-29	12551-12552	s	_	
62-30	12552-12553	,	_	
62-31	12554-12556	TE	_	
62-32	12557-12559	of	_	
62-33	12560-12564	3.51	_	
62-34	12565-12567	ms	_	
62-35	12567-12568	,	_	
62-36	12569-12571	FA	_	
62-37	12572-12574	of	_	
62-38	12575-12576	9	_	
62-39	12576-12577	°	_	
62-40	12577-12578	)	_	
62-41	12578-12579	.	_	

#Text=The functional and anatomical data were pre-processed and analyzed using FMRIB's Software Library (FSL; ww.fmrib.ox.ac.uk/fsl) using FSL FEAT v. 6.00.
63-1	12580-12583	The	_	
63-2	12584-12594	functional	_	
63-3	12595-12598	and	_	
63-4	12599-12609	anatomical	_	
63-5	12610-12614	data	_	
63-6	12615-12619	were	_	
63-7	12620-12633	pre-processed	_	
63-8	12634-12637	and	_	
63-9	12638-12646	analyzed	_	
63-10	12647-12652	using	_	
63-11	12653-12660	FMRIB's	_	
63-12	12661-12669	Software	_	
63-13	12670-12677	Library	_	
63-14	12678-12679	(	_	
63-15	12679-12682	FSL	_	
63-16	12682-12683	;	_	
63-17	12684-12701	ww.fmrib.ox.ac.uk	_	
63-18	12701-12702	/	_	
63-19	12702-12705	fsl	_	
63-20	12705-12706	)	_	
63-21	12707-12712	using	_	
63-22	12713-12716	FSL	_	
63-23	12717-12721	FEAT	_	
63-24	12722-12723	v	_	
63-25	12723-12724	.	_	
63-26	12725-12729	6.00	_	
63-27	12729-12730	.	_	

#Text=Preprocessing included: motion correction with MCFLIRT, spatial smoothing with a Gaussian kernel of full-width half-maximum 5 mm, high-pass temporal filtering (Gaussian-weighed least squares straight line fitting with sigma = 100 s), grand-mean intensity normalization of the entire 4D dataset by a single multiplicative factor, and skull stripping of structural images with BET.
64-1	12731-12744	Preprocessing	_	
64-2	12745-12753	included	_	
64-3	12753-12754	:	_	
64-4	12755-12761	motion	_	
64-5	12762-12772	correction	_	
64-6	12773-12777	with	_	
64-7	12778-12785	MCFLIRT	_	
64-8	12785-12786	,	_	
64-9	12787-12794	spatial	_	
64-10	12795-12804	smoothing	_	
64-11	12805-12809	with	_	
64-12	12810-12811	a	_	
64-13	12812-12820	Gaussian	_	
64-14	12821-12827	kernel	_	
64-15	12828-12830	of	_	
64-16	12831-12841	full-width	_	
64-17	12842-12854	half-maximum	_	
64-18	12855-12856	5	_	
64-19	12857-12859	mm	_	
64-20	12859-12860	,	_	
64-21	12861-12870	high-pass	_	
64-22	12871-12879	temporal	_	
64-23	12880-12889	filtering	_	
64-24	12890-12891	(	_	
64-25	12891-12907	Gaussian-weighed	_	
64-26	12908-12913	least	_	
64-27	12914-12921	squares	_	
64-28	12922-12930	straight	_	
64-29	12931-12935	line	_	
64-30	12936-12943	fitting	_	
64-31	12944-12948	with	_	
64-32	12949-12954	sigma	_	
64-33	12955-12956	=	_	
64-34	12957-12960	100	_	
64-35	12961-12962	s	_	
64-36	12962-12963	)	_	
64-37	12963-12964	,	_	
64-38	12965-12975	grand-mean	_	
64-39	12976-12985	intensity	_	
64-40	12986-12999	normalization	_	
64-41	13000-13002	of	_	
64-42	13003-13006	the	_	
64-43	13007-13013	entire	_	
64-44	13014-13016	4D	_	
64-45	13017-13024	dataset	_	
64-46	13025-13027	by	_	
64-47	13028-13029	a	_	
64-48	13030-13036	single	_	
64-49	13037-13051	multiplicative	_	
64-50	13052-13058	factor	_	
64-51	13058-13059	,	_	
64-52	13060-13063	and	_	
64-53	13064-13069	skull	_	
64-54	13070-13079	stripping	_	
64-55	13080-13082	of	_	
64-56	13083-13093	structural	_	
64-57	13094-13100	images	_	
64-58	13101-13105	with	_	
64-59	13106-13109	BET	_	
64-60	13109-13110	.	_	

#Text=Functional scans were excluded if they displayed a relative mean displacement >0.3 mm in any plane.
65-1	13111-13121	Functional	_	
65-2	13122-13127	scans	_	
65-3	13128-13132	were	_	
65-4	13133-13141	excluded	_	
65-5	13142-13144	if	_	
65-6	13145-13149	they	_	
65-7	13150-13159	displayed	_	
65-8	13160-13161	a	_	
65-9	13162-13170	relative	_	
65-10	13171-13175	mean	_	
65-11	13176-13188	displacement	_	
65-12	13189-13190	>	_	
65-13	13190-13193	0.3	_	
65-14	13194-13196	mm	_	
65-15	13197-13199	in	_	
65-16	13200-13203	any	_	
65-17	13204-13209	plane	_	
65-18	13209-13210	.	_	

#Text=Registration of functional data to the T1-weighted anatomical slices and registration of structural images to the 2 mm Montreal Neurological Institute (MNI) standard-space template were done using FLIRT utilizing a 12-parameter affine transformation.
66-1	13211-13223	Registration	_	
66-2	13224-13226	of	_	
66-3	13227-13237	functional	_	
66-4	13238-13242	data	_	
66-5	13243-13245	to	_	
66-6	13246-13249	the	_	
66-7	13250-13252	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[37]	
66-8	13252-13253	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[37]	
66-9	13253-13261	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[37]	
66-10	13262-13272	anatomical	_	
66-11	13273-13279	slices	_	
66-12	13280-13283	and	_	
66-13	13284-13296	registration	_	
66-14	13297-13299	of	_	
66-15	13300-13310	structural	_	
66-16	13311-13317	images	_	
66-17	13318-13320	to	_	
66-18	13321-13324	the	_	
66-19	13325-13326	2	_	
66-20	13327-13329	mm	_	
66-21	13330-13338	Montreal	_	
66-22	13339-13351	Neurological	_	
66-23	13352-13361	Institute	_	
66-24	13362-13363	(	_	
66-25	13363-13366	MNI	_	
66-26	13366-13367	)	_	
66-27	13368-13382	standard-space	_	
66-28	13383-13391	template	_	
66-29	13392-13396	were	_	
66-30	13397-13401	done	_	
66-31	13402-13407	using	_	
66-32	13408-13413	FLIRT	_	
66-33	13414-13423	utilizing	_	
66-34	13424-13425	a	_	
66-35	13426-13428	12	_	
66-36	13428-13429	-	_	
66-37	13429-13438	parameter	_	
66-38	13439-13445	affine	_	
66-39	13446-13460	transformation	_	
66-40	13460-13461	.	_	

#Text=Individual time-series statistical analysis was carried out using FILM with local autocorrelation correction.
67-1	13462-13472	Individual	_	
67-2	13473-13484	time-series	_	
67-3	13485-13496	statistical	_	
67-4	13497-13505	analysis	_	
67-5	13506-13509	was	_	
67-6	13510-13517	carried	_	
67-7	13518-13521	out	_	
67-8	13522-13527	using	_	
67-9	13528-13532	FILM	_	
67-10	13533-13537	with	_	
67-11	13538-13543	local	_	
67-12	13544-13559	autocorrelation	_	
67-13	13560-13570	correction	_	
67-14	13570-13571	.	_	

#Text=A block design was utilized for both the Easy and Distress phases with the task block serving as the regressor of interest.
68-1	13572-13573	A	_	
68-2	13574-13579	block	_	
68-3	13580-13586	design	_	
68-4	13587-13590	was	_	
68-5	13591-13599	utilized	_	
68-6	13600-13603	for	_	
68-7	13604-13608	both	_	
68-8	13609-13612	the	_	
68-9	13613-13617	Easy	_	
68-10	13618-13621	and	_	
68-11	13622-13630	Distress	_	
68-12	13631-13637	phases	_	
68-13	13638-13642	with	_	
68-14	13643-13646	the	_	
68-15	13647-13651	task	_	
68-16	13652-13657	block	_	
68-17	13658-13665	serving	_	
68-18	13666-13668	as	_	
68-19	13669-13672	the	_	
68-20	13673-13682	regressor	_	
68-21	13683-13685	of	_	
68-22	13686-13694	interest	_	
68-23	13694-13695	.	_	

#Text=The regressor was constructed as a block convolved with a hemodynamic response function that was modeled using a gamma function.
69-1	13696-13699	The	_	
69-2	13700-13709	regressor	_	
69-3	13710-13713	was	_	
69-4	13714-13725	constructed	_	
69-5	13726-13728	as	_	
69-6	13729-13730	a	_	
69-7	13731-13736	block	_	
69-8	13737-13746	convolved	_	
69-9	13747-13751	with	_	
69-10	13752-13753	a	_	
69-11	13754-13765	hemodynamic	_	
69-12	13766-13774	response	_	
69-13	13775-13783	function	_	
69-14	13784-13788	that	_	
69-15	13789-13792	was	_	
69-16	13793-13800	modeled	_	
69-17	13801-13806	using	_	
69-18	13807-13808	a	_	
69-19	13809-13814	gamma	_	
69-20	13815-13823	function	_	
69-21	13823-13824	.	_	

#Text=A first-level analysis was conducted for each individual on each phase separately (Easy and Distress) using a general linear model (GLM) consisting of a contrast for each phase as [Easy – Rest] or [Distress – Rest].
70-1	13825-13826	A	_	
70-2	13827-13838	first-level	_	
70-3	13839-13847	analysis	_	
70-4	13848-13851	was	_	
70-5	13852-13861	conducted	_	
70-6	13862-13865	for	_	
70-7	13866-13870	each	_	
70-8	13871-13881	individual	_	
70-9	13882-13884	on	_	
70-10	13885-13889	each	_	
70-11	13890-13895	phase	_	
70-12	13896-13906	separately	_	
70-13	13907-13908	(	_	
70-14	13908-13912	Easy	_	
70-15	13913-13916	and	_	
70-16	13917-13925	Distress	_	
70-17	13925-13926	)	_	
70-18	13927-13932	using	_	
70-19	13933-13934	a	_	
70-20	13935-13942	general	_	
70-21	13943-13949	linear	_	
70-22	13950-13955	model	_	
70-23	13956-13957	(	_	
70-24	13957-13960	GLM	_	
70-25	13960-13961	)	_	
70-26	13962-13972	consisting	_	
70-27	13973-13975	of	_	
70-28	13976-13977	a	_	
70-29	13978-13986	contrast	_	
70-30	13987-13990	for	_	
70-31	13991-13995	each	_	
70-32	13996-14001	phase	_	
70-33	14002-14004	as	_	
70-34	14005-14006	[	_	
70-35	14006-14010	Easy	_	
70-36	14011-14012	–	_	
70-37	14013-14017	Rest	_	
70-38	14017-14018	]	_	
70-39	14019-14021	or	_	
70-40	14022-14023	[	_	
70-41	14023-14031	Distress	_	
70-42	14032-14033	–	_	
70-43	14034-14038	Rest	_	
70-44	14038-14039	]	_	
70-45	14039-14040	.	_	

#Text=The motion-correction time courses were included as covariates of no interest.
71-1	14041-14044	The	_	
71-2	14045-14062	motion-correction	_	
71-3	14063-14067	time	_	
71-4	14068-14075	courses	_	
71-5	14076-14080	were	_	
71-6	14081-14089	included	_	
71-7	14090-14092	as	_	
71-8	14093-14103	covariates	_	
71-9	14104-14106	of	_	
71-10	14107-14109	no	_	
71-11	14110-14118	interest	_	
71-12	14118-14119	.	_	

#Text=For each individual, a fixed effects GLM was conducted to obtain a subtraction contrast consisting of neural activations associated with distress [(Distress - Rest) - (Easy - Rest)].
72-1	14120-14123	For	_	
72-2	14124-14128	each	_	
72-3	14129-14139	individual	_	
72-4	14139-14140	,	_	
72-5	14141-14142	a	_	
72-6	14143-14148	fixed	_	
72-7	14149-14156	effects	_	
72-8	14157-14160	GLM	_	
72-9	14161-14164	was	_	
72-10	14165-14174	conducted	_	
72-11	14175-14177	to	_	
72-12	14178-14184	obtain	_	
72-13	14185-14186	a	_	
72-14	14187-14198	subtraction	_	
72-15	14199-14207	contrast	_	
72-16	14208-14218	consisting	_	
72-17	14219-14221	of	_	
72-18	14222-14228	neural	_	
72-19	14229-14240	activations	_	
72-20	14241-14251	associated	_	
72-21	14252-14256	with	_	
72-22	14257-14265	distress	_	
72-23	14266-14267	[	_	
72-24	14267-14268	(	_	
72-25	14268-14276	Distress	_	
72-26	14277-14278	-	_	
72-27	14279-14283	Rest	_	
72-28	14283-14284	)	_	
72-29	14285-14286	-	_	
72-30	14287-14288	(	_	
72-31	14288-14292	Easy	_	
72-32	14293-14294	-	_	
72-33	14295-14299	Rest	_	
72-34	14299-14300	)	_	
72-35	14300-14301	]	_	
72-36	14301-14302	.	_	

#Text=Regions-of-interest (ROIs) were identified a priori based on empirical and theoretical evidence for their association with response to stress paradigms and goal directed behavior.
73-1	14303-14322	Regions-of-interest	_	
73-2	14323-14324	(	_	
73-3	14324-14328	ROIs	_	
73-4	14328-14329	)	_	
73-5	14330-14334	were	_	
73-6	14335-14345	identified	_	
73-7	14346-14347	a	_	
73-8	14348-14354	priori	_	
73-9	14355-14360	based	_	
73-10	14361-14363	on	_	
73-11	14364-14373	empirical	_	
73-12	14374-14377	and	_	
73-13	14378-14389	theoretical	_	
73-14	14390-14398	evidence	_	
73-15	14399-14402	for	_	
73-16	14403-14408	their	_	
73-17	14409-14420	association	_	
73-18	14421-14425	with	_	
73-19	14426-14434	response	_	
73-20	14435-14437	to	_	
73-21	14438-14444	stress	_	
73-22	14445-14454	paradigms	_	
73-23	14455-14458	and	_	
73-24	14459-14463	goal	_	
73-25	14464-14472	directed	_	
73-26	14473-14481	behavior	_	
73-27	14481-14482	.	_	

#Text=These included the anterior cingulate cortex (ACC), amygdala, right insula, inferior frontal gyrus (IFG), middle frontal gyrus (MFG), and frontal medial cortex (FMC), and were created as lateralized masks from both the Harvard-Oxford Subcortical and Cortical probabilistic atlases set at 10% and overlaid on the MNI152 standard-space T1-weighted average structural template image.
74-1	14483-14488	These	_	
74-2	14489-14497	included	_	
74-3	14498-14501	the	_	
74-4	14502-14510	anterior	_	
74-5	14511-14520	cingulate	_	
74-6	14521-14527	cortex	_	
74-7	14528-14529	(	_	
74-8	14529-14532	ACC	_	
74-9	14532-14533	)	_	
74-10	14533-14534	,	_	
74-11	14535-14543	amygdala	_	
74-12	14543-14544	,	_	
74-13	14545-14550	right	_	
74-14	14551-14557	insula	_	
74-15	14557-14558	,	_	
74-16	14559-14567	inferior	_	
74-17	14568-14575	frontal	_	
74-18	14576-14581	gyrus	_	
74-19	14582-14583	(	_	
74-20	14583-14586	IFG	_	
74-21	14586-14587	)	_	
74-22	14587-14588	,	_	
74-23	14589-14595	middle	_	
74-24	14596-14603	frontal	_	
74-25	14604-14609	gyrus	_	
74-26	14610-14611	(	_	
74-27	14611-14614	MFG	_	
74-28	14614-14615	)	_	
74-29	14615-14616	,	_	
74-30	14617-14620	and	_	
74-31	14621-14628	frontal	_	
74-32	14629-14635	medial	_	
74-33	14636-14642	cortex	_	
74-34	14643-14644	(	_	
74-35	14644-14647	FMC	_	
74-36	14647-14648	)	_	
74-37	14648-14649	,	_	
74-38	14650-14653	and	_	
74-39	14654-14658	were	_	
74-40	14659-14666	created	_	
74-41	14667-14669	as	_	
74-42	14670-14681	lateralized	_	
74-43	14682-14687	masks	_	
74-44	14688-14692	from	_	
74-45	14693-14697	both	_	
74-46	14698-14701	the	_	
74-47	14702-14716	Harvard-Oxford	_	
74-48	14717-14728	Subcortical	_	
74-49	14729-14732	and	_	
74-50	14733-14741	Cortical	_	
74-51	14742-14755	probabilistic	_	
74-52	14756-14763	atlases	_	
74-53	14764-14767	set	_	
74-54	14768-14770	at	_	
74-55	14771-14774	10%	_	
74-56	14775-14778	and	_	
74-57	14779-14787	overlaid	_	
74-58	14788-14790	on	_	
74-59	14791-14794	the	_	
74-60	14795-14801	MNI152	_	
74-61	14802-14816	standard-space	_	
74-62	14817-14819	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
74-63	14819-14820	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
74-64	14820-14828	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
74-65	14829-14836	average	_	
74-66	14837-14847	structural	_	
74-67	14848-14856	template	_	
74-68	14857-14862	image	_	
74-69	14862-14863	.	_	

#Text=Percent signal change was extracted from the contrast of parameter estimates [(Distress - Rest) - (Easy - Rest)] from each ROI utilizing featquery and then entered in to SPSS Version 22.
75-1	14864-14871	Percent	_	
75-2	14872-14878	signal	_	
75-3	14879-14885	change	_	
75-4	14886-14889	was	_	
75-5	14890-14899	extracted	_	
75-6	14900-14904	from	_	
75-7	14905-14908	the	_	
75-8	14909-14917	contrast	_	
75-9	14918-14920	of	_	
75-10	14921-14930	parameter	_	
75-11	14931-14940	estimates	_	
75-12	14941-14942	[	_	
75-13	14942-14943	(	_	
75-14	14943-14951	Distress	_	
75-15	14952-14953	-	_	
75-16	14954-14958	Rest	_	
75-17	14958-14959	)	_	
75-18	14960-14961	-	_	
75-19	14962-14963	(	_	
75-20	14963-14967	Easy	_	
75-21	14968-14969	-	_	
75-22	14970-14974	Rest	_	
75-23	14974-14975	)	_	
75-24	14975-14976	]	_	
75-25	14977-14981	from	_	
75-26	14982-14986	each	_	
75-27	14987-14990	ROI	_	
75-28	14991-15000	utilizing	_	
75-29	15001-15010	featquery	_	
75-30	15011-15014	and	_	
75-31	15015-15019	then	_	
75-32	15020-15027	entered	_	
75-33	15028-15030	in	_	
75-34	15031-15033	to	_	
75-35	15034-15038	SPSS	_	
75-36	15039-15046	Version	_	
75-37	15047-15049	22	_	
75-38	15049-15050	.	_	

#Text=Data Analysis
#Text=Because the PASAT-M had not previously been imaged, our goal was first to validate that the task elicited distress by examining within and between group task-induced self-report, physiological, and neural responses to distress.
76-1	15051-15055	Data	_	
76-2	15056-15064	Analysis	_	
76-3	15065-15072	Because	_	
76-4	15073-15076	the	_	
76-5	15077-15084	PASAT-M	_	
76-6	15085-15088	had	_	
76-7	15089-15092	not	_	
76-8	15093-15103	previously	_	
76-9	15104-15108	been	_	
76-10	15109-15115	imaged	_	
76-11	15115-15116	,	_	
76-12	15117-15120	our	_	
76-13	15121-15125	goal	_	
76-14	15126-15129	was	_	
76-15	15130-15135	first	_	
76-16	15136-15138	to	_	
76-17	15139-15147	validate	_	
76-18	15148-15152	that	_	
76-19	15153-15156	the	_	
76-20	15157-15161	task	_	
76-21	15162-15170	elicited	_	
76-22	15171-15179	distress	_	
76-23	15180-15182	by	_	
76-24	15183-15192	examining	_	
76-25	15193-15199	within	_	
76-26	15200-15203	and	_	
76-27	15204-15211	between	_	
76-28	15212-15217	group	_	
76-29	15218-15230	task-induced	_	
76-30	15231-15242	self-report	_	
76-31	15242-15243	,	_	
76-32	15244-15257	physiological	_	
76-33	15257-15258	,	_	
76-34	15259-15262	and	_	
76-35	15263-15269	neural	_	
76-36	15270-15279	responses	_	
76-37	15280-15282	to	_	
76-38	15283-15291	distress	_	
76-39	15291-15292	.	_	

#Text=Next, we constructed within and between group whole-brain activation maps, employing the contrast of [(Distress - Rest) - (Easy - Rest)], including demeaned values of relevant covariates, using FMRIB's Local Analysis of Mixed Effects (FLAME) stage 1.
77-1	15293-15297	Next	_	
77-2	15297-15298	,	_	
77-3	15299-15301	we	_	
77-4	15302-15313	constructed	_	
77-5	15314-15320	within	_	
77-6	15321-15324	and	_	
77-7	15325-15332	between	_	
77-8	15333-15338	group	_	
77-9	15339-15350	whole-brain	_	
77-10	15351-15361	activation	_	
77-11	15362-15366	maps	_	
77-12	15366-15367	,	_	
77-13	15368-15377	employing	_	
77-14	15378-15381	the	_	
77-15	15382-15390	contrast	_	
77-16	15391-15393	of	_	
77-17	15394-15395	[	_	
77-18	15395-15396	(	_	
77-19	15396-15404	Distress	_	
77-20	15405-15406	-	_	
77-21	15407-15411	Rest	_	
77-22	15411-15412	)	_	
77-23	15413-15414	-	_	
77-24	15415-15416	(	_	
77-25	15416-15420	Easy	_	
77-26	15421-15422	-	_	
77-27	15423-15427	Rest	_	
77-28	15427-15428	)	_	
77-29	15428-15429	]	_	
77-30	15429-15430	,	_	
77-31	15431-15440	including	_	
77-32	15441-15449	demeaned	_	
77-33	15450-15456	values	_	
77-34	15457-15459	of	_	
77-35	15460-15468	relevant	_	
77-36	15469-15479	covariates	_	
77-37	15479-15480	,	_	
77-38	15481-15486	using	_	
77-39	15487-15494	FMRIB's	_	
77-40	15495-15500	Local	_	
77-41	15501-15509	Analysis	_	
77-42	15510-15512	of	_	
77-43	15513-15518	Mixed	_	
77-44	15519-15526	Effects	_	
77-45	15527-15528	(	_	
77-46	15528-15533	FLAME	_	
77-47	15533-15534	)	_	
77-48	15535-15540	stage	_	
77-49	15541-15542	1	_	
77-50	15542-15543	.	_	

#Text=Z (Gaussianised T/F) statistic images were thresholded using clusters determined by Z>3.0 and a (corrected) cluster significance threshold of p=0.05.
78-1	15544-15545	Z	_	
78-2	15546-15547	(	_	
78-3	15547-15559	Gaussianised	_	
78-4	15560-15561	T	_	
78-5	15561-15562	/	_	
78-6	15562-15563	F	_	
78-7	15563-15564	)	_	
78-8	15565-15574	statistic	_	
78-9	15575-15581	images	_	
78-10	15582-15586	were	_	
78-11	15587-15598	thresholded	_	
78-12	15599-15604	using	_	
78-13	15605-15613	clusters	_	
78-14	15614-15624	determined	_	
78-15	15625-15627	by	_	
78-16	15628-15629	Z	_	
78-17	15629-15630	>	_	
78-18	15630-15633	3.0	_	
78-19	15634-15637	and	_	
78-20	15638-15639	a	_	
78-21	15640-15641	(	_	
78-22	15641-15650	corrected	_	
78-23	15650-15651	)	_	
78-24	15652-15659	cluster	_	
78-25	15660-15672	significance	_	
78-26	15673-15682	threshold	_	
78-27	15683-15685	of	_	
78-28	15686-15687	p	_	
78-29	15687-15688	=	_	
78-30	15688-15692	0.05	_	
78-31	15692-15693	.	_	

#Text=We used ANCOVA to examine between group differences in response to distress within our a priori ROIs.
79-1	15694-15696	We	_	
79-2	15697-15701	used	_	
79-3	15702-15708	ANCOVA	_	
79-4	15709-15711	to	_	
79-5	15712-15719	examine	_	
79-6	15720-15727	between	_	
79-7	15728-15733	group	_	
79-8	15734-15745	differences	_	
79-9	15746-15748	in	_	
79-10	15749-15757	response	_	
79-11	15758-15760	to	_	
79-12	15761-15769	distress	_	
79-13	15770-15776	within	_	
79-14	15777-15780	our	_	
79-15	15781-15782	a	_	
79-16	15783-15789	priori	_	
79-17	15790-15794	ROIs	_	
79-18	15794-15795	.	_	

#Text=To determine if the effects of neural activation to distress on DT within ROIs were moderated by group, we used moderated ordinary least-squares regression analysis using the PROCESS macro in SPSS.
80-1	15796-15798	To	_	
80-2	15799-15808	determine	_	
80-3	15809-15811	if	_	
80-4	15812-15815	the	_	
80-5	15816-15823	effects	_	
80-6	15824-15826	of	_	
80-7	15827-15833	neural	_	
80-8	15834-15844	activation	_	
80-9	15845-15847	to	_	
80-10	15848-15856	distress	_	
80-11	15857-15859	on	_	
80-12	15860-15862	DT	_	
80-13	15863-15869	within	_	
80-14	15870-15874	ROIs	_	
80-15	15875-15879	were	_	
80-16	15880-15889	moderated	_	
80-17	15890-15892	by	_	
80-18	15893-15898	group	_	
80-19	15898-15899	,	_	
80-20	15900-15902	we	_	
80-21	15903-15907	used	_	
80-22	15908-15917	moderated	_	
80-23	15918-15926	ordinary	_	
80-24	15927-15940	least-squares	_	
80-25	15941-15951	regression	_	
80-26	15952-15960	analysis	_	
80-27	15961-15966	using	_	
80-28	15967-15970	the	_	
80-29	15971-15978	PROCESS	_	
80-30	15979-15984	macro	_	
80-31	15985-15987	in	_	
80-32	15988-15992	SPSS	_	
80-33	15992-15993	.	_	

#Text=We conducted a psychophysiological interaction (PPI) analysis to explore task specific changes in functional connectivity.
81-1	15994-15996	We	_	
81-2	15997-16006	conducted	_	
81-3	16007-16008	a	_	
81-4	16009-16028	psychophysiological	_	
81-5	16029-16040	interaction	_	
81-6	16041-16042	(	_	
81-7	16042-16045	PPI	_	
81-8	16045-16046	)	_	
81-9	16047-16055	analysis	_	
81-10	16056-16058	to	_	
81-11	16059-16066	explore	_	
81-12	16067-16071	task	_	
81-13	16072-16080	specific	_	
81-14	16081-16088	changes	_	
81-15	16089-16091	in	_	
81-16	16092-16102	functional	_	
81-17	16103-16115	connectivity	_	
81-18	16115-16116	.	_	

#Text=Specifically, we examined the impact of distress on the strength of time-course correlations between an empirically defined ROI with all other regions of the brain.
82-1	16117-16129	Specifically	_	
82-2	16129-16130	,	_	
82-3	16131-16133	we	_	
82-4	16134-16142	examined	_	
82-5	16143-16146	the	_	
82-6	16147-16153	impact	_	
82-7	16154-16156	of	_	
82-8	16157-16165	distress	_	
82-9	16166-16168	on	_	
82-10	16169-16172	the	_	
82-11	16173-16181	strength	_	
82-12	16182-16184	of	_	
82-13	16185-16196	time-course	_	
82-14	16197-16209	correlations	_	
82-15	16210-16217	between	_	
82-16	16218-16220	an	_	
82-17	16221-16232	empirically	_	
82-18	16233-16240	defined	_	
82-19	16241-16244	ROI	_	
82-20	16245-16249	with	_	
82-21	16250-16253	all	_	
82-22	16254-16259	other	_	
82-23	16260-16267	regions	_	
82-24	16268-16270	of	_	
82-25	16271-16274	the	_	
82-26	16275-16280	brain	_	
82-27	16280-16281	.	_	

#Text=The seed ROI was identified if (1) it was an a priori ROI, and (2) there were observed groups difference in task activation to distress [Distress-Rest]-[Easy-Rest].
83-1	16282-16285	The	_	
83-2	16286-16290	seed	_	
83-3	16291-16294	ROI	_	
83-4	16295-16298	was	_	
83-5	16299-16309	identified	_	
83-6	16310-16312	if	_	
83-7	16313-16314	(	_	
83-8	16314-16315	1	_	
83-9	16315-16316	)	_	
83-10	16317-16319	it	_	
83-11	16320-16323	was	_	
83-12	16324-16326	an	_	
83-13	16327-16328	a	_	
83-14	16329-16335	priori	_	
83-15	16336-16339	ROI	_	
83-16	16339-16340	,	_	
83-17	16341-16344	and	_	
83-18	16345-16346	(	_	
83-19	16346-16347	2	_	
83-20	16347-16348	)	_	
83-21	16349-16354	there	_	
83-22	16355-16359	were	_	
83-23	16360-16368	observed	_	
83-24	16369-16375	groups	_	
83-25	16376-16386	difference	_	
83-26	16387-16389	in	_	
83-27	16390-16394	task	_	
83-28	16395-16405	activation	_	
83-29	16406-16408	to	_	
83-30	16409-16417	distress	_	
83-31	16418-16419	[	_	
83-32	16419-16432	Distress-Rest	_	
83-33	16432-16433	]	_	
83-34	16433-16434	-	_	
83-35	16434-16435	[	_	
83-36	16435-16444	Easy-Rest	_	
83-37	16444-16445	]	_	
83-38	16445-16446	.	_	

#Text=Based on this criterion, the right MFG was chosen as the seed ROI (see Figure 3 and Table 3).
84-1	16447-16452	Based	_	
84-2	16453-16455	on	_	
84-3	16456-16460	this	_	
84-4	16461-16470	criterion	_	
84-5	16470-16471	,	_	
84-6	16472-16475	the	_	
84-7	16476-16481	right	_	
84-8	16482-16485	MFG	_	
84-9	16486-16489	was	_	
84-10	16490-16496	chosen	_	
84-11	16497-16499	as	_	
84-12	16500-16503	the	_	
84-13	16504-16508	seed	_	
84-14	16509-16512	ROI	_	
84-15	16513-16514	(	_	
84-16	16514-16517	see	_	
84-17	16518-16524	Figure	_	
84-18	16525-16526	3	_	
84-19	16527-16530	and	_	
84-20	16531-16536	Table	_	
84-21	16537-16538	3	_	
84-22	16538-16539	)	_	
84-23	16539-16540	.	_	

#Text=For each participant, the time-course of activity of the right MFG was extracted from each volume within a participant-specific mask of the seed region for both the distress and easy phases of the task.
85-1	16541-16544	For	_	
85-2	16545-16549	each	_	
85-3	16550-16561	participant	_	
85-4	16561-16562	,	_	
85-5	16563-16566	the	_	
85-6	16567-16578	time-course	_	
85-7	16579-16581	of	_	
85-8	16582-16590	activity	_	
85-9	16591-16593	of	_	
85-10	16594-16597	the	_	
85-11	16598-16603	right	_	
85-12	16604-16607	MFG	_	
85-13	16608-16611	was	_	
85-14	16612-16621	extracted	_	
85-15	16622-16626	from	_	
85-16	16627-16631	each	_	
85-17	16632-16638	volume	_	
85-18	16639-16645	within	_	
85-19	16646-16647	a	_	
85-20	16648-16668	participant-specific	_	
85-21	16669-16673	mask	_	
85-22	16674-16676	of	_	
85-23	16677-16680	the	_	
85-24	16681-16685	seed	_	
85-25	16686-16692	region	_	
85-26	16693-16696	for	_	
85-27	16697-16701	both	_	
85-28	16702-16705	the	_	
85-29	16706-16714	distress	_	
85-30	16715-16718	and	_	
85-31	16719-16723	easy	_	
85-32	16724-16730	phases	_	
85-33	16731-16733	of	_	
85-34	16734-16737	the	_	
85-35	16738-16742	task	_	
85-36	16742-16743	.	_	

#Text=First level fixed-effects GLM analyses were conducted separately for the distress and easy runs and included three regressors: psychological (i.e., [Easy – Rest] or [Distress – Rest]), physiological (i.e., time-course of activation in the seed region for each volume for [Easy – Rest] or [Distress – Rest]), and PPI (i.e., interaction of psychological and physiological regressors).
86-1	16744-16749	First	_	
86-2	16750-16755	level	_	
86-3	16756-16769	fixed-effects	_	
86-4	16770-16773	GLM	_	
86-5	16774-16782	analyses	_	
86-6	16783-16787	were	_	
86-7	16788-16797	conducted	_	
86-8	16798-16808	separately	_	
86-9	16809-16812	for	_	
86-10	16813-16816	the	_	
86-11	16817-16825	distress	_	
86-12	16826-16829	and	_	
86-13	16830-16834	easy	_	
86-14	16835-16839	runs	_	
86-15	16840-16843	and	_	
86-16	16844-16852	included	_	
86-17	16853-16858	three	_	
86-18	16859-16869	regressors	_	
86-19	16869-16870	:	_	
86-20	16871-16884	psychological	_	
86-21	16885-16886	(	_	
86-22	16886-16889	i.e	_	
86-23	16889-16890	.	_	
86-24	16890-16891	,	_	
86-25	16892-16893	[	_	
86-26	16893-16897	Easy	_	
86-27	16898-16899	–	_	
86-28	16900-16904	Rest	_	
86-29	16904-16905	]	_	
86-30	16906-16908	or	_	
86-31	16909-16910	[	_	
86-32	16910-16918	Distress	_	
86-33	16919-16920	–	_	
86-34	16921-16925	Rest	_	
86-35	16925-16926	]	_	
86-36	16926-16927	)	_	
86-37	16927-16928	,	_	
86-38	16929-16942	physiological	_	
86-39	16943-16944	(	_	
86-40	16944-16947	i.e	_	
86-41	16947-16948	.	_	
86-42	16948-16949	,	_	
86-43	16950-16961	time-course	_	
86-44	16962-16964	of	_	
86-45	16965-16975	activation	_	
86-46	16976-16978	in	_	
86-47	16979-16982	the	_	
86-48	16983-16987	seed	_	
86-49	16988-16994	region	_	
86-50	16995-16998	for	_	
86-51	16999-17003	each	_	
86-52	17004-17010	volume	_	
86-53	17011-17014	for	_	
86-54	17015-17016	[	_	
86-55	17016-17020	Easy	_	
86-56	17021-17022	–	_	
86-57	17023-17027	Rest	_	
86-58	17027-17028	]	_	
86-59	17029-17031	or	_	
86-60	17032-17033	[	_	
86-61	17033-17041	Distress	_	
86-62	17042-17043	–	_	
86-63	17044-17048	Rest	_	
86-64	17048-17049	]	_	
86-65	17049-17050	)	_	
86-66	17050-17051	,	_	
86-67	17052-17055	and	_	
86-68	17056-17059	PPI	_	
86-69	17060-17061	(	_	
86-70	17061-17064	i.e	_	
86-71	17064-17065	.	_	
86-72	17065-17066	,	_	
86-73	17067-17078	interaction	_	
86-74	17079-17081	of	_	
86-75	17082-17095	psychological	_	
86-76	17096-17099	and	_	
86-77	17100-17113	physiological	_	
86-78	17114-17124	regressors	_	
86-79	17124-17125	)	_	
86-80	17125-17126	.	_	

#Text=The PPI regressor provided the measure for brain regions whose correlation to the right MFG changed as a function of task state.
87-1	17127-17130	The	_	
87-2	17131-17134	PPI	_	
87-3	17135-17144	regressor	_	
87-4	17145-17153	provided	_	
87-5	17154-17157	the	_	
87-6	17158-17165	measure	_	
87-7	17166-17169	for	_	
87-8	17170-17175	brain	_	
87-9	17176-17183	regions	_	
87-10	17184-17189	whose	_	
87-11	17190-17201	correlation	_	
87-12	17202-17204	to	_	
87-13	17205-17208	the	_	
87-14	17209-17214	right	_	
87-15	17215-17218	MFG	_	
87-16	17219-17226	changed	_	
87-17	17227-17229	as	_	
87-18	17230-17231	a	_	
87-19	17232-17240	function	_	
87-20	17241-17243	of	_	
87-21	17244-17248	task	_	
87-22	17249-17254	state	_	
87-23	17254-17255	.	_	

#Text=A higher-level fixed effects GLM was then conducted for each individual to obtain a subtraction contrast consisting of activations in response to distress correlated with the right MFG activation (Distress PPI - Easy PPI).
88-1	17256-17257	A	_	
88-2	17258-17270	higher-level	_	
88-3	17271-17276	fixed	_	
88-4	17277-17284	effects	_	
88-5	17285-17288	GLM	_	
88-6	17289-17292	was	_	
88-7	17293-17297	then	_	
88-8	17298-17307	conducted	_	
88-9	17308-17311	for	_	
88-10	17312-17316	each	_	
88-11	17317-17327	individual	_	
88-12	17328-17330	to	_	
88-13	17331-17337	obtain	_	
88-14	17338-17339	a	_	
88-15	17340-17351	subtraction	_	
88-16	17352-17360	contrast	_	
88-17	17361-17371	consisting	_	
88-18	17372-17374	of	_	
88-19	17375-17386	activations	_	
88-20	17387-17389	in	_	
88-21	17390-17398	response	_	
88-22	17399-17401	to	_	
88-23	17402-17410	distress	_	
88-24	17411-17421	correlated	_	
88-25	17422-17426	with	_	
88-26	17427-17430	the	_	
88-27	17431-17436	right	_	
88-28	17437-17440	MFG	_	
88-29	17441-17451	activation	_	
88-30	17452-17453	(	_	
88-31	17453-17461	Distress	_	
88-32	17462-17465	PPI	_	
88-33	17466-17467	-	_	
88-34	17468-17472	Easy	_	
88-35	17473-17476	PPI	_	
88-36	17476-17477	)	_	
88-37	17477-17478	.	_	

#Text=Utilizing the (Distress PPI - Easy PPI) contrast as a DV, a voxelwise multiple regression analysis was conducted consisting of four IVs: gender, group (i.e., substance user or healthy control), distress tolerance (DT), and the Group × DT interaction term.
89-1	17479-17488	Utilizing	_	
89-2	17489-17492	the	_	
89-3	17493-17494	(	_	
89-4	17494-17502	Distress	_	
89-5	17503-17506	PPI	_	
89-6	17507-17508	-	_	
89-7	17509-17513	Easy	_	
89-8	17514-17517	PPI	_	
89-9	17517-17518	)	_	
89-10	17519-17527	contrast	_	
89-11	17528-17530	as	_	
89-12	17531-17532	a	_	
89-13	17533-17535	DV	_	
89-14	17535-17536	,	_	
89-15	17537-17538	a	_	
89-16	17539-17548	voxelwise	_	
89-17	17549-17557	multiple	_	
89-18	17558-17568	regression	_	
89-19	17569-17577	analysis	_	
89-20	17578-17581	was	_	
89-21	17582-17591	conducted	_	
89-22	17592-17602	consisting	_	
89-23	17603-17605	of	_	
89-24	17606-17610	four	_	
89-25	17611-17614	IVs	_	
89-26	17614-17615	:	_	
89-27	17616-17622	gender	_	
89-28	17622-17623	,	_	
89-29	17624-17629	group	_	
89-30	17630-17631	(	_	
89-31	17631-17634	i.e	_	
89-32	17634-17635	.	_	
89-33	17635-17636	,	_	
89-34	17637-17646	substance	_	
89-35	17647-17651	user	_	
89-36	17652-17654	or	_	
89-37	17655-17662	healthy	_	
89-38	17663-17670	control	_	
89-39	17670-17671	)	_	
89-40	17671-17672	,	_	
89-41	17673-17681	distress	_	
89-42	17682-17691	tolerance	_	
89-43	17692-17693	(	_	
89-44	17693-17695	DT	_	
89-45	17695-17696	)	_	
89-46	17696-17697	,	_	
89-47	17698-17701	and	_	
89-48	17702-17705	the	_	
89-49	17706-17711	Group	_	
89-50	17712-17713	×	_	
89-51	17714-17716	DT	_	
89-52	17717-17728	interaction	_	
89-53	17729-17733	term	_	
89-54	17733-17734	.	_	

#Text=Z (Gaussianised T/F) statistic images were thresholded using clusters determined by Z>2.6 and a (corrected) cluster significance threshold of p=0.05.
90-1	17735-17736	Z	_	
90-2	17737-17738	(	_	
90-3	17738-17750	Gaussianised	_	
90-4	17751-17752	T	_	
90-5	17752-17753	/	_	
90-6	17753-17754	F	_	
90-7	17754-17755	)	_	
90-8	17756-17765	statistic	_	
90-9	17766-17772	images	_	
90-10	17773-17777	were	_	
90-11	17778-17789	thresholded	_	
90-12	17790-17795	using	_	
90-13	17796-17804	clusters	_	
90-14	17805-17815	determined	_	
90-15	17816-17818	by	_	
90-16	17819-17820	Z	_	
90-17	17820-17821	>	_	
90-18	17821-17824	2.6	_	
90-19	17825-17828	and	_	
90-20	17829-17830	a	_	
90-21	17831-17832	(	_	
90-22	17832-17841	corrected	_	
90-23	17841-17842	)	_	
90-24	17843-17850	cluster	_	
90-25	17851-17863	significance	_	
90-26	17864-17873	threshold	_	
90-27	17874-17876	of	_	
90-28	17877-17878	p	_	
90-29	17878-17879	=	_	
90-30	17879-17883	0.05	_	
90-31	17883-17884	.	_	

#Text=RESULTS
#Text=Sample Characteristics
#Text=As indicated in Table 1, there were no group differences in age, ethnicity, or IQ.
91-1	17885-17892	RESULTS	_	
91-2	17893-17899	Sample	_	
91-3	17900-17915	Characteristics	_	
91-4	17916-17918	As	_	
91-5	17919-17928	indicated	_	
91-6	17929-17931	in	_	
91-7	17932-17937	Table	_	
91-8	17938-17939	1	_	
91-9	17939-17940	,	_	
91-10	17941-17946	there	_	
91-11	17947-17951	were	_	
91-12	17952-17954	no	_	
91-13	17955-17960	group	_	
91-14	17961-17972	differences	_	
91-15	17973-17975	in	_	
91-16	17976-17979	age	_	
91-17	17979-17980	,	_	
91-18	17981-17990	ethnicity	_	
91-19	17990-17991	,	_	
91-20	17992-17994	or	_	
91-21	17995-17997	IQ	_	
91-22	17997-17998	.	_	

#Text=There were significantly more females among the healthy controls then the substance users.
92-1	17999-18004	There	_	
92-2	18005-18009	were	_	
92-3	18010-18023	significantly	_	
92-4	18024-18028	more	_	
92-5	18029-18036	females	_	
92-6	18037-18042	among	_	
92-7	18043-18046	the	_	
92-8	18047-18054	healthy	_	
92-9	18055-18063	controls	_	
92-10	18064-18068	then	_	
92-11	18069-18072	the	_	
92-12	18073-18082	substance	_	
92-13	18083-18088	users	_	
92-14	18088-18089	.	_	

#Text=As such, gender was included as a covariate in all group analyses.
93-1	18090-18092	As	_	
93-2	18093-18097	such	_	
93-3	18097-18098	,	_	
93-4	18099-18105	gender	_	
93-5	18106-18109	was	_	
93-6	18110-18118	included	_	
93-7	18119-18121	as	_	
93-8	18122-18123	a	_	
93-9	18124-18133	covariate	_	
93-10	18134-18136	in	_	
93-11	18137-18140	all	_	
93-12	18141-18146	group	_	
93-13	18147-18155	analyses	_	
93-14	18155-18156	.	_	

#Text=Substance users reported additional use of alcohol, heroin, marijuana, ecstasy, PCP, and prescription opiates (Table S1).
94-1	18157-18166	Substance	_	
94-2	18167-18172	users	_	
94-3	18173-18181	reported	_	
94-4	18182-18192	additional	_	
94-5	18193-18196	use	_	
94-6	18197-18199	of	_	
94-7	18200-18207	alcohol	_	
94-8	18207-18208	,	_	
94-9	18209-18215	heroin	_	
94-10	18215-18216	,	_	
94-11	18217-18226	marijuana	_	
94-12	18226-18227	,	_	
94-13	18228-18235	ecstasy	_	
94-14	18235-18236	,	_	
94-15	18237-18240	PCP	_	
94-16	18240-18241	,	_	
94-17	18242-18245	and	_	
94-18	18246-18258	prescription	_	
94-19	18259-18266	opiates	_	
94-20	18267-18268	(	_	
94-21	18268-18273	Table	_	
94-22	18274-18276	S1	_	
94-23	18276-18277	)	_	
94-24	18277-18278	.	_	

#Text=Behavioral performance on the PASAT-M
#Text=Behavioral data for the PASAT-M is displayed in Table 1.
95-1	18279-18289	Behavioral	_	
95-2	18290-18301	performance	_	
95-3	18302-18304	on	_	
95-4	18305-18308	the	_	
95-5	18309-18316	PASAT-M	_	
95-6	18317-18327	Behavioral	_	
95-7	18328-18332	data	_	
95-8	18333-18336	for	_	
95-9	18337-18340	the	_	
95-10	18341-18348	PASAT-M	_	
95-11	18349-18351	is	_	
95-12	18352-18361	displayed	_	
95-13	18362-18364	in	_	
95-14	18365-18370	Table	_	
95-15	18371-18372	1	_	
95-16	18372-18373	.	_	

#Text=Raw scores are reported for DT (i.e., total persistence time), although this variable was log transformed due to positive skew and all analyses were conducted on the log transformed scores.
96-1	18374-18377	Raw	_	
96-2	18378-18384	scores	_	
96-3	18385-18388	are	_	
96-4	18389-18397	reported	_	
96-5	18398-18401	for	_	
96-6	18402-18404	DT	_	
96-7	18405-18406	(	_	
96-8	18406-18409	i.e	_	
96-9	18409-18410	.	_	
96-10	18410-18411	,	_	
96-11	18412-18417	total	_	
96-12	18418-18429	persistence	_	
96-13	18430-18434	time	_	
96-14	18434-18435	)	_	
96-15	18435-18436	,	_	
96-16	18437-18445	although	_	
96-17	18446-18450	this	_	
96-18	18451-18459	variable	_	
96-19	18460-18463	was	_	
96-20	18464-18467	log	_	
96-21	18468-18479	transformed	_	
96-22	18480-18483	due	_	
96-23	18484-18486	to	_	
96-24	18487-18495	positive	_	
96-25	18496-18500	skew	_	
96-26	18501-18504	and	_	
96-27	18505-18508	all	_	
96-28	18509-18517	analyses	_	
96-29	18518-18522	were	_	
96-30	18523-18532	conducted	_	
96-31	18533-18535	on	_	
96-32	18536-18539	the	_	
96-33	18540-18543	log	_	
96-34	18544-18555	transformed	_	
96-35	18556-18562	scores	_	
96-36	18562-18563	.	_	

#Text=Substance users demonstrated significantly lower DT then controls.
97-1	18564-18573	Substance	_	
97-2	18574-18579	users	_	
97-3	18580-18592	demonstrated	_	
97-4	18593-18606	significantly	_	
97-5	18607-18612	lower	_	
97-6	18613-18615	DT	_	
97-7	18616-18620	then	_	
97-8	18621-18629	controls	_	
97-9	18629-18630	.	_	

#Text=There were no group differences in performance or motivation.
98-1	18631-18636	There	_	
98-2	18637-18641	were	_	
98-3	18642-18644	no	_	
98-4	18645-18650	group	_	
98-5	18651-18662	differences	_	
98-6	18663-18665	in	_	
98-7	18666-18677	performance	_	
98-8	18678-18680	or	_	
98-9	18681-18691	motivation	_	
98-10	18691-18692	.	_	

#Text=Partial correlation and ANCOVA, controlling for group status, demonstrated that DT was not associated significantly with age (r=−.097, p=.53), gender [F(1,45)=0.10, p=.76], race [F(1,45)=3.13, p=.08], IQ (r=−.018, p=.91), motivation (r=−.185, p=.23), task performance (r=0.164, p=.29), or task order [F(1,45)=0.29].
99-1	18693-18700	Partial	_	
99-2	18701-18712	correlation	_	
99-3	18713-18716	and	_	
99-4	18717-18723	ANCOVA	_	
99-5	18723-18724	,	_	
99-6	18725-18736	controlling	_	
99-7	18737-18740	for	_	
99-8	18741-18746	group	_	
99-9	18747-18753	status	_	
99-10	18753-18754	,	_	
99-11	18755-18767	demonstrated	_	
99-12	18768-18772	that	_	
99-13	18773-18775	DT	_	
99-14	18776-18779	was	_	
99-15	18780-18783	not	_	
99-16	18784-18794	associated	_	
99-17	18795-18808	significantly	_	
99-18	18809-18813	with	_	
99-19	18814-18817	age	_	
99-20	18818-18819	(	_	
99-21	18819-18820	r	_	
99-22	18820-18821	=	_	
99-23	18821-18822	−	_	
99-24	18822-18826	.097	_	
99-25	18826-18827	,	_	
99-26	18828-18829	p	_	
99-27	18829-18830	=	_	
99-28	18830-18833	.53	_	
99-29	18833-18834	)	_	
99-30	18834-18835	,	_	
99-31	18836-18842	gender	_	
99-32	18843-18844	[	_	
99-33	18844-18845	F	_	
99-34	18845-18846	(	_	
99-35	18846-18850	1,45	_	
99-36	18850-18851	)	_	
99-37	18851-18852	=	_	
99-38	18852-18856	0.10	_	
99-39	18856-18857	,	_	
99-40	18858-18859	p	_	
99-41	18859-18860	=	_	
99-42	18860-18863	.76	_	
99-43	18863-18864	]	_	
99-44	18864-18865	,	_	
99-45	18866-18870	race	_	
99-46	18871-18872	[	_	
99-47	18872-18873	F	_	
99-48	18873-18874	(	_	
99-49	18874-18878	1,45	_	
99-50	18878-18879	)	_	
99-51	18879-18880	=	_	
99-52	18880-18884	3.13	_	
99-53	18884-18885	,	_	
99-54	18886-18887	p	_	
99-55	18887-18888	=	_	
99-56	18888-18891	.08	_	
99-57	18891-18892	]	_	
99-58	18892-18893	,	_	
99-59	18894-18896	IQ	_	
99-60	18897-18898	(	_	
99-61	18898-18899	r	_	
99-62	18899-18900	=	_	
99-63	18900-18901	−	_	
99-64	18901-18905	.018	_	
99-65	18905-18906	,	_	
99-66	18907-18908	p	_	
99-67	18908-18909	=	_	
99-68	18909-18912	.91	_	
99-69	18912-18913	)	_	
99-70	18913-18914	,	_	
99-71	18915-18925	motivation	_	
99-72	18926-18927	(	_	
99-73	18927-18928	r	_	
99-74	18928-18929	=	_	
99-75	18929-18930	−	_	
99-76	18930-18934	.185	_	
99-77	18934-18935	,	_	
99-78	18936-18937	p	_	
99-79	18937-18938	=	_	
99-80	18938-18941	.23	_	
99-81	18941-18942	)	_	
99-82	18942-18943	,	_	
99-83	18944-18948	task	_	
99-84	18949-18960	performance	_	
99-85	18961-18962	(	_	
99-86	18962-18963	r	_	
99-87	18963-18964	=	_	
99-88	18964-18969	0.164	_	
99-89	18969-18970	,	_	
99-90	18971-18972	p	_	
99-91	18972-18973	=	_	
99-92	18973-18976	.29	_	
99-93	18976-18977	)	_	
99-94	18977-18978	,	_	
99-95	18979-18981	or	_	
99-96	18982-18986	task	_	
99-97	18987-18992	order	_	
99-98	18993-18994	[	_	
99-99	18994-18995	F	_	
99-100	18995-18996	(	_	
99-101	18996-19000	1,45	_	
99-102	19000-19001	)	_	
99-103	19001-19002	=	_	
99-104	19002-19006	0.29	_	
99-105	19006-19007	]	_	
99-106	19007-19008	.	_	

#Text=Among substance users, DT was also not associated with the number of days without cocaine use prior to the assessment (M=3.9±6.5; r=−0.093, p=.69) or level of nicotine dependence (FTND; r=−.216, p=.21).
100-1	19009-19014	Among	_	
100-2	19015-19024	substance	_	
100-3	19025-19030	users	_	
100-4	19030-19031	,	_	
100-5	19032-19034	DT	_	
100-6	19035-19038	was	_	
100-7	19039-19043	also	_	
100-8	19044-19047	not	_	
100-9	19048-19058	associated	_	
100-10	19059-19063	with	_	
100-11	19064-19067	the	_	
100-12	19068-19074	number	_	
100-13	19075-19077	of	_	
100-14	19078-19082	days	_	
100-15	19083-19090	without	_	
100-16	19091-19098	cocaine	_	
100-17	19099-19102	use	_	
100-18	19103-19108	prior	_	
100-19	19109-19111	to	_	
100-20	19112-19115	the	_	
100-21	19116-19126	assessment	_	
100-22	19127-19128	(	_	
100-23	19128-19129	M	_	
100-24	19129-19130	=	_	
100-25	19130-19133	3.9	_	
100-26	19133-19134	±	_	
100-27	19134-19137	6.5	_	
100-28	19137-19138	;	_	
100-29	19139-19140	r	_	
100-30	19140-19141	=	_	
100-31	19141-19142	−	_	
100-32	19142-19147	0.093	_	
100-33	19147-19148	,	_	
100-34	19149-19150	p	_	
100-35	19150-19151	=	_	
100-36	19151-19154	.69	_	
100-37	19154-19155	)	_	
100-38	19156-19158	or	_	
100-39	19159-19164	level	_	
100-40	19165-19167	of	_	
100-41	19168-19176	nicotine	_	
100-42	19177-19187	dependence	_	
100-43	19188-19189	(	_	
100-44	19189-19193	FTND	_	
100-45	19193-19194	;	_	
100-46	19195-19196	r	_	
100-47	19196-19197	=	_	
100-48	19197-19198	−	_	
100-49	19198-19202	.216	_	
100-50	19202-19203	,	_	
100-51	19204-19205	p	_	
100-52	19205-19206	=	_	
100-53	19206-19209	.21	_	
100-54	19209-19210	)	_	
100-55	19210-19211	.	_	

#Text=PASAT-M Task Effects
#Text=Self-report and physiological response to the PASAT-M
#Text=Self-report and physiological responses to the PASAT-M are reported in Table 1.
101-1	19212-19219	PASAT-M	_	
101-2	19220-19224	Task	_	
101-3	19225-19232	Effects	_	
101-4	19233-19244	Self-report	_	
101-5	19245-19248	and	_	
101-6	19249-19262	physiological	_	
101-7	19263-19271	response	_	
101-8	19272-19274	to	_	
101-9	19275-19278	the	_	
101-10	19279-19286	PASAT-M	_	
101-11	19287-19298	Self-report	_	
101-12	19299-19302	and	_	
101-13	19303-19316	physiological	_	
101-14	19317-19326	responses	_	
101-15	19327-19329	to	_	
101-16	19330-19333	the	_	
101-17	19334-19341	PASAT-M	_	
101-18	19342-19345	are	_	
101-19	19346-19354	reported	_	
101-20	19355-19357	in	_	
101-21	19358-19363	Table	_	
101-22	19364-19365	1	_	
101-23	19365-19366	.	_	

#Text=Changes in self-reported distress, skin conductance response (SCR), and heart rate (HR) during the task were examined with group × time repeated measures ANCOVA, with gender as a covariate.
102-1	19367-19374	Changes	_	
102-2	19375-19377	in	_	
102-3	19378-19391	self-reported	_	
102-4	19392-19400	distress	_	
102-5	19400-19401	,	_	
102-6	19402-19406	skin	_	
102-7	19407-19418	conductance	_	
102-8	19419-19427	response	_	
102-9	19428-19429	(	_	
102-10	19429-19432	SCR	_	
102-11	19432-19433	)	_	
102-12	19433-19434	,	_	
102-13	19435-19438	and	_	
102-14	19439-19444	heart	_	
102-15	19445-19449	rate	_	
102-16	19450-19451	(	_	
102-17	19451-19453	HR	_	
102-18	19453-19454	)	_	
102-19	19455-19461	during	_	
102-20	19462-19465	the	_	
102-21	19466-19470	task	_	
102-22	19471-19475	were	_	
102-23	19476-19484	examined	_	
102-24	19485-19489	with	_	
102-25	19490-19495	group	_	
102-26	19496-19497	×	_	
102-27	19498-19502	time	_	
102-28	19503-19511	repeated	_	
102-29	19512-19520	measures	_	
102-30	19521-19527	ANCOVA	_	
102-31	19527-19528	,	_	
102-32	19529-19533	with	_	
102-33	19534-19540	gender	_	
102-34	19541-19543	as	_	
102-35	19544-19545	a	_	
102-36	19546-19555	covariate	_	
102-37	19555-19556	.	_	

#Text=There was a significant effect of time for self-report distress, SCR, and HR from pre-task through the distress phase and no significant group × time interaction effects.
103-1	19557-19562	There	_	
103-2	19563-19566	was	_	
103-3	19567-19568	a	_	
103-4	19569-19580	significant	_	
103-5	19581-19587	effect	_	
103-6	19588-19590	of	_	
103-7	19591-19595	time	_	
103-8	19596-19599	for	_	
103-9	19600-19611	self-report	_	
103-10	19612-19620	distress	_	
103-11	19620-19621	,	_	
103-12	19622-19625	SCR	_	
103-13	19625-19626	,	_	
103-14	19627-19630	and	_	
103-15	19631-19633	HR	_	
103-16	19634-19638	from	_	
103-17	19639-19647	pre-task	_	
103-18	19648-19655	through	_	
103-19	19656-19659	the	_	
103-20	19660-19668	distress	_	
103-21	19669-19674	phase	_	
103-22	19675-19678	and	_	
103-23	19679-19681	no	_	
103-24	19682-19693	significant	_	
103-25	19694-19699	group	_	
103-26	19700-19701	×	_	
103-27	19702-19706	time	_	
103-28	19707-19718	interaction	_	
103-29	19719-19726	effects	_	
103-30	19726-19727	.	_	

#Text=Taken together and by design, self-report and physiological indices indicate an increase in distress for both groups from the easy to distress phase of the task.
104-1	19728-19733	Taken	_	
104-2	19734-19742	together	_	
104-3	19743-19746	and	_	
104-4	19747-19749	by	_	
104-5	19750-19756	design	_	
104-6	19756-19757	,	_	
104-7	19758-19769	self-report	_	
104-8	19770-19773	and	_	
104-9	19774-19787	physiological	_	
104-10	19788-19795	indices	_	
104-11	19796-19804	indicate	_	
104-12	19805-19807	an	_	
104-13	19808-19816	increase	_	
104-14	19817-19819	in	_	
104-15	19820-19828	distress	_	
104-16	19829-19832	for	_	
104-17	19833-19837	both	_	
104-18	19838-19844	groups	_	
104-19	19845-19849	from	_	
104-20	19850-19853	the	_	
104-21	19854-19858	easy	_	
104-22	19859-19861	to	_	
104-23	19862-19870	distress	_	
104-24	19871-19876	phase	_	
104-25	19877-19879	of	_	
104-26	19880-19883	the	_	
104-27	19884-19888	task	_	
104-28	19888-19889	.	_	

#Text=A priori ROI activation in response to the PASAT-M
#Text=Mean percent signal change in response to distress [(Distress - Rest) - (Easy - Rest)] within a priori ROIs are displayed in Table 2 for substance users and healthy controls.
105-1	19890-19891	A	_	
105-2	19892-19898	priori	_	
105-3	19899-19902	ROI	_	
105-4	19903-19913	activation	_	
105-5	19914-19916	in	_	
105-6	19917-19925	response	_	
105-7	19926-19928	to	_	
105-8	19929-19932	the	_	
105-9	19933-19940	PASAT-M	_	
105-10	19941-19945	Mean	_	
105-11	19946-19953	percent	_	
105-12	19954-19960	signal	_	
105-13	19961-19967	change	_	
105-14	19968-19970	in	_	
105-15	19971-19979	response	_	
105-16	19980-19982	to	_	
105-17	19983-19991	distress	_	
105-18	19992-19993	[	_	
105-19	19993-19994	(	_	
105-20	19994-20002	Distress	_	
105-21	20003-20004	-	_	
105-22	20005-20009	Rest	_	
105-23	20009-20010	)	_	
105-24	20011-20012	-	_	
105-25	20013-20014	(	_	
105-26	20014-20018	Easy	_	
105-27	20019-20020	-	_	
105-28	20021-20025	Rest	_	
105-29	20025-20026	)	_	
105-30	20026-20027	]	_	
105-31	20028-20034	within	_	
105-32	20035-20036	a	_	
105-33	20037-20043	priori	_	
105-34	20044-20048	ROIs	_	
105-35	20049-20052	are	_	
105-36	20053-20062	displayed	_	
105-37	20063-20065	in	_	
105-38	20066-20071	Table	_	
105-39	20072-20073	2	_	
105-40	20074-20077	for	_	
105-41	20078-20087	substance	_	
105-42	20088-20093	users	_	
105-43	20094-20097	and	_	
105-44	20098-20105	healthy	_	
105-45	20106-20114	controls	_	
105-46	20114-20115	.	_	

#Text=Healthy controls displayed deactivation in the MFG, vmPFC, ACC, and left IFG, while showing increased activation in the right IFG, right insula and amygdala.
106-1	20116-20123	Healthy	_	
106-2	20124-20132	controls	_	
106-3	20133-20142	displayed	_	
106-4	20143-20155	deactivation	_	
106-5	20156-20158	in	_	
106-6	20159-20162	the	_	
106-7	20163-20166	MFG	_	
106-8	20166-20167	,	_	
106-9	20168-20173	vmPFC	_	
106-10	20173-20174	,	_	
106-11	20175-20178	ACC	_	
106-12	20178-20179	,	_	
106-13	20180-20183	and	_	
106-14	20184-20188	left	_	
106-15	20189-20192	IFG	_	
106-16	20192-20193	,	_	
106-17	20194-20199	while	_	
106-18	20200-20207	showing	_	
106-19	20208-20217	increased	_	
106-20	20218-20228	activation	_	
106-21	20229-20231	in	_	
106-22	20232-20235	the	_	
106-23	20236-20241	right	_	
106-24	20242-20245	IFG	_	
106-25	20245-20246	,	_	
106-26	20247-20252	right	_	
106-27	20253-20259	insula	_	
106-28	20260-20263	and	_	
106-29	20264-20272	amygdala	_	
106-30	20272-20273	.	_	

#Text=In contrast, substance users displayed deactivation across all hypothesized ROIs.
107-1	20274-20276	In	_	
107-2	20277-20285	contrast	_	
107-3	20285-20286	,	_	
107-4	20287-20296	substance	_	
107-5	20297-20302	users	_	
107-6	20303-20312	displayed	_	
107-7	20313-20325	deactivation	_	
107-8	20326-20332	across	_	
107-9	20333-20336	all	_	
107-10	20337-20349	hypothesized	_	
107-11	20350-20354	ROIs	_	
107-12	20354-20355	.	_	

#Text=An ANCOVA examined between group differences in ROI response to distress, controlling for gender.
108-1	20356-20358	An	_	
108-2	20359-20365	ANCOVA	_	
108-3	20366-20374	examined	_	
108-4	20375-20382	between	_	
108-5	20383-20388	group	_	
108-6	20389-20400	differences	_	
108-7	20401-20403	in	_	
108-8	20404-20407	ROI	_	
108-9	20408-20416	response	_	
108-10	20417-20419	to	_	
108-11	20420-20428	distress	_	
108-12	20428-20429	,	_	
108-13	20430-20441	controlling	_	
108-14	20442-20445	for	_	
108-15	20446-20452	gender	_	
108-16	20452-20453	.	_	

#Text=Compared to controls, substance users had less activity in the right and left MFG and right IFG, and trended toward greater deactivation in the left IFG.
109-1	20454-20462	Compared	_	
109-2	20463-20465	to	_	
109-3	20466-20474	controls	_	
109-4	20474-20475	,	_	
109-5	20476-20485	substance	_	
109-6	20486-20491	users	_	
109-7	20492-20495	had	_	
109-8	20496-20500	less	_	
109-9	20501-20509	activity	_	
109-10	20510-20512	in	_	
109-11	20513-20516	the	_	
109-12	20517-20522	right	_	
109-13	20523-20526	and	_	
109-14	20527-20531	left	_	
109-15	20532-20535	MFG	_	
109-16	20536-20539	and	_	
109-17	20540-20545	right	_	
109-18	20546-20549	IFG	_	
109-19	20549-20550	,	_	
109-20	20551-20554	and	_	
109-21	20555-20562	trended	_	
109-22	20563-20569	toward	_	
109-23	20570-20577	greater	_	
109-24	20578-20590	deactivation	_	
109-25	20591-20593	in	_	
109-26	20594-20597	the	_	
109-27	20598-20602	left	_	
109-28	20603-20606	IFG	_	
109-29	20606-20607	.	_	

#Text=Mean percent signal change during the baseline phase of the PASAT-M (Easy-Rest) within a priori ROIs is displayed in Table S2.
110-1	20608-20612	Mean	_	
110-2	20613-20620	percent	_	
110-3	20621-20627	signal	_	
110-4	20628-20634	change	_	
110-5	20635-20641	during	_	
110-6	20642-20645	the	_	
110-7	20646-20654	baseline	_	
110-8	20655-20660	phase	_	
110-9	20661-20663	of	_	
110-10	20664-20667	the	_	
110-11	20668-20675	PASAT-M	_	
110-12	20676-20677	(	_	
110-13	20677-20686	Easy-Rest	_	
110-14	20686-20687	)	_	
110-15	20688-20694	within	_	
110-16	20695-20696	a	_	
110-17	20697-20703	priori	_	
110-18	20704-20708	ROIs	_	
110-19	20709-20711	is	_	
110-20	20712-20721	displayed	_	
110-21	20722-20724	in	_	
110-22	20725-20730	Table	_	
110-23	20731-20733	S2	_	
110-24	20733-20734	.	_	

#Text=Substance users demonstrated greater activation in the right insula, and less deactivation in the amygdala during the Easy phase of the task compared to healthy controls.
111-1	20735-20744	Substance	_	
111-2	20745-20750	users	_	
111-3	20751-20763	demonstrated	_	
111-4	20764-20771	greater	_	
111-5	20772-20782	activation	_	
111-6	20783-20785	in	_	
111-7	20786-20789	the	_	
111-8	20790-20795	right	_	
111-9	20796-20802	insula	_	
111-10	20802-20803	,	_	
111-11	20804-20807	and	_	
111-12	20808-20812	less	_	
111-13	20813-20825	deactivation	_	
111-14	20826-20828	in	_	
111-15	20829-20832	the	_	
111-16	20833-20841	amygdala	_	
111-17	20842-20848	during	_	
111-18	20849-20852	the	_	
111-19	20853-20857	Easy	_	
111-20	20858-20863	phase	_	
111-21	20864-20866	of	_	
111-22	20867-20870	the	_	
111-23	20871-20875	task	_	
111-24	20876-20884	compared	_	
111-25	20885-20887	to	_	
111-26	20888-20895	healthy	_	
111-27	20896-20904	controls	_	
111-28	20904-20905	.	_	

#Text=Neural response to distress, group, and distress tolerance
#Text=The interactive effect of neural response to distress and group on DT was estimated with separate OLS regression models predicting DT for each ROI, with group as the moderator and gender as a covariate.
112-1	20906-20912	Neural	_	
112-2	20913-20921	response	_	
112-3	20922-20924	to	_	
112-4	20925-20933	distress	_	
112-5	20933-20934	,	_	
112-6	20935-20940	group	_	
112-7	20940-20941	,	_	
112-8	20942-20945	and	_	
112-9	20946-20954	distress	_	
112-10	20955-20964	tolerance	_	
112-11	20965-20968	The	_	
112-12	20969-20980	interactive	_	
112-13	20981-20987	effect	_	
112-14	20988-20990	of	_	
112-15	20991-20997	neural	_	
112-16	20998-21006	response	_	
112-17	21007-21009	to	_	
112-18	21010-21018	distress	_	
112-19	21019-21022	and	_	
112-20	21023-21028	group	_	
112-21	21029-21031	on	_	
112-22	21032-21034	DT	_	
112-23	21035-21038	was	_	
112-24	21039-21048	estimated	_	
112-25	21049-21053	with	_	
112-26	21054-21062	separate	_	
112-27	21063-21066	OLS	_	
112-28	21067-21077	regression	_	
112-29	21078-21084	models	_	
112-30	21085-21095	predicting	_	
112-31	21096-21098	DT	_	
112-32	21099-21102	for	_	
112-33	21103-21107	each	_	
112-34	21108-21111	ROI	_	
112-35	21111-21112	,	_	
112-36	21113-21117	with	_	
112-37	21118-21123	group	_	
112-38	21124-21126	as	_	
112-39	21127-21130	the	_	
112-40	21131-21140	moderator	_	
112-41	21141-21144	and	_	
112-42	21145-21151	gender	_	
112-43	21152-21154	as	_	
112-44	21155-21156	a	_	
112-45	21157-21166	covariate	_	
112-46	21166-21167	.	_	

#Text=The interaction term was significant for models including the right insula, ACC, right amygdala, bilateral MFG, right IFG, and right vmPFC (Table S31).
113-1	21168-21171	The	_	
113-2	21172-21183	interaction	_	
113-3	21184-21188	term	_	
113-4	21189-21192	was	_	
113-5	21193-21204	significant	_	
113-6	21205-21208	for	_	
113-7	21209-21215	models	_	
113-8	21216-21225	including	_	
113-9	21226-21229	the	_	
113-10	21230-21235	right	_	
113-11	21236-21242	insula	_	
113-12	21242-21243	,	_	
113-13	21244-21247	ACC	_	
113-14	21247-21248	,	_	
113-15	21249-21254	right	_	
113-16	21255-21263	amygdala	_	
113-17	21263-21264	,	_	
113-18	21265-21274	bilateral	_	
113-19	21275-21278	MFG	_	
113-20	21278-21279	,	_	
113-21	21280-21285	right	_	
113-22	21286-21289	IFG	_	
113-23	21289-21290	,	_	
113-24	21291-21294	and	_	
113-25	21295-21300	right	_	
113-26	21301-21306	vmPFC	_	
113-27	21307-21308	(	_	
113-28	21308-21313	Table	_	
113-29	21314-21317	S31	_	
113-30	21317-21318	)	_	
113-31	21318-21319	.	_	

#Text=To further understand the nature of this moderation, conditional effects (“simple slopes”) of each ROI on DT were estimated for each group (Table S4).
114-1	21320-21322	To	_	
114-2	21323-21330	further	_	
114-3	21331-21341	understand	_	
114-4	21342-21345	the	_	
114-5	21346-21352	nature	_	
114-6	21353-21355	of	_	
114-7	21356-21360	this	_	
114-8	21361-21371	moderation	_	
114-9	21371-21372	,	_	
114-10	21373-21384	conditional	_	
114-11	21385-21392	effects	_	
114-12	21393-21394	(	_	
114-13	21394-21395	“	_	
114-14	21395-21401	simple	_	
114-15	21402-21408	slopes	_	
114-16	21408-21409	”	_	
114-17	21409-21410	)	_	
114-18	21411-21413	of	_	
114-19	21414-21418	each	_	
114-20	21419-21422	ROI	_	
114-21	21423-21425	on	_	
114-22	21426-21428	DT	_	
114-23	21429-21433	were	_	
114-24	21434-21443	estimated	_	
114-25	21444-21447	for	_	
114-26	21448-21452	each	_	
114-27	21453-21458	group	_	
114-28	21459-21460	(	_	
114-29	21460-21465	Table	_	
114-30	21466-21468	S4	_	
114-31	21468-21469	)	_	
114-32	21469-21470	.	_	

#Text=As illustrated in Figure 2, increased activation in response to distress was positively associated with DT among substance users, but not controls within the bilateral MFG, right insula, ACC, right IFG, and right vmPFC.
115-1	21471-21473	As	_	
115-2	21474-21485	illustrated	_	
115-3	21486-21488	in	_	
115-4	21489-21495	Figure	_	
115-5	21496-21497	2	_	
115-6	21497-21498	,	_	
115-7	21499-21508	increased	_	
115-8	21509-21519	activation	_	
115-9	21520-21522	in	_	
115-10	21523-21531	response	_	
115-11	21532-21534	to	_	
115-12	21535-21543	distress	_	
115-13	21544-21547	was	_	
115-14	21548-21558	positively	_	
115-15	21559-21569	associated	_	
115-16	21570-21574	with	_	
115-17	21575-21577	DT	_	
115-18	21578-21583	among	_	
115-19	21584-21593	substance	_	
115-20	21594-21599	users	_	
115-21	21599-21600	,	_	
115-22	21601-21604	but	_	
115-23	21605-21608	not	_	
115-24	21609-21617	controls	_	
115-25	21618-21624	within	_	
115-26	21625-21628	the	_	
115-27	21629-21638	bilateral	_	
115-28	21639-21642	MFG	_	
115-29	21642-21643	,	_	
115-30	21644-21649	right	_	
115-31	21650-21656	insula	_	
115-32	21656-21657	,	_	
115-33	21658-21661	ACC	_	
115-34	21661-21662	,	_	
115-35	21663-21668	right	_	
115-36	21669-21672	IFG	_	
115-37	21672-21673	,	_	
115-38	21674-21677	and	_	
115-39	21678-21683	right	_	
115-40	21684-21689	vmPFC	_	
115-41	21689-21690	.	_	

#Text=Whole brain neural activation in response to the PASAT-M
#Text=Exploratory whole brain neural activation as a result of distress during the PASAT-M was obtained with the contrast of [(Distress - Rest) - (Easy - Rest)].
116-1	21691-21696	Whole	_	
116-2	21697-21702	brain	_	
116-3	21703-21709	neural	_	
116-4	21710-21720	activation	_	
116-5	21721-21723	in	_	
116-6	21724-21732	response	_	
116-7	21733-21735	to	_	
116-8	21736-21739	the	_	
116-9	21740-21747	PASAT-M	_	
116-10	21748-21759	Exploratory	_	
116-11	21760-21765	whole	_	
116-12	21766-21771	brain	_	
116-13	21772-21778	neural	_	
116-14	21779-21789	activation	_	
116-15	21790-21792	as	_	
116-16	21793-21794	a	_	
116-17	21795-21801	result	_	
116-18	21802-21804	of	_	
116-19	21805-21813	distress	_	
116-20	21814-21820	during	_	
116-21	21821-21824	the	_	
116-22	21825-21832	PASAT-M	_	
116-23	21833-21836	was	_	
116-24	21837-21845	obtained	_	
116-25	21846-21850	with	_	
116-26	21851-21854	the	_	
116-27	21855-21863	contrast	_	
116-28	21864-21866	of	_	
116-29	21867-21868	[	_	
116-30	21868-21869	(	_	
116-31	21869-21877	Distress	_	
116-32	21878-21879	-	_	
116-33	21880-21884	Rest	_	
116-34	21884-21885	)	_	
116-35	21886-21887	-	_	
116-36	21888-21889	(	_	
116-37	21889-21893	Easy	_	
116-38	21894-21895	-	_	
116-39	21896-21900	Rest	_	
116-40	21900-21901	)	_	
116-41	21901-21902	]	_	
116-42	21902-21903	.	_	

#Text=As displayed in Figure 3a-b and Table S5a-b, healthy controls and substance users demonstrated a robust neural response to distress in multiple areas, with substance users displaying a more robust deactivation map, although similar regions were observed across both groups.
117-1	21904-21906	As	_	
117-2	21907-21916	displayed	_	
117-3	21917-21919	in	_	
117-4	21920-21926	Figure	_	
117-5	21927-21931	3a-b	_	
117-6	21932-21935	and	_	
117-7	21936-21941	Table	_	
117-8	21942-21947	S5a-b	_	
117-9	21947-21948	,	_	
117-10	21949-21956	healthy	_	
117-11	21957-21965	controls	_	
117-12	21966-21969	and	_	
117-13	21970-21979	substance	_	
117-14	21980-21985	users	_	
117-15	21986-21998	demonstrated	_	
117-16	21999-22000	a	_	
117-17	22001-22007	robust	_	
117-18	22008-22014	neural	_	
117-19	22015-22023	response	_	
117-20	22024-22026	to	_	
117-21	22027-22035	distress	_	
117-22	22036-22038	in	_	
117-23	22039-22047	multiple	_	
117-24	22048-22053	areas	_	
117-25	22053-22054	,	_	
117-26	22055-22059	with	_	
117-27	22060-22069	substance	_	
117-28	22070-22075	users	_	
117-29	22076-22086	displaying	_	
117-30	22087-22088	a	_	
117-31	22089-22093	more	_	
117-32	22094-22100	robust	_	
117-33	22101-22113	deactivation	_	
117-34	22114-22117	map	_	
117-35	22117-22118	,	_	
117-36	22119-22127	although	_	
117-37	22128-22135	similar	_	
117-38	22136-22143	regions	_	
117-39	22144-22148	were	_	
117-40	22149-22157	observed	_	
117-41	22158-22164	across	_	
117-42	22165-22169	both	_	
117-43	22170-22176	groups	_	
117-44	22176-22177	.	_	

#Text=Regressing group onto the contrast of [(Distress - Rest) - (Easy - Rest)] resulted in significant group differences (Figure 3c & Table 3), with the substance users displaying less activity than controls in the superior frontal gyrus, lateral occipital cortex, left occipital fusiform gyrus, right MFG, juxtapositional lobule cortex, precentral gyrus, and precuneus.
118-1	22178-22188	Regressing	_	
118-2	22189-22194	group	_	
118-3	22195-22199	onto	_	
118-4	22200-22203	the	_	
118-5	22204-22212	contrast	_	
118-6	22213-22215	of	_	
118-7	22216-22217	[	_	
118-8	22217-22218	(	_	
118-9	22218-22226	Distress	_	
118-10	22227-22228	-	_	
118-11	22229-22233	Rest	_	
118-12	22233-22234	)	_	
118-13	22235-22236	-	_	
118-14	22237-22238	(	_	
118-15	22238-22242	Easy	_	
118-16	22243-22244	-	_	
118-17	22245-22249	Rest	_	
118-18	22249-22250	)	_	
118-19	22250-22251	]	_	
118-20	22252-22260	resulted	_	
118-21	22261-22263	in	_	
118-22	22264-22275	significant	_	
118-23	22276-22281	group	_	
118-24	22282-22293	differences	_	
118-25	22294-22295	(	_	
118-26	22295-22301	Figure	_	
118-27	22302-22304	3c	_	
118-28	22305-22306	&	_	
118-29	22307-22312	Table	_	
118-30	22313-22314	3	_	
118-31	22314-22315	)	_	
118-32	22315-22316	,	_	
118-33	22317-22321	with	_	
118-34	22322-22325	the	_	
118-35	22326-22335	substance	_	
118-36	22336-22341	users	_	
118-37	22342-22352	displaying	_	
118-38	22353-22357	less	_	
118-39	22358-22366	activity	_	
118-40	22367-22371	than	_	
118-41	22372-22380	controls	_	
118-42	22381-22383	in	_	
118-43	22384-22387	the	_	
118-44	22388-22396	superior	_	
118-45	22397-22404	frontal	_	
118-46	22405-22410	gyrus	_	
118-47	22410-22411	,	_	
118-48	22412-22419	lateral	_	
118-49	22420-22429	occipital	_	
118-50	22430-22436	cortex	_	
118-51	22436-22437	,	_	
118-52	22438-22442	left	_	
118-53	22443-22452	occipital	_	
118-54	22453-22461	fusiform	_	
118-55	22462-22467	gyrus	_	
118-56	22467-22468	,	_	
118-57	22469-22474	right	_	
118-58	22475-22478	MFG	_	
118-59	22478-22479	,	_	
118-60	22480-22495	juxtapositional	_	
118-61	22496-22502	lobule	_	
118-62	22503-22509	cortex	_	
118-63	22509-22510	,	_	
118-64	22511-22521	precentral	_	
118-65	22522-22527	gyrus	_	
118-66	22527-22528	,	_	
118-67	22529-22532	and	_	
118-68	22533-22542	precuneus	_	
118-69	22542-22543	.	_	

#Text=Functional connectivity and association with distress tolerance
#Text=The right MFG was chosen as a seed ROI for PPI functional connectivity analyses due to its concordance with our a priori ROIs, as well as its observed group difference in task activation to distress.
119-1	22544-22554	Functional	_	
119-2	22555-22567	connectivity	_	
119-3	22568-22571	and	_	
119-4	22572-22583	association	_	
119-5	22584-22588	with	_	
119-6	22589-22597	distress	_	
119-7	22598-22607	tolerance	_	
119-8	22608-22611	The	_	
119-9	22612-22617	right	_	
119-10	22618-22621	MFG	_	
119-11	22622-22625	was	_	
119-12	22626-22632	chosen	_	
119-13	22633-22635	as	_	
119-14	22636-22637	a	_	
119-15	22638-22642	seed	_	
119-16	22643-22646	ROI	_	
119-17	22647-22650	for	_	
119-18	22651-22654	PPI	_	
119-19	22655-22665	functional	_	
119-20	22666-22678	connectivity	_	
119-21	22679-22687	analyses	_	
119-22	22688-22691	due	_	
119-23	22692-22694	to	_	
119-24	22695-22698	its	_	
119-25	22699-22710	concordance	_	
119-26	22711-22715	with	_	
119-27	22716-22719	our	_	
119-28	22720-22721	a	_	
119-29	22722-22728	priori	_	
119-30	22729-22733	ROIs	_	
119-31	22733-22734	,	_	
119-32	22735-22737	as	_	
119-33	22738-22742	well	_	
119-34	22743-22745	as	_	
119-35	22746-22749	its	_	
119-36	22750-22758	observed	_	
119-37	22759-22764	group	_	
119-38	22765-22775	difference	_	
119-39	22776-22778	in	_	
119-40	22779-22783	task	_	
119-41	22784-22794	activation	_	
119-42	22795-22797	to	_	
119-43	22798-22806	distress	_	
119-44	22806-22807	.	_	

#Text=The right MFG PPI voxel-wise multiple regression analysis on the Group × DT interaction term revealed that PASAT-M induced distress was negatively associated with right MFG functional connectivity in two clusters, one including the right SFG and one aligned with our a priori ROIs, namely the vmPFC and subgenual ACC (vmPFC/sgACC) (Figure 4, Table S6).
120-1	22808-22811	The	_	
120-2	22812-22817	right	_	
120-3	22818-22821	MFG	_	
120-4	22822-22825	PPI	_	
120-5	22826-22836	voxel-wise	_	
120-6	22837-22845	multiple	_	
120-7	22846-22856	regression	_	
120-8	22857-22865	analysis	_	
120-9	22866-22868	on	_	
120-10	22869-22872	the	_	
120-11	22873-22878	Group	_	
120-12	22879-22880	×	_	
120-13	22881-22883	DT	_	
120-14	22884-22895	interaction	_	
120-15	22896-22900	term	_	
120-16	22901-22909	revealed	_	
120-17	22910-22914	that	_	
120-18	22915-22922	PASAT-M	_	
120-19	22923-22930	induced	_	
120-20	22931-22939	distress	_	
120-21	22940-22943	was	_	
120-22	22944-22954	negatively	_	
120-23	22955-22965	associated	_	
120-24	22966-22970	with	_	
120-25	22971-22976	right	_	
120-26	22977-22980	MFG	_	
120-27	22981-22991	functional	_	
120-28	22992-23004	connectivity	_	
120-29	23005-23007	in	_	
120-30	23008-23011	two	_	
120-31	23012-23020	clusters	_	
120-32	23020-23021	,	_	
120-33	23022-23025	one	_	
120-34	23026-23035	including	_	
120-35	23036-23039	the	_	
120-36	23040-23045	right	_	
120-37	23046-23049	SFG	_	
120-38	23050-23053	and	_	
120-39	23054-23057	one	_	
120-40	23058-23065	aligned	_	
120-41	23066-23070	with	_	
120-42	23071-23074	our	_	
120-43	23075-23076	a	_	
120-44	23077-23083	priori	_	
120-45	23084-23088	ROIs	_	
120-46	23088-23089	,	_	
120-47	23090-23096	namely	_	
120-48	23097-23100	the	_	
120-49	23101-23106	vmPFC	_	
120-50	23107-23110	and	_	
120-51	23111-23120	subgenual	_	
120-52	23121-23124	ACC	_	
120-53	23125-23126	(	_	
120-54	23126-23131	vmPFC	_	
120-55	23131-23132	/	_	
120-56	23132-23137	sgACC	_	
120-57	23137-23138	)	_	
120-58	23139-23140	(	_	
120-59	23140-23146	Figure	_	
120-60	23147-23148	4	_	
120-61	23148-23149	,	_	
120-62	23150-23155	Table	_	
120-63	23156-23158	S6	_	
120-64	23158-23159	)	_	
120-65	23159-23160	.	_	

#Text=Mean percent signal change in the vmPFC/sgACC was extracted for each participant and included in an OLS regression model predicting DT, with group as the moderator and gender as a covariate.
121-1	23161-23165	Mean	_	
121-2	23166-23173	percent	_	
121-3	23174-23180	signal	_	
121-4	23181-23187	change	_	
121-5	23188-23190	in	_	
121-6	23191-23194	the	_	
121-7	23195-23200	vmPFC	_	
121-8	23200-23201	/	_	
121-9	23201-23206	sgACC	_	
121-10	23207-23210	was	_	
121-11	23211-23220	extracted	_	
121-12	23221-23224	for	_	
121-13	23225-23229	each	_	
121-14	23230-23241	participant	_	
121-15	23242-23245	and	_	
121-16	23246-23254	included	_	
121-17	23255-23257	in	_	
121-18	23258-23260	an	_	
121-19	23261-23264	OLS	_	
121-20	23265-23275	regression	_	
121-21	23276-23281	model	_	
121-22	23282-23292	predicting	_	
121-23	23293-23295	DT	_	
121-24	23295-23296	,	_	
121-25	23297-23301	with	_	
121-26	23302-23307	group	_	
121-27	23308-23310	as	_	
121-28	23311-23314	the	_	
121-29	23315-23324	moderator	_	
121-30	23325-23328	and	_	
121-31	23329-23335	gender	_	
121-32	23336-23338	as	_	
121-33	23339-23340	a	_	
121-34	23341-23350	covariate	_	
121-35	23350-23351	.	_	

#Text=The interaction term was significant [β =1.349, SE=0.424, 95% CI: 0.488, 2.211, p<.01] (Table S7).
122-1	23352-23355	The	_	
122-2	23356-23367	interaction	_	
122-3	23368-23372	term	_	
122-4	23373-23376	was	_	
122-5	23377-23388	significant	_	
122-6	23389-23390	[	_	
122-7	23390-23391	β	_	
122-8	23392-23393	=	_	
122-9	23393-23398	1.349	_	
122-10	23398-23399	,	_	
122-11	23400-23402	SE	_	
122-12	23402-23403	=	_	
122-13	23403-23408	0.424	_	
122-14	23408-23409	,	_	
122-15	23410-23413	95%	_	
122-16	23414-23416	CI	_	
122-17	23416-23417	:	_	
122-18	23418-23423	0.488	_	
122-19	23423-23424	,	_	
122-20	23425-23430	2.211	_	
122-21	23430-23431	,	_	
122-22	23432-23433	p	_	
122-23	23433-23434	<	_	
122-24	23434-23437	.01	_	
122-25	23437-23438	]	_	
122-26	23439-23440	(	_	
122-27	23440-23445	Table	_	
122-28	23446-23448	S7	_	
122-29	23448-23449	)	_	
122-30	23449-23450	.	_	

#Text=Conditional effects of the rMFG-vmPFC/sgACC connectivity strength on DT were estimated for each group using OLS regression.
123-1	23451-23462	Conditional	_	
123-2	23463-23470	effects	_	
123-3	23471-23473	of	_	
123-4	23474-23477	the	_	
123-5	23478-23488	rMFG-vmPFC	_	
123-6	23488-23489	/	_	
123-7	23489-23494	sgACC	_	
123-8	23495-23507	connectivity	_	
123-9	23508-23516	strength	_	
123-10	23517-23519	on	_	
123-11	23520-23522	DT	_	
123-12	23523-23527	were	_	
123-13	23528-23537	estimated	_	
123-14	23538-23541	for	_	
123-15	23542-23546	each	_	
123-16	23547-23552	group	_	
123-17	23553-23558	using	_	
123-18	23559-23562	OLS	_	
123-19	23563-23573	regression	_	
123-20	23573-23574	.	_	

#Text=As illustrated in Figure 5, increased right MFG-vmPFC/sgACC connectivity in response to distress was associated with greater DT among substance users [β=1.065, SE=0.250, 95% CI: 0.558, 1.572, p<.001], but not controls [β =−0.284, SE=0.346, 95% CI: −0.987, 0.419, p=.417].
124-1	23575-23577	As	_	
124-2	23578-23589	illustrated	_	
124-3	23590-23592	in	_	
124-4	23593-23599	Figure	_	
124-5	23600-23601	5	_	
124-6	23601-23602	,	_	
124-7	23603-23612	increased	_	
124-8	23613-23618	right	_	
124-9	23619-23628	MFG-vmPFC	_	
124-10	23628-23629	/	_	
124-11	23629-23634	sgACC	_	
124-12	23635-23647	connectivity	_	
124-13	23648-23650	in	_	
124-14	23651-23659	response	_	
124-15	23660-23662	to	_	
124-16	23663-23671	distress	_	
124-17	23672-23675	was	_	
124-18	23676-23686	associated	_	
124-19	23687-23691	with	_	
124-20	23692-23699	greater	_	
124-21	23700-23702	DT	_	
124-22	23703-23708	among	_	
124-23	23709-23718	substance	_	
124-24	23719-23724	users	_	
124-25	23725-23726	[	_	
124-26	23726-23727	β	_	
124-27	23727-23728	=	_	
124-28	23728-23733	1.065	_	
124-29	23733-23734	,	_	
124-30	23735-23737	SE	_	
124-31	23737-23738	=	_	
124-32	23738-23743	0.250	_	
124-33	23743-23744	,	_	
124-34	23745-23748	95%	_	
124-35	23749-23751	CI	_	
124-36	23751-23752	:	_	
124-37	23753-23758	0.558	_	
124-38	23758-23759	,	_	
124-39	23760-23765	1.572	_	
124-40	23765-23766	,	_	
124-41	23767-23768	p	_	
124-42	23768-23769	<	_	
124-43	23769-23773	.001	_	
124-44	23773-23774	]	_	
124-45	23774-23775	,	_	
124-46	23776-23779	but	_	
124-47	23780-23783	not	_	
124-48	23784-23792	controls	_	
124-49	23793-23794	[	_	
124-50	23794-23795	β	_	
124-51	23796-23797	=	_	
124-52	23797-23798	−	_	
124-53	23798-23803	0.284	_	
124-54	23803-23804	,	_	
124-55	23805-23807	SE	_	
124-56	23807-23808	=	_	
124-57	23808-23813	0.346	_	
124-58	23813-23814	,	_	
124-59	23815-23818	95%	_	
124-60	23819-23821	CI	_	
124-61	23821-23822	:	_	
124-62	23823-23824	−	_	
124-63	23824-23829	0.987	_	
124-64	23829-23830	,	_	
124-65	23831-23836	0.419	_	
124-66	23836-23837	,	_	
124-67	23838-23839	p	_	
124-68	23839-23840	=	_	
124-69	23840-23844	.417	_	
124-70	23844-23845	]	_	
124-71	23845-23846	.	_	

#Text=DISCUSSION
#Text=In the current study, we modified a computerized distress tolerance task for use in fMRI in order to examine the neural correlates of distress tolerance among and between a healthy control and regular substance using sample.
125-1	23847-23857	DISCUSSION	_	
125-2	23858-23860	In	_	
125-3	23861-23864	the	_	
125-4	23865-23872	current	_	
125-5	23873-23878	study	_	
125-6	23878-23879	,	_	
125-7	23880-23882	we	_	
125-8	23883-23891	modified	_	
125-9	23892-23893	a	_	
125-10	23894-23906	computerized	_	
125-11	23907-23915	distress	_	
125-12	23916-23925	tolerance	_	
125-13	23926-23930	task	_	
125-14	23931-23934	for	_	
125-15	23935-23938	use	_	
125-16	23939-23941	in	_	
125-17	23942-23946	fMRI	_	
125-18	23947-23949	in	_	
125-19	23950-23955	order	_	
125-20	23956-23958	to	_	
125-21	23959-23966	examine	_	
125-22	23967-23970	the	_	
125-23	23971-23977	neural	_	
125-24	23978-23988	correlates	_	
125-25	23989-23991	of	_	
125-26	23992-24000	distress	_	
125-27	24001-24010	tolerance	_	
125-28	24011-24016	among	_	
125-29	24017-24020	and	_	
125-30	24021-24028	between	_	
125-31	24029-24030	a	_	
125-32	24031-24038	healthy	_	
125-33	24039-24046	control	_	
125-34	24047-24050	and	_	
125-35	24051-24058	regular	_	
125-36	24059-24068	substance	_	
125-37	24069-24074	using	_	
125-38	24075-24081	sample	_	
125-39	24081-24082	.	_	

#Text=The PASAT-M differentiated healthy controls from substance users on levels of distress tolerance, with substance users evidencing significantly lower distress tolerance, which is in line with previous research.
126-1	24083-24086	The	_	
126-2	24087-24094	PASAT-M	_	
126-3	24095-24109	differentiated	_	
126-4	24110-24117	healthy	_	
126-5	24118-24126	controls	_	
126-6	24127-24131	from	_	
126-7	24132-24141	substance	_	
126-8	24142-24147	users	_	
126-9	24148-24150	on	_	
126-10	24151-24157	levels	_	
126-11	24158-24160	of	_	
126-12	24161-24169	distress	_	
126-13	24170-24179	tolerance	_	
126-14	24179-24180	,	_	
126-15	24181-24185	with	_	
126-16	24186-24195	substance	_	
126-17	24196-24201	users	_	
126-18	24202-24212	evidencing	_	
126-19	24213-24226	significantly	_	
126-20	24227-24232	lower	_	
126-21	24233-24241	distress	_	
126-22	24242-24251	tolerance	_	
126-23	24251-24252	,	_	
126-24	24253-24258	which	_	
126-25	24259-24261	is	_	
126-26	24262-24264	in	_	
126-27	24265-24269	line	_	
126-28	24270-24274	with	_	
126-29	24275-24283	previous	_	
126-30	24284-24292	research	_	
126-31	24292-24293	.	_	

#Text=As predicted, among substance users, higher distress tolerance during the task was associated with increased neural activation in the right insula, ACC, bilateral MFG, right IFG, and right vmPFC, as well as increased functional connectivity during distress between the right MFG and a vmPFC/sgACC cluster.
127-1	24294-24296	As	_	
127-2	24297-24306	predicted	_	
127-3	24306-24307	,	_	
127-4	24308-24313	among	_	
127-5	24314-24323	substance	_	
127-6	24324-24329	users	_	
127-7	24329-24330	,	_	
127-8	24331-24337	higher	_	
127-9	24338-24346	distress	_	
127-10	24347-24356	tolerance	_	
127-11	24357-24363	during	_	
127-12	24364-24367	the	_	
127-13	24368-24372	task	_	
127-14	24373-24376	was	_	
127-15	24377-24387	associated	_	
127-16	24388-24392	with	_	
127-17	24393-24402	increased	_	
127-18	24403-24409	neural	_	
127-19	24410-24420	activation	_	
127-20	24421-24423	in	_	
127-21	24424-24427	the	_	
127-22	24428-24433	right	_	
127-23	24434-24440	insula	_	
127-24	24440-24441	,	_	
127-25	24442-24445	ACC	_	
127-26	24445-24446	,	_	
127-27	24447-24456	bilateral	_	
127-28	24457-24460	MFG	_	
127-29	24460-24461	,	_	
127-30	24462-24467	right	_	
127-31	24468-24471	IFG	_	
127-32	24471-24472	,	_	
127-33	24473-24476	and	_	
127-34	24477-24482	right	_	
127-35	24483-24488	vmPFC	_	
127-36	24488-24489	,	_	
127-37	24490-24492	as	_	
127-38	24493-24497	well	_	
127-39	24498-24500	as	_	
127-40	24501-24510	increased	_	
127-41	24511-24521	functional	_	
127-42	24522-24534	connectivity	_	
127-43	24535-24541	during	_	
127-44	24542-24550	distress	_	
127-45	24551-24558	between	_	
127-46	24559-24562	the	_	
127-47	24563-24568	right	_	
127-48	24569-24572	MFG	_	
127-49	24573-24576	and	_	
127-50	24577-24578	a	_	
127-51	24579-24584	vmPFC	_	
127-52	24584-24585	/	_	
127-53	24585-24590	sgACC	_	
127-54	24591-24598	cluster	_	
127-55	24598-24599	.	_	

#Text=A ceiling effect for distress tolerance was observed among healthy controls, limiting the interpretation of between group differences in the relation between neural response to the task and distress tolerance.
128-1	24600-24601	A	_	
128-2	24602-24609	ceiling	_	
128-3	24610-24616	effect	_	
128-4	24617-24620	for	_	
128-5	24621-24629	distress	_	
128-6	24630-24639	tolerance	_	
128-7	24640-24643	was	_	
128-8	24644-24652	observed	_	
128-9	24653-24658	among	_	
128-10	24659-24666	healthy	_	
128-11	24667-24675	controls	_	
128-12	24675-24676	,	_	
128-13	24677-24685	limiting	_	
128-14	24686-24689	the	_	
128-15	24690-24704	interpretation	_	
128-16	24705-24707	of	_	
128-17	24708-24715	between	_	
128-18	24716-24721	group	_	
128-19	24722-24733	differences	_	
128-20	24734-24736	in	_	
128-21	24737-24740	the	_	
128-22	24741-24749	relation	_	
128-23	24750-24757	between	_	
128-24	24758-24764	neural	_	
128-25	24765-24773	response	_	
128-26	24774-24776	to	_	
128-27	24777-24780	the	_	
128-28	24781-24785	task	_	
128-29	24786-24789	and	_	
128-30	24790-24798	distress	_	
128-31	24799-24808	tolerance	_	
128-32	24808-24809	.	_	

#Text=PASAT-M as a measure of distress tolerance
#Text=As designed, the modified distress tolerance task elicited increases in self-report and physiological indices of distress in both groups, and engaged brain regions consistent with tasks designed to elicit distress among either substance users or healthy control samples.
129-1	24810-24817	PASAT-M	_	
129-2	24818-24820	as	_	
129-3	24821-24822	a	_	
129-4	24823-24830	measure	_	
129-5	24831-24833	of	_	
129-6	24834-24842	distress	_	
129-7	24843-24852	tolerance	_	
129-8	24853-24855	As	_	
129-9	24856-24864	designed	_	
129-10	24864-24865	,	_	
129-11	24866-24869	the	_	
129-12	24870-24878	modified	_	
129-13	24879-24887	distress	_	
129-14	24888-24897	tolerance	_	
129-15	24898-24902	task	_	
129-16	24903-24911	elicited	_	
129-17	24912-24921	increases	_	
129-18	24922-24924	in	_	
129-19	24925-24936	self-report	_	
129-20	24937-24940	and	_	
129-21	24941-24954	physiological	_	
129-22	24955-24962	indices	_	
129-23	24963-24965	of	_	
129-24	24966-24974	distress	_	
129-25	24975-24977	in	_	
129-26	24978-24982	both	_	
129-27	24983-24989	groups	_	
129-28	24989-24990	,	_	
129-29	24991-24994	and	_	
129-30	24995-25002	engaged	_	
129-31	25003-25008	brain	_	
129-32	25009-25016	regions	_	
129-33	25017-25027	consistent	_	
129-34	25028-25032	with	_	
129-35	25033-25038	tasks	_	
129-36	25039-25047	designed	_	
129-37	25048-25050	to	_	
129-38	25051-25057	elicit	_	
129-39	25058-25066	distress	_	
129-40	25067-25072	among	_	
129-41	25073-25079	either	_	
129-42	25080-25089	substance	_	
129-43	25090-25095	users	_	
129-44	25096-25098	or	_	
129-45	25099-25106	healthy	_	
129-46	25107-25114	control	_	
129-47	25115-25122	samples	_	
129-48	25122-25123	.	_	

#Text=All participants demonstrated increased activation in motor planning and execution substrates (left precentral gyrus), as well as deactivation in areas associated with response inhibition and self-awareness (inferior frontal gyrus), working memory and emotion processing (middle frontal gyrus), recognition memory (precuneus), and reward anticipation (caudate).
130-1	25124-25127	All	_	
130-2	25128-25140	participants	_	
130-3	25141-25153	demonstrated	_	
130-4	25154-25163	increased	_	
130-5	25164-25174	activation	_	
130-6	25175-25177	in	_	
130-7	25178-25183	motor	_	
130-8	25184-25192	planning	_	
130-9	25193-25196	and	_	
130-10	25197-25206	execution	_	
130-11	25207-25217	substrates	_	
130-12	25218-25219	(	_	
130-13	25219-25223	left	_	
130-14	25224-25234	precentral	_	
130-15	25235-25240	gyrus	_	
130-16	25240-25241	)	_	
130-17	25241-25242	,	_	
130-18	25243-25245	as	_	
130-19	25246-25250	well	_	
130-20	25251-25253	as	_	
130-21	25254-25266	deactivation	_	
130-22	25267-25269	in	_	
130-23	25270-25275	areas	_	
130-24	25276-25286	associated	_	
130-25	25287-25291	with	_	
130-26	25292-25300	response	_	
130-27	25301-25311	inhibition	_	
130-28	25312-25315	and	_	
130-29	25316-25330	self-awareness	_	
130-30	25331-25332	(	_	
130-31	25332-25340	inferior	_	
130-32	25341-25348	frontal	_	
130-33	25349-25354	gyrus	_	
130-34	25354-25355	)	_	
130-35	25355-25356	,	_	
130-36	25357-25364	working	_	
130-37	25365-25371	memory	_	
130-38	25372-25375	and	_	
130-39	25376-25383	emotion	_	
130-40	25384-25394	processing	_	
130-41	25395-25396	(	_	
130-42	25396-25402	middle	_	
130-43	25403-25410	frontal	_	
130-44	25411-25416	gyrus	_	
130-45	25416-25417	)	_	
130-46	25417-25418	,	_	
130-47	25419-25430	recognition	_	
130-48	25431-25437	memory	_	
130-49	25438-25439	(	_	
130-50	25439-25448	precuneus	_	
130-51	25448-25449	)	_	
130-52	25449-25450	,	_	
130-53	25451-25454	and	_	
130-54	25455-25461	reward	_	
130-55	25462-25474	anticipation	_	
130-56	25475-25476	(	_	
130-57	25476-25483	caudate	_	
130-58	25483-25484	)	_	
130-59	25484-25485	.	_	

#Text=This is in line with task demands, as the increased speed of number presentations and forced failure would be expected to accompany the increased frequency of motor responding with the joystick, as well as decreased anticipation of reward.
131-1	25486-25490	This	_	
131-2	25491-25493	is	_	
131-3	25494-25496	in	_	
131-4	25497-25501	line	_	
131-5	25502-25506	with	_	
131-6	25507-25511	task	_	
131-7	25512-25519	demands	_	
131-8	25519-25520	,	_	
131-9	25521-25523	as	_	
131-10	25524-25527	the	_	
131-11	25528-25537	increased	_	
131-12	25538-25543	speed	_	
131-13	25544-25546	of	_	
131-14	25547-25553	number	_	
131-15	25554-25567	presentations	_	
131-16	25568-25571	and	_	
131-17	25572-25578	forced	_	
131-18	25579-25586	failure	_	
131-19	25587-25592	would	_	
131-20	25593-25595	be	_	
131-21	25596-25604	expected	_	
131-22	25605-25607	to	_	
131-23	25608-25617	accompany	_	
131-24	25618-25621	the	_	
131-25	25622-25631	increased	_	
131-26	25632-25641	frequency	_	
131-27	25642-25644	of	_	
131-28	25645-25650	motor	_	
131-29	25651-25661	responding	_	
131-30	25662-25666	with	_	
131-31	25667-25670	the	_	
131-32	25671-25679	joystick	_	
131-33	25679-25680	,	_	
131-34	25681-25683	as	_	
131-35	25684-25688	well	_	
131-36	25689-25691	as	_	
131-37	25692-25701	decreased	_	
131-38	25702-25714	anticipation	_	
131-39	25715-25717	of	_	
131-40	25718-25724	reward	_	
131-41	25724-25725	.	_	

#Text=Critically, substance users demonstrated greater deactivations than controls in regions associated with response inhibition and action monitoring (juxtapositional lobule cortex), attentional reorientation (middle frontal gyrus), and recognition memory (precuneus).
132-1	25726-25736	Critically	_	
132-2	25736-25737	,	_	
132-3	25738-25747	substance	_	
132-4	25748-25753	users	_	
132-5	25754-25766	demonstrated	_	
132-6	25767-25774	greater	_	
132-7	25775-25788	deactivations	_	
132-8	25789-25793	than	_	
132-9	25794-25802	controls	_	
132-10	25803-25805	in	_	
132-11	25806-25813	regions	_	
132-12	25814-25824	associated	_	
132-13	25825-25829	with	_	
132-14	25830-25838	response	_	
132-15	25839-25849	inhibition	_	
132-16	25850-25853	and	_	
132-17	25854-25860	action	_	
132-18	25861-25871	monitoring	_	
132-19	25872-25873	(	_	
132-20	25873-25888	juxtapositional	_	
132-21	25889-25895	lobule	_	
132-22	25896-25902	cortex	_	
132-23	25902-25903	)	_	
132-24	25903-25904	,	_	
132-25	25905-25916	attentional	_	
132-26	25917-25930	reorientation	_	
132-27	25931-25932	(	_	
132-28	25932-25938	middle	_	
132-29	25939-25946	frontal	_	
132-30	25947-25952	gyrus	_	
132-31	25952-25953	)	_	
132-32	25953-25954	,	_	
132-33	25955-25958	and	_	
132-34	25959-25970	recognition	_	
132-35	25971-25977	memory	_	
132-36	25978-25979	(	_	
132-37	25979-25988	precuneus	_	
132-38	25988-25989	)	_	
132-39	25989-25990	.	_	

#Text=This may reflect greater challenges for substance users in activating neural regions responsible for detecting and responding to task demands in an ongoing manner while experiencing affective distress.
133-1	25991-25995	This	_	
133-2	25996-25999	may	_	
133-3	26000-26007	reflect	_	
133-4	26008-26015	greater	_	
133-5	26016-26026	challenges	_	
133-6	26027-26030	for	_	
133-7	26031-26040	substance	_	
133-8	26041-26046	users	_	
133-9	26047-26049	in	_	
133-10	26050-26060	activating	_	
133-11	26061-26067	neural	_	
133-12	26068-26075	regions	_	
133-13	26076-26087	responsible	_	
133-14	26088-26091	for	_	
133-15	26092-26101	detecting	_	
133-16	26102-26105	and	_	
133-17	26106-26116	responding	_	
133-18	26117-26119	to	_	
133-19	26120-26124	task	_	
133-20	26125-26132	demands	_	
133-21	26133-26135	in	_	
133-22	26136-26138	an	_	
133-23	26139-26146	ongoing	_	
133-24	26147-26153	manner	_	
133-25	26154-26159	while	_	
133-26	26160-26172	experiencing	_	
133-27	26173-26182	affective	_	
133-28	26183-26191	distress	_	
133-29	26191-26192	.	_	

#Text=Support that these differences are not due to differences in task engagement is reflected in similar group responses of self-reported motivation, task behavioral data, and activation patterns in regions associated with motor attention, representation, and execution.
134-1	26193-26200	Support	_	
134-2	26201-26205	that	_	
134-3	26206-26211	these	_	
134-4	26212-26223	differences	_	
134-5	26224-26227	are	_	
134-6	26228-26231	not	_	
134-7	26232-26235	due	_	
134-8	26236-26238	to	_	
134-9	26239-26250	differences	_	
134-10	26251-26253	in	_	
134-11	26254-26258	task	_	
134-12	26259-26269	engagement	_	
134-13	26270-26272	is	_	
134-14	26273-26282	reflected	_	
134-15	26283-26285	in	_	
134-16	26286-26293	similar	_	
134-17	26294-26299	group	_	
134-18	26300-26309	responses	_	
134-19	26310-26312	of	_	
134-20	26313-26326	self-reported	_	
134-21	26327-26337	motivation	_	
134-22	26337-26338	,	_	
134-23	26339-26343	task	_	
134-24	26344-26354	behavioral	_	
134-25	26355-26359	data	_	
134-26	26359-26360	,	_	
134-27	26361-26364	and	_	
134-28	26365-26375	activation	_	
134-29	26376-26384	patterns	_	
134-30	26385-26387	in	_	
134-31	26388-26395	regions	_	
134-32	26396-26406	associated	_	
134-33	26407-26411	with	_	
134-34	26412-26417	motor	_	
134-35	26418-26427	attention	_	
134-36	26427-26428	,	_	
134-37	26429-26443	representation	_	
134-38	26443-26444	,	_	
134-39	26445-26448	and	_	
134-40	26449-26458	execution	_	
134-41	26458-26459	.	_	

#Text=Neural indices of distress tolerance
#Text=The PASAT-M differentiated healthy controls from substance users on levels of distress tolerance, with substance users evidencing significantly lower distress tolerance, which is in line with previous research.
135-1	26460-26466	Neural	_	
135-2	26467-26474	indices	_	
135-3	26475-26477	of	_	
135-4	26478-26486	distress	_	
135-5	26487-26496	tolerance	_	
135-6	26497-26500	The	_	
135-7	26501-26508	PASAT-M	_	
135-8	26509-26523	differentiated	_	
135-9	26524-26531	healthy	_	
135-10	26532-26540	controls	_	
135-11	26541-26545	from	_	
135-12	26546-26555	substance	_	
135-13	26556-26561	users	_	
135-14	26562-26564	on	_	
135-15	26565-26571	levels	_	
135-16	26572-26574	of	_	
135-17	26575-26583	distress	_	
135-18	26584-26593	tolerance	_	
135-19	26593-26594	,	_	
135-20	26595-26599	with	_	
135-21	26600-26609	substance	_	
135-22	26610-26615	users	_	
135-23	26616-26626	evidencing	_	
135-24	26627-26640	significantly	_	
135-25	26641-26646	lower	_	
135-26	26647-26655	distress	_	
135-27	26656-26665	tolerance	_	
135-28	26665-26666	,	_	
135-29	26667-26672	which	_	
135-30	26673-26675	is	_	
135-31	26676-26678	in	_	
135-32	26679-26683	line	_	
135-33	26684-26688	with	_	
135-34	26689-26697	previous	_	
135-35	26698-26706	research	_	
135-36	26706-26707	.	_	

#Text=However, only among substance users did we observe regions of interest associated with distress tolerance, namely the right insula, ACC, right IFG, bilateral MFG, and right vmPFC.
136-1	26708-26715	However	_	
136-2	26715-26716	,	_	
136-3	26717-26721	only	_	
136-4	26722-26727	among	_	
136-5	26728-26737	substance	_	
136-6	26738-26743	users	_	
136-7	26744-26747	did	_	
136-8	26748-26750	we	_	
136-9	26751-26758	observe	_	
136-10	26759-26766	regions	_	
136-11	26767-26769	of	_	
136-12	26770-26778	interest	_	
136-13	26779-26789	associated	_	
136-14	26790-26794	with	_	
136-15	26795-26803	distress	_	
136-16	26804-26813	tolerance	_	
136-17	26813-26814	,	_	
136-18	26815-26821	namely	_	
136-19	26822-26825	the	_	
136-20	26826-26831	right	_	
136-21	26832-26838	insula	_	
136-22	26838-26839	,	_	
136-23	26840-26843	ACC	_	
136-24	26843-26844	,	_	
136-25	26845-26850	right	_	
136-26	26851-26854	IFG	_	
136-27	26854-26855	,	_	
136-28	26856-26865	bilateral	_	
136-29	26866-26869	MFG	_	
136-30	26869-26870	,	_	
136-31	26871-26874	and	_	
136-32	26875-26880	right	_	
136-33	26881-26886	vmPFC	_	
136-34	26886-26887	.	_	

#Text=The positive association between distress tolerance and activation in the prefrontal cortex and ACC is in line with evidence indicating that emotion regulation processes depend upon these regions initiating inhibitory control, working memory, and goal directed behavior.
137-1	26888-26891	The	_	
137-2	26892-26900	positive	_	
137-3	26901-26912	association	_	
137-4	26913-26920	between	_	
137-5	26921-26929	distress	_	
137-6	26930-26939	tolerance	_	
137-7	26940-26943	and	_	
137-8	26944-26954	activation	_	
137-9	26955-26957	in	_	
137-10	26958-26961	the	_	
137-11	26962-26972	prefrontal	_	
137-12	26973-26979	cortex	_	
137-13	26980-26983	and	_	
137-14	26984-26987	ACC	_	
137-15	26988-26990	is	_	
137-16	26991-26993	in	_	
137-17	26994-26998	line	_	
137-18	26999-27003	with	_	
137-19	27004-27012	evidence	_	
137-20	27013-27023	indicating	_	
137-21	27024-27028	that	_	
137-22	27029-27036	emotion	_	
137-23	27037-27047	regulation	_	
137-24	27048-27057	processes	_	
137-25	27058-27064	depend	_	
137-26	27065-27069	upon	_	
137-27	27070-27075	these	_	
137-28	27076-27083	regions	_	
137-29	27084-27094	initiating	_	
137-30	27095-27105	inhibitory	_	
137-31	27106-27113	control	_	
137-32	27113-27114	,	_	
137-33	27115-27122	working	_	
137-34	27123-27129	memory	_	
137-35	27129-27130	,	_	
137-36	27131-27134	and	_	
137-37	27135-27139	goal	_	
137-38	27140-27148	directed	_	
137-39	27149-27157	behavior	_	
137-40	27157-27158	.	_	

#Text=As part of the salience network (SN), the right anterior insula plays a critical role in detecting and evaluating stimuli in order to engage task oriented responding, suggesting that reduced activation in the right insula may lead to less recruitment and engagement of prefrontal regions primarily responsible for cognitive control processes.
138-1	27159-27161	As	_	
138-2	27162-27166	part	_	
138-3	27167-27169	of	_	
138-4	27170-27173	the	_	
138-5	27174-27182	salience	_	
138-6	27183-27190	network	_	
138-7	27191-27192	(	_	
138-8	27192-27194	SN	_	
138-9	27194-27195	)	_	
138-10	27195-27196	,	_	
138-11	27197-27200	the	_	
138-12	27201-27206	right	_	
138-13	27207-27215	anterior	_	
138-14	27216-27222	insula	_	
138-15	27223-27228	plays	_	
138-16	27229-27230	a	_	
138-17	27231-27239	critical	_	
138-18	27240-27244	role	_	
138-19	27245-27247	in	_	
138-20	27248-27257	detecting	_	
138-21	27258-27261	and	_	
138-22	27262-27272	evaluating	_	
138-23	27273-27280	stimuli	_	
138-24	27281-27283	in	_	
138-25	27284-27289	order	_	
138-26	27290-27292	to	_	
138-27	27293-27299	engage	_	
138-28	27300-27304	task	_	
138-29	27305-27313	oriented	_	
138-30	27314-27324	responding	_	
138-31	27324-27325	,	_	
138-32	27326-27336	suggesting	_	
138-33	27337-27341	that	_	
138-34	27342-27349	reduced	_	
138-35	27350-27360	activation	_	
138-36	27361-27363	in	_	
138-37	27364-27367	the	_	
138-38	27368-27373	right	_	
138-39	27374-27380	insula	_	
138-40	27381-27384	may	_	
138-41	27385-27389	lead	_	
138-42	27390-27392	to	_	
138-43	27393-27397	less	_	
138-44	27398-27409	recruitment	_	
138-45	27410-27413	and	_	
138-46	27414-27424	engagement	_	
138-47	27425-27427	of	_	
138-48	27428-27438	prefrontal	_	
138-49	27439-27446	regions	_	
138-50	27447-27456	primarily	_	
138-51	27457-27468	responsible	_	
138-52	27469-27472	for	_	
138-53	27473-27482	cognitive	_	
138-54	27483-27490	control	_	
138-55	27491-27500	processes	_	
138-56	27500-27501	.	_	

#Text=We also investigated whether task-related functional connectivity was associated with distress tolerance.
139-1	27502-27504	We	_	
139-2	27505-27509	also	_	
139-3	27510-27522	investigated	_	
139-4	27523-27530	whether	_	
139-5	27531-27543	task-related	_	
139-6	27544-27554	functional	_	
139-7	27555-27567	connectivity	_	
139-8	27568-27571	was	_	
139-9	27572-27582	associated	_	
139-10	27583-27587	with	_	
139-11	27588-27596	distress	_	
139-12	27597-27606	tolerance	_	
139-13	27606-27607	.	_	

#Text=An analysis of the psychophysiological interactions (PPI) using the right MFG as the seed region demonstrated a significant interaction between right MFG-vmPFC/sgACC connectivity and group in predicting distress tolerance, with follow-up analyses indicating that substance users with higher distress tolerance demonstrated greater functional connectivity during the distress phase of the task between the right MFG and vmPFC/sgACC.
140-1	27608-27610	An	_	
140-2	27611-27619	analysis	_	
140-3	27620-27622	of	_	
140-4	27623-27626	the	_	
140-5	27627-27646	psychophysiological	_	
140-6	27647-27659	interactions	_	
140-7	27660-27661	(	_	
140-8	27661-27664	PPI	_	
140-9	27664-27665	)	_	
140-10	27666-27671	using	_	
140-11	27672-27675	the	_	
140-12	27676-27681	right	_	
140-13	27682-27685	MFG	_	
140-14	27686-27688	as	_	
140-15	27689-27692	the	_	
140-16	27693-27697	seed	_	
140-17	27698-27704	region	_	
140-18	27705-27717	demonstrated	_	
140-19	27718-27719	a	_	
140-20	27720-27731	significant	_	
140-21	27732-27743	interaction	_	
140-22	27744-27751	between	_	
140-23	27752-27757	right	_	
140-24	27758-27767	MFG-vmPFC	_	
140-25	27767-27768	/	_	
140-26	27768-27773	sgACC	_	
140-27	27774-27786	connectivity	_	
140-28	27787-27790	and	_	
140-29	27791-27796	group	_	
140-30	27797-27799	in	_	
140-31	27800-27810	predicting	_	
140-32	27811-27819	distress	_	
140-33	27820-27829	tolerance	_	
140-34	27829-27830	,	_	
140-35	27831-27835	with	_	
140-36	27836-27845	follow-up	_	
140-37	27846-27854	analyses	_	
140-38	27855-27865	indicating	_	
140-39	27866-27870	that	_	
140-40	27871-27880	substance	_	
140-41	27881-27886	users	_	
140-42	27887-27891	with	_	
140-43	27892-27898	higher	_	
140-44	27899-27907	distress	_	
140-45	27908-27917	tolerance	_	
140-46	27918-27930	demonstrated	_	
140-47	27931-27938	greater	_	
140-48	27939-27949	functional	_	
140-49	27950-27962	connectivity	_	
140-50	27963-27969	during	_	
140-51	27970-27973	the	_	
140-52	27974-27982	distress	_	
140-53	27983-27988	phase	_	
140-54	27989-27991	of	_	
140-55	27992-27995	the	_	
140-56	27996-28000	task	_	
140-57	28001-28008	between	_	
140-58	28009-28012	the	_	
140-59	28013-28018	right	_	
140-60	28019-28022	MFG	_	
140-61	28023-28026	and	_	
140-62	28027-28032	vmPFC	_	
140-63	28032-28033	/	_	
140-64	28033-28038	sgACC	_	
140-65	28038-28039	.	_	

#Text=Both the subgenual ACC and vmPFC are associated with signaling emotional significance and goal valuation, while the MFG has an important role in emotion regulation via cognitive control in non-substance using, and substance dependent samples.
141-1	28040-28044	Both	_	
141-2	28045-28048	the	_	
141-3	28049-28058	subgenual	_	
141-4	28059-28062	ACC	_	
141-5	28063-28066	and	_	
141-6	28067-28072	vmPFC	_	
141-7	28073-28076	are	_	
141-8	28077-28087	associated	_	
141-9	28088-28092	with	_	
141-10	28093-28102	signaling	_	
141-11	28103-28112	emotional	_	
141-12	28113-28125	significance	_	
141-13	28126-28129	and	_	
141-14	28130-28134	goal	_	
141-15	28135-28144	valuation	_	
141-16	28144-28145	,	_	
141-17	28146-28151	while	_	
141-18	28152-28155	the	_	
141-19	28156-28159	MFG	_	
141-20	28160-28163	has	_	
141-21	28164-28166	an	_	
141-22	28167-28176	important	_	
141-23	28177-28181	role	_	
141-24	28182-28184	in	_	
141-25	28185-28192	emotion	_	
141-26	28193-28203	regulation	_	
141-27	28204-28207	via	_	
141-28	28208-28217	cognitive	_	
141-29	28218-28225	control	_	
141-30	28226-28228	in	_	
141-31	28229-28242	non-substance	_	
141-32	28243-28248	using	_	
141-33	28248-28249	,	_	
141-34	28250-28253	and	_	
141-35	28254-28263	substance	_	
141-36	28264-28273	dependent	_	
141-37	28274-28281	samples	_	
141-38	28281-28282	.	_	

#Text=Our finding is in line with theory suggesting impairment in the ability of substance users to exert emotion regulation and cognitive control in the face of distress via top down mechanisms.
142-1	28283-28286	Our	_	
142-2	28287-28294	finding	_	
142-3	28295-28297	is	_	
142-4	28298-28300	in	_	
142-5	28301-28305	line	_	
142-6	28306-28310	with	_	
142-7	28311-28317	theory	_	
142-8	28318-28328	suggesting	_	
142-9	28329-28339	impairment	_	
142-10	28340-28342	in	_	
142-11	28343-28346	the	_	
142-12	28347-28354	ability	_	
142-13	28355-28357	of	_	
142-14	28358-28367	substance	_	
142-15	28368-28373	users	_	
142-16	28374-28376	to	_	
142-17	28377-28382	exert	_	
142-18	28383-28390	emotion	_	
142-19	28391-28401	regulation	_	
142-20	28402-28405	and	_	
142-21	28406-28415	cognitive	_	
142-22	28416-28423	control	_	
142-23	28424-28426	in	_	
142-24	28427-28430	the	_	
142-25	28431-28435	face	_	
142-26	28436-28438	of	_	
142-27	28439-28447	distress	_	
142-28	28448-28451	via	_	
142-29	28452-28455	top	_	
142-30	28456-28460	down	_	
142-31	28461-28471	mechanisms	_	
142-32	28471-28472	.	_	

#Text=In particular, reported a positive correlation between perceived stress during an acute stressor prior to task onset, and functional connectivity between the dlPFC and vmPFC during successful self-control in a goal directed food choice task.
143-1	28473-28475	In	_	
143-2	28476-28486	particular	_	
143-3	28486-28487	,	_	
143-4	28488-28496	reported	_	
143-5	28497-28498	a	_	
143-6	28499-28507	positive	_	
143-7	28508-28519	correlation	_	
143-8	28520-28527	between	_	
143-9	28528-28537	perceived	_	
143-10	28538-28544	stress	_	
143-11	28545-28551	during	_	
143-12	28552-28554	an	_	
143-13	28555-28560	acute	_	
143-14	28561-28569	stressor	_	
143-15	28570-28575	prior	_	
143-16	28576-28578	to	_	
143-17	28579-28583	task	_	
143-18	28584-28589	onset	_	
143-19	28589-28590	,	_	
143-20	28591-28594	and	_	
143-21	28595-28605	functional	_	
143-22	28606-28618	connectivity	_	
143-23	28619-28626	between	_	
143-24	28627-28630	the	_	
143-25	28631-28636	dlPFC	_	
143-26	28637-28640	and	_	
143-27	28641-28646	vmPFC	_	
143-28	28647-28653	during	_	
143-29	28654-28664	successful	_	
143-30	28665-28677	self-control	_	
143-31	28678-28680	in	_	
143-32	28681-28682	a	_	
143-33	28683-28687	goal	_	
143-34	28688-28696	directed	_	
143-35	28697-28701	food	_	
143-36	28702-28708	choice	_	
143-37	28709-28713	task	_	
143-38	28713-28714	.	_	

#Text=Our finding extends this research by directly measuring task specific functional connectivity during a distress task in which the choice to quit a goal directed behavior (i.e., low distress tolerance) is measured.
144-1	28715-28718	Our	_	
144-2	28719-28726	finding	_	
144-3	28727-28734	extends	_	
144-4	28735-28739	this	_	
144-5	28740-28748	research	_	
144-6	28749-28751	by	_	
144-7	28752-28760	directly	_	
144-8	28761-28770	measuring	_	
144-9	28771-28775	task	_	
144-10	28776-28784	specific	_	
144-11	28785-28795	functional	_	
144-12	28796-28808	connectivity	_	
144-13	28809-28815	during	_	
144-14	28816-28817	a	_	
144-15	28818-28826	distress	_	
144-16	28827-28831	task	_	
144-17	28832-28834	in	_	
144-18	28835-28840	which	_	
144-19	28841-28844	the	_	
144-20	28845-28851	choice	_	
144-21	28852-28854	to	_	
144-22	28855-28859	quit	_	
144-23	28860-28861	a	_	
144-24	28862-28866	goal	_	
144-25	28867-28875	directed	_	
144-26	28876-28884	behavior	_	
144-27	28885-28886	(	_	
144-28	28886-28889	i.e	_	
144-29	28889-28890	.	_	
144-30	28890-28891	,	_	
144-31	28892-28895	low	_	
144-32	28896-28904	distress	_	
144-33	28905-28914	tolerance	_	
144-34	28914-28915	)	_	
144-35	28916-28918	is	_	
144-36	28919-28927	measured	_	
144-37	28927-28928	.	_	

#Text=Contrary to our working hypothesis, neural activation as a result of distress induced by the PASAT-M did not predict distress tolerance among healthy controls.
145-1	28929-28937	Contrary	_	
145-2	28938-28940	to	_	
145-3	28941-28944	our	_	
145-4	28945-28952	working	_	
145-5	28953-28963	hypothesis	_	
145-6	28963-28964	,	_	
145-7	28965-28971	neural	_	
145-8	28972-28982	activation	_	
145-9	28983-28985	as	_	
145-10	28986-28987	a	_	
145-11	28988-28994	result	_	
145-12	28995-28997	of	_	
145-13	28998-29006	distress	_	
145-14	29007-29014	induced	_	
145-15	29015-29017	by	_	
145-16	29018-29021	the	_	
145-17	29022-29029	PASAT-M	_	
145-18	29030-29033	did	_	
145-19	29034-29037	not	_	
145-20	29038-29045	predict	_	
145-21	29046-29054	distress	_	
145-22	29055-29064	tolerance	_	
145-23	29065-29070	among	_	
145-24	29071-29078	healthy	_	
145-25	29079-29087	controls	_	
145-26	29087-29088	.	_	

#Text=Although task effects indicated elevations in distress and engagement on the task, a clear ceiling effect is noteworthy, such that the majority of healthy control participants persisted on the task for the entire duration of the distress tolerance phase, limiting the within group variability in levels of distress tolerance.
146-1	29089-29097	Although	_	
146-2	29098-29102	task	_	
146-3	29103-29110	effects	_	
146-4	29111-29120	indicated	_	
146-5	29121-29131	elevations	_	
146-6	29132-29134	in	_	
146-7	29135-29143	distress	_	
146-8	29144-29147	and	_	
146-9	29148-29158	engagement	_	
146-10	29159-29161	on	_	
146-11	29162-29165	the	_	
146-12	29166-29170	task	_	
146-13	29170-29171	,	_	
146-14	29172-29173	a	_	
146-15	29174-29179	clear	_	
146-16	29180-29187	ceiling	_	
146-17	29188-29194	effect	_	
146-18	29195-29197	is	_	
146-19	29198-29208	noteworthy	_	
146-20	29208-29209	,	_	
146-21	29210-29214	such	_	
146-22	29215-29219	that	_	
146-23	29220-29223	the	_	
146-24	29224-29232	majority	_	
146-25	29233-29235	of	_	
146-26	29236-29243	healthy	_	
146-27	29244-29251	control	_	
146-28	29252-29264	participants	_	
146-29	29265-29274	persisted	_	
146-30	29275-29277	on	_	
146-31	29278-29281	the	_	
146-32	29282-29286	task	_	
146-33	29287-29290	for	_	
146-34	29291-29294	the	_	
146-35	29295-29301	entire	_	
146-36	29302-29310	duration	_	
146-37	29311-29313	of	_	
146-38	29314-29317	the	_	
146-39	29318-29326	distress	_	
146-40	29327-29336	tolerance	_	
146-41	29337-29342	phase	_	
146-42	29342-29343	,	_	
146-43	29344-29352	limiting	_	
146-44	29353-29356	the	_	
146-45	29357-29363	within	_	
146-46	29364-29369	group	_	
146-47	29370-29381	variability	_	
146-48	29382-29384	in	_	
146-49	29385-29391	levels	_	
146-50	29392-29394	of	_	
146-51	29395-29403	distress	_	
146-52	29404-29413	tolerance	_	
146-53	29413-29414	.	_	

#Text=The healthy controls evidenced significantly less deactivation in the bilateral MFG and significantly greater activation in right IFG during distress, which was not observed in the substance users and may reflect a more effective cortico-limbic response to distress in healthy controls.
147-1	29415-29418	The	_	
147-2	29419-29426	healthy	_	
147-3	29427-29435	controls	_	
147-4	29436-29445	evidenced	_	
147-5	29446-29459	significantly	_	
147-6	29460-29464	less	_	
147-7	29465-29477	deactivation	_	
147-8	29478-29480	in	_	
147-9	29481-29484	the	_	
147-10	29485-29494	bilateral	_	
147-11	29495-29498	MFG	_	
147-12	29499-29502	and	_	
147-13	29503-29516	significantly	_	
147-14	29517-29524	greater	_	
147-15	29525-29535	activation	_	
147-16	29536-29538	in	_	
147-17	29539-29544	right	_	
147-18	29545-29548	IFG	_	
147-19	29549-29555	during	_	
147-20	29556-29564	distress	_	
147-21	29564-29565	,	_	
147-22	29566-29571	which	_	
147-23	29572-29575	was	_	
147-24	29576-29579	not	_	
147-25	29580-29588	observed	_	
147-26	29589-29591	in	_	
147-27	29592-29595	the	_	
147-28	29596-29605	substance	_	
147-29	29606-29611	users	_	
147-30	29612-29615	and	_	
147-31	29616-29619	may	_	
147-32	29620-29627	reflect	_	
147-33	29628-29629	a	_	
147-34	29630-29634	more	_	
147-35	29635-29644	effective	_	
147-36	29645-29659	cortico-limbic	_	
147-37	29660-29668	response	_	
147-38	29669-29671	to	_	
147-39	29672-29680	distress	_	
147-40	29681-29683	in	_	
147-41	29684-29691	healthy	_	
147-42	29692-29700	controls	_	
147-43	29700-29701	.	_	

#Text=Given evidence of task effects on distress, as well as the ceiling effect in levels of distress tolerance, it is premature to conclude that neural response to distress is unrelated to distress tolerance within a healthy population.
148-1	29702-29707	Given	_	
148-2	29708-29716	evidence	_	
148-3	29717-29719	of	_	
148-4	29720-29724	task	_	
148-5	29725-29732	effects	_	
148-6	29733-29735	on	_	
148-7	29736-29744	distress	_	
148-8	29744-29745	,	_	
148-9	29746-29748	as	_	
148-10	29749-29753	well	_	
148-11	29754-29756	as	_	
148-12	29757-29760	the	_	
148-13	29761-29768	ceiling	_	
148-14	29769-29775	effect	_	
148-15	29776-29778	in	_	
148-16	29779-29785	levels	_	
148-17	29786-29788	of	_	
148-18	29789-29797	distress	_	
148-19	29798-29807	tolerance	_	
148-20	29807-29808	,	_	
148-21	29809-29811	it	_	
148-22	29812-29814	is	_	
148-23	29815-29824	premature	_	
148-24	29825-29827	to	_	
148-25	29828-29836	conclude	_	
148-26	29837-29841	that	_	
148-27	29842-29848	neural	_	
148-28	29849-29857	response	_	
148-29	29858-29860	to	_	
148-30	29861-29869	distress	_	
148-31	29870-29872	is	_	
148-32	29873-29882	unrelated	_	
148-33	29883-29885	to	_	
148-34	29886-29894	distress	_	
148-35	29895-29904	tolerance	_	
148-36	29905-29911	within	_	
148-37	29912-29913	a	_	
148-38	29914-29921	healthy	_	
148-39	29922-29932	population	_	
148-40	29932-29933	.	_	

#Text=Moreover, the ability to accurately characterize group differences is compromised.
149-1	29934-29942	Moreover	_	
149-2	29942-29943	,	_	
149-3	29944-29947	the	_	
149-4	29948-29955	ability	_	
149-5	29956-29958	to	_	
149-6	29959-29969	accurately	_	
149-7	29970-29982	characterize	_	
149-8	29983-29988	group	_	
149-9	29989-30000	differences	_	
149-10	30001-30003	is	_	
149-11	30004-30015	compromised	_	
149-12	30015-30016	.	_	

#Text=Future studies are needed to determine if extending the duration of the distress tolerance phase will capture a greater range of levels of distress tolerance among healthy controls.
150-1	30017-30023	Future	_	
150-2	30024-30031	studies	_	
150-3	30032-30035	are	_	
150-4	30036-30042	needed	_	
150-5	30043-30045	to	_	
150-6	30046-30055	determine	_	
150-7	30056-30058	if	_	
150-8	30059-30068	extending	_	
150-9	30069-30072	the	_	
150-10	30073-30081	duration	_	
150-11	30082-30084	of	_	
150-12	30085-30088	the	_	
150-13	30089-30097	distress	_	
150-14	30098-30107	tolerance	_	
150-15	30108-30113	phase	_	
150-16	30114-30118	will	_	
150-17	30119-30126	capture	_	
150-18	30127-30128	a	_	
150-19	30129-30136	greater	_	
150-20	30137-30142	range	_	
150-21	30143-30145	of	_	
150-22	30146-30152	levels	_	
150-23	30153-30155	of	_	
150-24	30156-30164	distress	_	
150-25	30165-30174	tolerance	_	
150-26	30175-30180	among	_	
150-27	30181-30188	healthy	_	
150-28	30189-30197	controls	_	
150-29	30197-30198	.	_	

#Text=Limitations and future directions
#Text=A number of limitations are of note.
151-1	30199-30210	Limitations	_	
151-2	30211-30214	and	_	
151-3	30215-30221	future	_	
151-4	30222-30232	directions	_	
151-5	30233-30234	A	_	
151-6	30235-30241	number	_	
151-7	30242-30244	of	_	
151-8	30245-30256	limitations	_	
151-9	30257-30260	are	_	
151-10	30261-30263	of	_	
151-11	30264-30268	note	_	
151-12	30268-30269	.	_	

#Text=Our sample included regular non-treatment seeking cocaine users who also reported daily cigarette use and use of additional substances on a weekly or less basis.
152-1	30270-30273	Our	_	
152-2	30274-30280	sample	_	
152-3	30281-30289	included	_	
152-4	30290-30297	regular	_	
152-5	30298-30311	non-treatment	_	
152-6	30312-30319	seeking	_	
152-7	30320-30327	cocaine	_	
152-8	30328-30333	users	_	
152-9	30334-30337	who	_	
152-10	30338-30342	also	_	
152-11	30343-30351	reported	_	
152-12	30352-30357	daily	_	
152-13	30358-30367	cigarette	_	
152-14	30368-30371	use	_	
152-15	30372-30375	and	_	
152-16	30376-30379	use	_	
152-17	30380-30382	of	_	
152-18	30383-30393	additional	_	
152-19	30394-30404	substances	_	
152-20	30405-30407	on	_	
152-21	30408-30409	a	_	
152-22	30410-30416	weekly	_	
152-23	30417-30419	or	_	
152-24	30420-30424	less	_	
152-25	30425-30430	basis	_	
152-26	30430-30431	.	_	

#Text=In addition, our substance using sample was predominately male.
153-1	30432-30434	In	_	
153-2	30435-30443	addition	_	
153-3	30443-30444	,	_	
153-4	30445-30448	our	_	
153-5	30449-30458	substance	_	
153-6	30459-30464	using	_	
153-7	30465-30471	sample	_	
153-8	30472-30475	was	_	
153-9	30476-30489	predominately	_	
153-10	30490-30494	male	_	
153-11	30494-30495	.	_	

#Text=As such, generalizability of our results is limited among treatment seeking substance users, females, and individuals who regularly use other substances.
154-1	30496-30498	As	_	
154-2	30499-30503	such	_	
154-3	30503-30504	,	_	
154-4	30505-30521	generalizability	_	
154-5	30522-30524	of	_	
154-6	30525-30528	our	_	
154-7	30529-30536	results	_	
154-8	30537-30539	is	_	
154-9	30540-30547	limited	_	
154-10	30548-30553	among	_	
154-11	30554-30563	treatment	_	
154-12	30564-30571	seeking	_	
154-13	30572-30581	substance	_	
154-14	30582-30587	users	_	
154-15	30587-30588	,	_	
154-16	30589-30596	females	_	
154-17	30596-30597	,	_	
154-18	30598-30601	and	_	
154-19	30602-30613	individuals	_	
154-20	30614-30617	who	_	
154-21	30618-30627	regularly	_	
154-22	30628-30631	use	_	
154-23	30632-30637	other	_	
154-24	30638-30648	substances	_	
154-25	30648-30649	.	_	

#Text=Low distress tolerance is associated with additional psychopathology and related constructs other than substance use disorder.
155-1	30650-30653	Low	_	
155-2	30654-30662	distress	_	
155-3	30663-30672	tolerance	_	
155-4	30673-30675	is	_	
155-5	30676-30686	associated	_	
155-6	30687-30691	with	_	
155-7	30692-30702	additional	_	
155-8	30703-30718	psychopathology	_	
155-9	30719-30722	and	_	
155-10	30723-30730	related	_	
155-11	30731-30741	constructs	_	
155-12	30742-30747	other	_	
155-13	30748-30752	than	_	
155-14	30753-30762	substance	_	
155-15	30763-30766	use	_	
155-16	30767-30775	disorder	_	
155-17	30775-30776	.	_	

#Text=It will be important for future work to rule out additional variables contributing to the current findings.
156-1	30777-30779	It	_	
156-2	30780-30784	will	_	
156-3	30785-30787	be	_	
156-4	30788-30797	important	_	
156-5	30798-30801	for	_	
156-6	30802-30808	future	_	
156-7	30809-30813	work	_	
156-8	30814-30816	to	_	
156-9	30817-30821	rule	_	
156-10	30822-30825	out	_	
156-11	30826-30836	additional	_	
156-12	30837-30846	variables	_	
156-13	30847-30859	contributing	_	
156-14	30860-30862	to	_	
156-15	30863-30866	the	_	
156-16	30867-30874	current	_	
156-17	30875-30883	findings	_	
156-18	30883-30884	.	_	

#Text=Moreover, it will be important to determine if these findings extend to other DT assessment paradigms (see for a review) as well as to investigate whether neural response to distress on the behavioral paradigms is associated with self-report indices of DT.
157-1	30885-30893	Moreover	_	
157-2	30893-30894	,	_	
157-3	30895-30897	it	_	
157-4	30898-30902	will	_	
157-5	30903-30905	be	_	
157-6	30906-30915	important	_	
157-7	30916-30918	to	_	
157-8	30919-30928	determine	_	
157-9	30929-30931	if	_	
157-10	30932-30937	these	_	
157-11	30938-30946	findings	_	
157-12	30947-30953	extend	_	
157-13	30954-30956	to	_	
157-14	30957-30962	other	_	
157-15	30963-30965	DT	_	
157-16	30966-30976	assessment	_	
157-17	30977-30986	paradigms	_	
157-18	30987-30988	(	_	
157-19	30988-30991	see	_	
157-20	30992-30995	for	_	
157-21	30996-30997	a	_	
157-22	30998-31004	review	_	
157-23	31004-31005	)	_	
157-24	31006-31008	as	_	
157-25	31009-31013	well	_	
157-26	31014-31016	as	_	
157-27	31017-31019	to	_	
157-28	31020-31031	investigate	_	
157-29	31032-31039	whether	_	
157-30	31040-31046	neural	_	
157-31	31047-31055	response	_	
157-32	31056-31058	to	_	
157-33	31059-31067	distress	_	
157-34	31068-31070	on	_	
157-35	31071-31074	the	_	
157-36	31075-31085	behavioral	_	
157-37	31086-31095	paradigms	_	
157-38	31096-31098	is	_	
157-39	31099-31109	associated	_	
157-40	31110-31114	with	_	
157-41	31115-31126	self-report	_	
157-42	31127-31134	indices	_	
157-43	31135-31137	of	_	
157-44	31138-31140	DT	_	
157-45	31140-31141	.	_	

#Text=Given the existing literature indicating the utility of behavioral measures of DT in predicting post-treatment relapse, a next step will be to examine the utility of the neural indices of distress tolerance in predicting treatment response.
158-1	31142-31147	Given	_	
158-2	31148-31151	the	_	
158-3	31152-31160	existing	_	
158-4	31161-31171	literature	_	
158-5	31172-31182	indicating	_	
158-6	31183-31186	the	_	
158-7	31187-31194	utility	_	
158-8	31195-31197	of	_	
158-9	31198-31208	behavioral	_	
158-10	31209-31217	measures	_	
158-11	31218-31220	of	_	
158-12	31221-31223	DT	_	
158-13	31224-31226	in	_	
158-14	31227-31237	predicting	_	
158-15	31238-31252	post-treatment	_	
158-16	31253-31260	relapse	_	
158-17	31260-31261	,	_	
158-18	31262-31263	a	_	
158-19	31264-31268	next	_	
158-20	31269-31273	step	_	
158-21	31274-31278	will	_	
158-22	31279-31281	be	_	
158-23	31282-31284	to	_	
158-24	31285-31292	examine	_	
158-25	31293-31296	the	_	
158-26	31297-31304	utility	_	
158-27	31305-31307	of	_	
158-28	31308-31311	the	_	
158-29	31312-31318	neural	_	
158-30	31319-31326	indices	_	
158-31	31327-31329	of	_	
158-32	31330-31338	distress	_	
158-33	31339-31348	tolerance	_	
158-34	31349-31351	in	_	
158-35	31352-31362	predicting	_	
158-36	31363-31372	treatment	_	
158-37	31373-31381	response	_	
158-38	31381-31382	.	_	

#Text=Despite these limitations, this study provides novel data on the neural mechanisms underlying distress tolerance among substance users, a construct implicated in the development and maintenance of multiple psychopathologies.
159-1	31383-31390	Despite	_	
159-2	31391-31396	these	_	
159-3	31397-31408	limitations	_	
159-4	31408-31409	,	_	
159-5	31410-31414	this	_	
159-6	31415-31420	study	_	
159-7	31421-31429	provides	_	
159-8	31430-31435	novel	_	
159-9	31436-31440	data	_	
159-10	31441-31443	on	_	
159-11	31444-31447	the	_	
159-12	31448-31454	neural	_	
159-13	31455-31465	mechanisms	_	
159-14	31466-31476	underlying	_	
159-15	31477-31485	distress	_	
159-16	31486-31495	tolerance	_	
159-17	31496-31501	among	_	
159-18	31502-31511	substance	_	
159-19	31512-31517	users	_	
159-20	31517-31518	,	_	
159-21	31519-31520	a	_	
159-22	31521-31530	construct	_	
159-23	31531-31541	implicated	_	
159-24	31542-31544	in	_	
159-25	31545-31548	the	_	
159-26	31549-31560	development	_	
159-27	31561-31564	and	_	
159-28	31565-31576	maintenance	_	
159-29	31577-31579	of	_	
159-30	31580-31588	multiple	_	
159-31	31589-31606	psychopathologies	_	
159-32	31606-31607	.	_	

#Text=Supplementary Material
#Text=AUTHORSHIP CONTRIBUTION
#Text=SD, TR, and EAS were responsible for the study concept and design.
160-1	31608-31621	Supplementary	_	
160-2	31622-31630	Material	_	
160-3	31631-31641	AUTHORSHIP	_	
160-4	31642-31654	CONTRIBUTION	_	
160-5	31655-31657	SD	_	
160-6	31657-31658	,	_	
160-7	31659-31661	TR	_	
160-8	31661-31662	,	_	
160-9	31663-31666	and	_	
160-10	31667-31670	EAS	_	
160-11	31671-31675	were	_	
160-12	31676-31687	responsible	_	
160-13	31688-31691	for	_	
160-14	31692-31695	the	_	
160-15	31696-31701	study	_	
160-16	31702-31709	concept	_	
160-17	31710-31713	and	_	
160-18	31714-31720	design	_	
160-19	31720-31721	.	_	

#Text=JR, RB, and JY contributed to data acquisition and processing.
161-1	31722-31724	JR	_	
161-2	31724-31725	,	_	
161-3	31726-31728	RB	_	
161-4	31728-31729	,	_	
161-5	31730-31733	and	_	
161-6	31734-31736	JY	_	
161-7	31737-31748	contributed	_	
161-8	31749-31751	to	_	
161-9	31752-31756	data	_	
161-10	31757-31768	acquisition	_	
161-11	31769-31772	and	_	
161-12	31773-31783	processing	_	
161-13	31783-31784	.	_	

#Text=SD, TR, and RB conducted the data analysis.
162-1	31785-31787	SD	_	
162-2	31787-31788	,	_	
162-3	31789-31791	TR	_	
162-4	31791-31792	,	_	
162-5	31793-31796	and	_	
162-6	31797-31799	RB	_	
162-7	31800-31809	conducted	_	
162-8	31810-31813	the	_	
162-9	31814-31818	data	_	
162-10	31819-31827	analysis	_	
162-11	31827-31828	.	_	

#Text=SD, RB, and JY drafted the manuscript.
163-1	31829-31831	SD	_	
163-2	31831-31832	,	_	
163-3	31833-31835	RB	_	
163-4	31835-31836	,	_	
163-5	31837-31840	and	_	
163-6	31841-31843	JY	_	
163-7	31844-31851	drafted	_	
163-8	31852-31855	the	_	
163-9	31856-31866	manuscript	_	
163-10	31866-31867	.	_	

#Text=TR and EAS provided critical revision of the manuscript for important intellectual content.
164-1	31868-31870	TR	_	
164-2	31871-31874	and	_	
164-3	31875-31878	EAS	_	
164-4	31879-31887	provided	_	
164-5	31888-31896	critical	_	
164-6	31897-31905	revision	_	
164-7	31906-31908	of	_	
164-8	31909-31912	the	_	
164-9	31913-31923	manuscript	_	
164-10	31924-31927	for	_	
164-11	31928-31937	important	_	
164-12	31938-31950	intellectual	_	
164-13	31951-31958	content	_	
164-14	31958-31959	.	_	

#Text=All authors critically reviewed content and approved the final version for publication.
165-1	31960-31963	All	_	
165-2	31964-31971	authors	_	
165-3	31972-31982	critically	_	
165-4	31983-31991	reviewed	_	
165-5	31992-31999	content	_	
165-6	32000-32003	and	_	
165-7	32004-32012	approved	_	
165-8	32013-32016	the	_	
165-9	32017-32022	final	_	
165-10	32023-32030	version	_	
165-11	32031-32034	for	_	
165-12	32035-32046	publication	_	
165-13	32046-32047	.	_	

#Text=FINANCIAL DISCLOSURES
#Text=The authors have no financial interests to declare.
166-1	32048-32057	FINANCIAL	_	
166-2	32058-32069	DISCLOSURES	_	
166-3	32070-32073	The	_	
166-4	32074-32081	authors	_	
166-5	32082-32086	have	_	
166-6	32087-32089	no	_	
166-7	32090-32099	financial	_	
166-8	32100-32109	interests	_	
166-9	32110-32112	to	_	
166-10	32113-32120	declare	_	
166-11	32120-32121	.	_	

#Text=Significant values in all models in Tables S3 and S4 were unchanged when including the mean percent signal change during the Easy-Rest contrast as a covariate.
167-1	32122-32133	Significant	_	
167-2	32134-32140	values	_	
167-3	32141-32143	in	_	
167-4	32144-32147	all	_	
167-5	32148-32154	models	_	
167-6	32155-32157	in	_	
167-7	32158-32164	Tables	_	
167-8	32165-32167	S3	_	
167-9	32168-32171	and	_	
167-10	32172-32174	S4	_	
167-11	32175-32179	were	_	
167-12	32180-32189	unchanged	_	
167-13	32190-32194	when	_	
167-14	32195-32204	including	_	
167-15	32205-32208	the	_	
167-16	32209-32213	mean	_	
167-17	32214-32221	percent	_	
167-18	32222-32228	signal	_	
167-19	32229-32235	change	_	
167-20	32236-32242	during	_	
167-21	32243-32246	the	_	
167-22	32247-32256	Easy-Rest	_	
167-23	32257-32265	contrast	_	
167-24	32266-32268	as	_	
167-25	32269-32270	a	_	
167-26	32271-32280	covariate	_	
167-27	32280-32281	.	_	

#Text=REFERENCES
#Text=Trait aggression and problematic alcohol use among college students: the moderating effect of distress tolerance.
168-1	32282-32292	REFERENCES	_	
168-2	32293-32298	Trait	_	
168-3	32299-32309	aggression	_	
168-4	32310-32313	and	_	
168-5	32314-32325	problematic	_	
168-6	32326-32333	alcohol	_	
168-7	32334-32337	use	_	
168-8	32338-32343	among	_	
168-9	32344-32351	college	_	
168-10	32352-32360	students	_	
168-11	32360-32361	:	_	
168-12	32362-32365	the	_	
168-13	32366-32376	moderating	_	
168-14	32377-32383	effect	_	
168-15	32384-32386	of	_	
168-16	32387-32395	distress	_	
168-17	32396-32405	tolerance	_	
168-18	32405-32406	.	_	

#Text=Pharmacologic and Behavioral Withdrawal From Addictive Drugs.
169-1	32407-32420	Pharmacologic	_	
169-2	32421-32424	and	_	
169-3	32425-32435	Behavioral	_	
169-4	32436-32446	Withdrawal	_	
169-5	32447-32451	From	_	
169-6	32452-32461	Addictive	_	
169-7	32462-32467	Drugs	_	
169-8	32467-32468	.	_	

#Text=Addiction Motivation Reformulated: An affective processing model of negative reinforcement.
170-1	32469-32478	Addiction	_	
170-2	32479-32489	Motivation	_	
170-3	32490-32502	Reformulated	_	
170-4	32502-32503	:	_	
170-5	32504-32506	An	_	
170-6	32507-32516	affective	_	
170-7	32517-32527	processing	_	
170-8	32528-32533	model	_	
170-9	32534-32536	of	_	
170-10	32537-32545	negative	_	
170-11	32546-32559	reinforcement	_	
170-12	32559-32560	.	_	

#Text=Deciding advantageously before knowing the advantageous strategy.
171-1	32561-32569	Deciding	_	
171-2	32570-32584	advantageously	_	
171-3	32585-32591	before	_	
171-4	32592-32599	knowing	_	
171-5	32600-32603	the	_	
171-6	32604-32616	advantageous	_	
171-7	32617-32625	strategy	_	
171-8	32625-32626	.	_	

#Text=Caudate responses to reward anticipation associated with delay discounting behavior in healthy youth.
172-1	32627-32634	Caudate	_	
172-2	32635-32644	responses	_	
172-3	32645-32647	to	_	
172-4	32648-32654	reward	_	
172-5	32655-32667	anticipation	_	
172-6	32668-32678	associated	_	
172-7	32679-32683	with	_	
172-8	32684-32689	delay	_	
172-9	32690-32701	discounting	_	
172-10	32702-32710	behavior	_	
172-11	32711-32713	in	_	
172-12	32714-32721	healthy	_	
172-13	32722-32727	youth	_	
172-14	32727-32728	.	_	

#Text=Pretreatment task persistence predicts smoking cessation outcome.
173-1	32729-32741	Pretreatment	_	
173-2	32742-32746	task	_	
173-3	32747-32758	persistence	_	
173-4	32759-32767	predicts	_	
173-5	32768-32775	smoking	_	
173-6	32776-32785	cessation	_	
173-7	32786-32793	outcome	_	
173-8	32793-32794	.	_	

#Text=Distress tolerance and duration of past smoking cessation attempts.
174-1	32795-32803	Distress	_	
174-2	32804-32813	tolerance	_	
174-3	32814-32817	and	_	
174-4	32818-32826	duration	_	
174-5	32827-32829	of	_	
174-6	32830-32834	past	_	
174-7	32835-32842	smoking	_	
174-8	32843-32852	cessation	_	
174-9	32853-32861	attempts	_	
174-10	32861-32862	.	_	

#Text=A prospective examination of distress tolerance and early smoking lapse in adult self-quitters.
175-1	32863-32864	A	_	
175-2	32865-32876	prospective	_	
175-3	32877-32888	examination	_	
175-4	32889-32891	of	_	
175-5	32892-32900	distress	_	
175-6	32901-32910	tolerance	_	
175-7	32911-32914	and	_	
175-8	32915-32920	early	_	
175-9	32921-32928	smoking	_	
175-10	32929-32934	lapse	_	
175-11	32935-32937	in	_	
175-12	32938-32943	adult	_	
175-13	32944-32957	self-quitters	_	
175-14	32957-32958	.	_	

#Text=Distress Tolerance as a Predictor of Early Treatment Dropout in a Residential Substance Abuse Treatment Facility.
176-1	32960-32968	Distress	_	
176-2	32969-32978	Tolerance	_	
176-3	32979-32981	as	_	
176-4	32982-32983	a	_	
176-5	32984-32993	Predictor	_	
176-6	32994-32996	of	_	
176-7	32997-33002	Early	_	
176-8	33003-33012	Treatment	_	
176-9	33013-33020	Dropout	_	
176-10	33021-33023	in	_	
176-11	33024-33025	a	_	
176-12	33026-33037	Residential	_	
176-13	33038-33047	Substance	_	
176-14	33048-33053	Abuse	_	
176-15	33054-33063	Treatment	_	
176-16	33064-33072	Facility	_	
176-17	33072-33073	.	_	

#Text=Psychological Distress Tolerance and Duration of Most Recent Abstinence Attempt Among Residential Treatment-Seeking Substance Abusers.
177-1	33074-33087	Psychological	_	
177-2	33088-33096	Distress	_	
177-3	33097-33106	Tolerance	_	
177-4	33107-33110	and	_	
177-5	33111-33119	Duration	_	
177-6	33120-33122	of	_	
177-7	33123-33127	Most	_	
177-8	33128-33134	Recent	_	
177-9	33135-33145	Abstinence	_	
177-10	33146-33153	Attempt	_	
177-11	33154-33159	Among	_	
177-12	33160-33171	Residential	_	
177-13	33172-33189	Treatment-Seeking	_	
177-14	33190-33199	Substance	_	
177-15	33200-33207	Abusers	_	
177-16	33207-33208	.	_	

#Text=The Montreal Imaging Stress Task: using functional imaging to investigate the effects of perceiving and processing psychosocial stress in the human brain.
178-1	33209-33212	The	_	
178-2	33213-33221	Montreal	_	
178-3	33222-33229	Imaging	_	
178-4	33230-33236	Stress	_	
178-5	33237-33241	Task	_	
178-6	33241-33242	:	_	
178-7	33243-33248	using	_	
178-8	33249-33259	functional	_	
178-9	33260-33267	imaging	_	
178-10	33268-33270	to	_	
178-11	33271-33282	investigate	_	
178-12	33283-33286	the	_	
178-13	33287-33294	effects	_	
178-14	33295-33297	of	_	
178-15	33298-33308	perceiving	_	
178-16	33309-33312	and	_	
178-17	33313-33323	processing	_	
178-18	33324-33336	psychosocial	_	
178-19	33337-33343	stress	_	
178-20	33344-33346	in	_	
178-21	33347-33350	the	_	
178-22	33351-33356	human	_	
178-23	33357-33362	brain	_	
178-24	33362-33363	.	_	

#Text=Neural correlates of processing stressful information: an event-related fMRI study.
179-1	33364-33370	Neural	_	
179-2	33371-33381	correlates	_	
179-3	33382-33384	of	_	
179-4	33385-33395	processing	_	
179-5	33396-33405	stressful	_	
179-6	33406-33417	information	_	
179-7	33417-33418	:	_	
179-8	33419-33421	an	_	
179-9	33422-33435	event-related	_	
179-10	33436-33440	fMRI	_	
179-11	33441-33446	study	_	
179-12	33446-33447	.	_	

#Text=Optimized EPI for fMRI studies of the orbitofrontal cortex.
180-1	33448-33457	Optimized	_	
180-2	33458-33461	EPI	_	
180-3	33462-33465	for	_	
180-4	33466-33470	fMRI	_	
180-5	33471-33478	studies	_	
180-6	33479-33481	of	_	
180-7	33482-33485	the	_	
180-8	33486-33499	orbitofrontal	_	
180-9	33500-33506	cortex	_	
180-10	33506-33507	.	_	

#Text=Distinct brain networks in recognition memory share a defined region in the precuneus.
181-1	33508-33516	Distinct	_	
181-2	33517-33522	brain	_	
181-3	33523-33531	networks	_	
181-4	33532-33534	in	_	
181-5	33535-33546	recognition	_	
181-6	33547-33553	memory	_	
181-7	33554-33559	share	_	
181-8	33560-33561	a	_	
181-9	33562-33569	defined	_	
181-10	33570-33576	region	_	
181-11	33577-33579	in	_	
181-12	33580-33583	the	_	
181-13	33584-33593	precuneus	_	
181-14	33593-33594	.	_	

#Text=Anterior cingulate activity correlates with blood pressure during stress.
182-1	33595-33603	Anterior	_	
182-2	33604-33613	cingulate	_	
182-3	33614-33622	activity	_	
182-4	33623-33633	correlates	_	
182-5	33634-33638	with	_	
182-6	33639-33644	blood	_	
182-7	33645-33653	pressure	_	
182-8	33654-33660	during	_	
182-9	33661-33667	stress	_	
182-10	33667-33668	.	_	

#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.
183-1	33669-33680	Dysfunction	_	
183-2	33681-33683	of	_	
183-3	33684-33687	the	_	
183-4	33688-33698	prefrontal	_	
183-5	33699-33705	cortex	_	
183-6	33706-33708	in	_	
183-7	33709-33718	addiction	_	
183-8	33718-33719	:	_	
183-9	33720-33732	neuroimaging	_	
183-10	33733-33741	findings	_	
183-11	33742-33745	and	_	
183-12	33746-33754	clinical	_	
183-13	33755-33767	implications	_	
183-14	33767-33768	.	_	

#Text=Self-control in decision-making involves modulation of the vmPMC valuation system.
184-1	33769-33781	Self-control	_	
184-2	33782-33784	in	_	
184-3	33785-33800	decision-making	_	
184-4	33801-33809	involves	_	
184-5	33810-33820	modulation	_	
184-6	33821-33823	of	_	
184-7	33824-33827	the	_	
184-8	33828-33833	vmPMC	_	
184-9	33834-33843	valuation	_	
184-10	33844-33850	system	_	
184-11	33850-33851	.	_	

#Text=PROCESS: A versatile computational tool for observed variable mediation, moderation, and conditional process modeling.
185-1	33852-33859	PROCESS	_	
185-2	33859-33860	:	_	
185-3	33861-33862	A	_	
185-4	33863-33872	versatile	_	
185-5	33873-33886	computational	_	
185-6	33887-33891	tool	_	
185-7	33892-33895	for	_	
185-8	33896-33904	observed	_	
185-9	33905-33913	variable	_	
185-10	33914-33923	mediation	_	
185-11	33923-33924	,	_	
185-12	33925-33935	moderation	_	
185-13	33935-33936	,	_	
185-14	33937-33940	and	_	
185-15	33941-33952	conditional	_	
185-16	33953-33960	process	_	
185-17	33961-33969	modeling	_	
185-18	33969-33970	.	_	

#Text=The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire.
186-1	33971-33974	The	_	
186-2	33975-33985	Fagerstrom	_	
186-3	33986-33990	Test	_	
186-4	33991-33994	for	_	
186-5	33995-34003	Nicotine	_	
186-6	34004-34014	Dependence	_	
186-7	34014-34015	:	_	
186-8	34016-34017	a	_	
186-9	34018-34026	revision	_	
186-10	34027-34029	of	_	
186-11	34030-34033	the	_	
186-12	34034-34044	Fagerstrom	_	
186-13	34045-34054	Tolerance	_	
186-14	34055-34068	Questionnaire	_	
186-15	34068-34069	.	_	

#Text=Executive Dysfunction in Cocaine Addiction: Evidence for Discordant Frontal, Cingulate, and Cerebellar Activity.
187-1	34070-34079	Executive	_	
187-2	34080-34091	Dysfunction	_	
187-3	34092-34094	in	_	
187-4	34095-34102	Cocaine	_	
187-5	34103-34112	Addiction	_	
187-6	34112-34113	:	_	
187-7	34114-34122	Evidence	_	
187-8	34123-34126	for	_	
187-9	34127-34137	Discordant	_	
187-10	34138-34145	Frontal	_	
187-11	34145-34146	,	_	
187-12	34147-34156	Cingulate	_	
187-13	34156-34157	,	_	
187-14	34158-34161	and	_	
187-15	34162-34172	Cerebellar	_	
187-16	34173-34181	Activity	_	
187-17	34181-34182	.	_	

#Text=A role of right middle frontal gyrus in reorienting of attention: a case study.
188-1	34183-34184	A	_	
188-2	34185-34189	role	_	
188-3	34190-34192	of	_	
188-4	34193-34198	right	_	
188-5	34199-34205	middle	_	
188-6	34206-34213	frontal	_	
188-7	34214-34219	gyrus	_	
188-8	34220-34222	in	_	
188-9	34223-34234	reorienting	_	
188-10	34235-34237	of	_	
188-11	34238-34247	attention	_	
188-12	34247-34248	:	_	
188-13	34249-34250	a	_	
188-14	34251-34255	case	_	
188-15	34256-34261	study	_	
188-16	34261-34262	.	_	

#Text=The role of prefrontal cortex in resolving distractor interference.
189-1	34263-34266	The	_	
189-2	34267-34271	role	_	
189-3	34272-34274	of	_	
189-4	34275-34285	prefrontal	_	
189-5	34286-34292	cortex	_	
189-6	34293-34295	in	_	
189-7	34296-34305	resolving	_	
189-8	34306-34316	distractor	_	
189-9	34317-34329	interference	_	
189-10	34329-34330	.	_	

#Text=Cingulate Hypoactivity in Cocaine Users During a GO-NOGO Task as Revealed by Event-Related Functional Magnetic Resonance Imaging.
190-1	34331-34340	Cingulate	_	
190-2	34341-34353	Hypoactivity	_	
190-3	34354-34356	in	_	
190-4	34357-34364	Cocaine	_	
190-5	34365-34370	Users	_	
190-6	34371-34377	During	_	
190-7	34378-34379	a	_	
190-8	34380-34387	GO-NOGO	_	
190-9	34388-34392	Task	_	
190-10	34393-34395	as	_	
190-11	34396-34404	Revealed	_	
190-12	34405-34407	by	_	
190-13	34408-34421	Event-Related	_	
190-14	34422-34432	Functional	_	
190-15	34433-34441	Magnetic	_	
190-16	34442-34451	Resonance	_	
190-17	34452-34459	Imaging	_	
190-18	34459-34460	.	_	

#Text=Drug addiction, dysregulation of reward, and allostasis.
191-1	34461-34465	Drug	_	
191-2	34466-34475	addiction	_	
191-3	34475-34476	,	_	
191-4	34477-34490	dysregulation	_	
191-5	34491-34493	of	_	
191-6	34494-34500	reward	_	
191-7	34500-34501	,	_	
191-8	34502-34505	and	_	
191-9	34506-34516	allostasis	_	
191-10	34516-34517	.	_	

#Text=Addiction and the brain antireward system.
192-1	34518-34527	Addiction	_	
192-2	34528-34531	and	_	
192-3	34532-34535	the	_	
192-4	34536-34541	brain	_	
192-5	34542-34552	antireward	_	
192-6	34553-34559	system	_	
192-7	34559-34560	.	_	

#Text=A modified computer version of the Paced Auditory Serial Addition Task (PASAT) as a laboratory-based stressor.
193-1	34561-34562	A	_	
193-2	34563-34571	modified	_	
193-3	34572-34580	computer	_	
193-4	34581-34588	version	_	
193-5	34589-34591	of	_	
193-6	34592-34595	the	_	
193-7	34596-34601	Paced	_	
193-8	34602-34610	Auditory	_	
193-9	34611-34617	Serial	_	
193-10	34618-34626	Addition	_	
193-11	34627-34631	Task	_	
193-12	34632-34633	(	_	
193-13	34633-34638	PASAT	_	
193-14	34638-34639	)	_	
193-15	34640-34642	as	_	
193-16	34643-34644	a	_	
193-17	34645-34661	laboratory-based	_	
193-18	34662-34670	stressor	_	
193-19	34670-34671	.	_	

#Text=Distress tolerance and psychopathological symptoms and disorders: A review of the empirical literature among adults.
194-1	34672-34680	Distress	_	
194-2	34681-34690	tolerance	_	
194-3	34691-34694	and	_	
194-4	34695-34713	psychopathological	_	
194-5	34714-34722	symptoms	_	
194-6	34723-34726	and	_	
194-7	34727-34736	disorders	_	
194-8	34736-34737	:	_	
194-9	34738-34739	A	_	
194-10	34740-34746	review	_	
194-11	34747-34749	of	_	
194-12	34750-34753	the	_	
194-13	34754-34763	empirical	_	
194-14	34764-34774	literature	_	
194-15	34775-34780	among	_	
194-16	34781-34787	adults	_	
194-17	34787-34788	.	_	

#Text=Inhibitory control and emotional stress regulation: neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction.
195-1	34789-34799	Inhibitory	_	
195-2	34800-34807	control	_	
195-3	34808-34811	and	_	
195-4	34812-34821	emotional	_	
195-5	34822-34828	stress	_	
195-6	34829-34839	regulation	_	
195-7	34839-34840	:	_	
195-8	34841-34853	neuroimaging	_	
195-9	34854-34862	evidence	_	
195-10	34863-34866	for	_	
195-11	34867-34881	frontal-limbic	_	
195-12	34882-34893	dysfunction	_	
195-13	34894-34896	in	_	
195-14	34897-34913	psycho-stimulant	_	
195-15	34914-34923	addiction	_	
195-16	34923-34924	.	_	

#Text=Stochastic dynamic causal modeling of working memory connections in cocaine dependence.
196-1	34925-34935	Stochastic	_	
196-2	34936-34943	dynamic	_	
196-3	34944-34950	causal	_	
196-4	34951-34959	modeling	_	
196-5	34960-34962	of	_	
196-6	34963-34970	working	_	
196-7	34971-34977	memory	_	
196-8	34978-34989	connections	_	
196-9	34990-34992	in	_	
196-10	34993-35000	cocaine	_	
196-11	35001-35011	dependence	_	
196-12	35011-35012	.	_	

#Text=Distress tolerance.
197-1	35013-35021	Distress	_	
197-2	35022-35031	tolerance	_	
197-3	35031-35032	.	_	

#Text=Acute Stress Impairs Self-Control in Goal-Directed Choice by Altering Multiple Functional Connections within the Brain's Decision Circuits.
198-1	35033-35038	Acute	_	
198-2	35039-35045	Stress	_	
198-3	35046-35053	Impairs	_	
198-4	35054-35066	Self-Control	_	
198-5	35067-35069	in	_	
198-6	35070-35083	Goal-Directed	_	
198-7	35084-35090	Choice	_	
198-8	35091-35093	by	_	
198-9	35094-35102	Altering	_	
198-10	35103-35111	Multiple	_	
198-11	35112-35122	Functional	_	
198-12	35123-35134	Connections	_	
198-13	35135-35141	within	_	
198-14	35142-35145	the	_	
198-15	35146-35153	Brain's	_	
198-16	35154-35162	Decision	_	
198-17	35163-35171	Circuits	_	
198-18	35171-35172	.	_	

#Text=Large-scale brain networks and psychopathology: a unifying triple network model.
199-1	35173-35184	Large-scale	_	
199-2	35185-35190	brain	_	
199-3	35191-35199	networks	_	
199-4	35200-35203	and	_	
199-5	35204-35219	psychopathology	_	
199-6	35219-35220	:	_	
199-7	35221-35222	a	_	
199-8	35223-35231	unifying	_	
199-9	35232-35238	triple	_	
199-10	35239-35246	network	_	
199-11	35247-35252	model	_	
199-12	35252-35253	.	_	

#Text=Saliency, switching, attention and control: a network model of insula function.
200-1	35254-35262	Saliency	_	
200-2	35262-35263	,	_	
200-3	35264-35273	switching	_	
200-4	35273-35274	,	_	
200-5	35275-35284	attention	_	
200-6	35285-35288	and	_	
200-7	35289-35296	control	_	
200-8	35296-35297	:	_	
200-9	35298-35299	a	_	
200-10	35300-35307	network	_	
200-11	35308-35313	model	_	
200-12	35314-35316	of	_	
200-13	35317-35323	insula	_	
200-14	35324-35332	function	_	
200-15	35332-35333	.	_	

#Text=Neural correlates of hot and cold executive functions in polysubstance addiction: Association between neuropsychological performance and resting brain metabolism as measured by positron emission tomography.
201-1	35334-35340	Neural	_	
201-2	35341-35351	correlates	_	
201-3	35352-35354	of	_	
201-4	35355-35358	hot	_	
201-5	35359-35362	and	_	
201-6	35363-35367	cold	_	
201-7	35368-35377	executive	_	
201-8	35378-35387	functions	_	
201-9	35388-35390	in	_	
201-10	35391-35404	polysubstance	_	
201-11	35405-35414	addiction	_	
201-12	35414-35415	:	_	
201-13	35416-35427	Association	_	
201-14	35428-35435	between	_	
201-15	35436-35454	neuropsychological	_	
201-16	35455-35466	performance	_	
201-17	35467-35470	and	_	
201-18	35471-35478	resting	_	
201-19	35479-35484	brain	_	
201-20	35485-35495	metabolism	_	
201-21	35496-35498	as	_	
201-22	35499-35507	measured	_	
201-23	35508-35510	by	_	
201-24	35511-35519	positron	_	
201-25	35520-35528	emission	_	
201-26	35529-35539	tomography	_	
201-27	35539-35540	.	_	

#Text=Self-awareness and the left inferior frontal gyrus: inner speech use during self-related processing.
202-1	35541-35555	Self-awareness	_	
202-2	35556-35559	and	_	
202-3	35560-35563	the	_	
202-4	35564-35568	left	_	
202-5	35569-35577	inferior	_	
202-6	35578-35585	frontal	_	
202-7	35586-35591	gyrus	_	
202-8	35591-35592	:	_	
202-9	35593-35598	inner	_	
202-10	35599-35605	speech	_	
202-11	35606-35609	use	_	
202-12	35610-35616	during	_	
202-13	35617-35629	self-related	_	
202-14	35630-35640	processing	_	
202-15	35640-35641	.	_	

#Text=Cocaine Abstinence Symptomatology and Treatment Attrition.
203-1	35642-35649	Cocaine	_	
203-2	35650-35660	Abstinence	_	
203-3	35661-35675	Symptomatology	_	
203-4	35676-35679	and	_	
203-5	35680-35689	Treatment	_	
203-6	35690-35699	Attrition	_	
203-7	35699-35700	.	_	

#Text=Tools of the trade: Psychophysiological interactions and functional connectivity.
204-1	35701-35706	Tools	_	
204-2	35707-35709	of	_	
204-3	35710-35713	the	_	
204-4	35714-35719	trade	_	
204-5	35719-35720	:	_	
204-6	35721-35740	Psychophysiological	_	
204-7	35741-35753	interactions	_	
204-8	35754-35757	and	_	
204-9	35758-35768	functional	_	
204-10	35769-35781	connectivity	_	
204-11	35781-35782	.	_	

#Text=A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder.
205-1	35783-35784	A	_	
205-2	35785-35791	neural	_	
205-3	35792-35797	model	_	
205-4	35798-35800	of	_	
205-5	35801-35810	voluntary	_	
205-6	35811-35814	and	_	
205-7	35815-35824	automatic	_	
205-8	35825-35832	emotion	_	
205-9	35833-35843	regulation	_	
205-10	35843-35844	:	_	
205-11	35845-35857	implications	_	
205-12	35858-35861	for	_	
205-13	35862-35875	understanding	_	
205-14	35876-35879	the	_	
205-15	35880-35895	pathophysiology	_	
205-16	35896-35899	and	_	
205-17	35900-35916	neurodevelopment	_	
205-18	35917-35919	of	_	
205-19	35920-35927	bipolar	_	
205-20	35928-35936	disorder	_	
205-21	35936-35937	.	_	

#Text=Is task persistence related to smoking and substance abuse?
206-1	35938-35940	Is	_	
206-2	35941-35945	task	_	
206-3	35946-35957	persistence	_	
206-4	35958-35965	related	_	
206-5	35966-35968	to	_	
206-6	35969-35976	smoking	_	
206-7	35977-35980	and	_	
206-8	35981-35990	substance	_	
206-9	35991-35996	abuse	_	
206-10	35996-35997	?	_	

#Text=The application of learned industriousness theory to addictive behaviors.
207-1	35998-36001	The	_	
207-2	36002-36013	application	_	
207-3	36014-36016	of	_	
207-4	36017-36024	learned	_	
207-5	36025-36040	industriousness	_	
207-6	36041-36047	theory	_	
207-7	36048-36050	to	_	
207-8	36051-36060	addictive	_	
207-9	36061-36070	behaviors	_	
207-10	36070-36071	.	_	

#Text=Ventromedial prefrontal-subcortical systems and the generation of affective meaning.
208-1	36072-36084	Ventromedial	_	
208-2	36085-36107	prefrontal-subcortical	_	
208-3	36108-36115	systems	_	
208-4	36116-36119	and	_	
208-5	36120-36123	the	_	
208-6	36124-36134	generation	_	
208-7	36135-36137	of	_	
208-8	36138-36147	affective	_	
208-9	36148-36155	meaning	_	
208-10	36155-36156	.	_	

#Text=Neural Circuits Underlying Emotional Distress in Humans.
209-1	36157-36163	Neural	_	
209-2	36164-36172	Circuits	_	
209-3	36173-36183	Underlying	_	
209-4	36184-36193	Emotional	_	
209-5	36194-36202	Distress	_	
209-6	36203-36205	in	_	
209-7	36206-36212	Humans	_	
209-8	36212-36213	.	_	

#Text=Persistence on a Stress-challenge Task Before Initiating Buprenorphine Treatment Was Associated With Successful Transition From Opioid Use to Early Abstinence.
210-1	36214-36225	Persistence	_	
210-2	36226-36228	on	_	
210-3	36229-36230	a	_	
210-4	36231-36247	Stress-challenge	_	
210-5	36248-36252	Task	_	
210-6	36253-36259	Before	_	
210-7	36260-36270	Initiating	_	
210-8	36271-36284	Buprenorphine	_	
210-9	36285-36294	Treatment	_	
210-10	36295-36298	Was	_	
210-11	36299-36309	Associated	_	
210-12	36310-36314	With	_	
210-13	36315-36325	Successful	_	
210-14	36326-36336	Transition	_	
210-15	36337-36341	From	_	
210-16	36342-36348	Opioid	_	
210-17	36349-36352	Use	_	
210-18	36353-36355	to	_	
210-19	36356-36361	Early	_	
210-20	36362-36372	Abstinence	_	
210-21	36372-36373	.	_	

#Text=Resting state functional connectivity in addiction: Lessons learned and a road ahead.
211-1	36374-36381	Resting	_	
211-2	36382-36387	state	_	
211-3	36388-36398	functional	_	
211-4	36399-36411	connectivity	_	
211-5	36412-36414	in	_	
211-6	36415-36424	addiction	_	
211-7	36424-36425	:	_	
211-8	36426-36433	Lessons	_	
211-9	36434-36441	learned	_	
211-10	36442-36445	and	_	
211-11	36446-36447	a	_	
211-12	36448-36452	road	_	
211-13	36453-36458	ahead	_	
211-14	36458-36459	.	_	

#Text=Roles for the pre-supplementary motor area and the right inferior frontal gyrus in stopping action: electrophysiological responses and functional and structural connectivity.
212-1	36460-36465	Roles	_	
212-2	36466-36469	for	_	
212-3	36470-36473	the	_	
212-4	36474-36491	pre-supplementary	_	
212-5	36492-36497	motor	_	
212-6	36498-36502	area	_	
212-7	36503-36506	and	_	
212-8	36507-36510	the	_	
212-9	36511-36516	right	_	
212-10	36517-36525	inferior	_	
212-11	36526-36533	frontal	_	
212-12	36534-36539	gyrus	_	
212-13	36540-36542	in	_	
212-14	36543-36551	stopping	_	
212-15	36552-36558	action	_	
212-16	36558-36559	:	_	
212-17	36560-36580	electrophysiological	_	
212-18	36581-36590	responses	_	
212-19	36591-36594	and	_	
212-20	36595-36605	functional	_	
212-21	36606-36609	and	_	
212-22	36610-36620	structural	_	
212-23	36621-36633	connectivity	_	
212-24	36633-36634	.	_	

#Text=Left inferior frontal gyrus is critical for response inhibition.
213-1	36635-36639	Left	_	
213-2	36640-36648	inferior	_	
213-3	36649-36656	frontal	_	
213-4	36657-36662	gyrus	_	
213-5	36663-36665	is	_	
213-6	36666-36674	critical	_	
213-7	36675-36678	for	_	
213-8	36679-36687	response	_	
213-9	36688-36698	inhibition	_	
213-10	36698-36699	.	_	

#Text=How does interoceptive awareness interact with the subjective experience of emotion?
214-1	36700-36703	How	_	
214-2	36704-36708	does	_	
214-3	36709-36722	interoceptive	_	
214-4	36723-36732	awareness	_	
214-5	36733-36741	interact	_	
214-6	36742-36746	with	_	
214-7	36747-36750	the	_	
214-8	36751-36761	subjective	_	
214-9	36762-36772	experience	_	
214-10	36773-36775	of	_	
214-11	36776-36783	emotion	_	
214-12	36783-36784	?	_	

#Text=An fMRI study.
215-1	36785-36787	An	_	
215-2	36788-36792	fMRI	_	
215-3	36793-36798	study	_	
215-4	36798-36799	.	_	

#Text=Examining the interactive effect of posttraumatic stress disorder, distress tolerance, and gender on residential substance use disorder treatment retention.
216-1	36800-36809	Examining	_	
216-2	36810-36813	the	_	
216-3	36814-36825	interactive	_	
216-4	36826-36832	effect	_	
216-5	36833-36835	of	_	
216-6	36836-36849	posttraumatic	_	
216-7	36850-36856	stress	_	
216-8	36857-36865	disorder	_	
216-9	36865-36866	,	_	
216-10	36867-36875	distress	_	
216-11	36876-36885	tolerance	_	
216-12	36885-36886	,	_	
216-13	36887-36890	and	_	
216-14	36891-36897	gender	_	
216-15	36898-36900	on	_	
216-16	36901-36912	residential	_	
216-17	36913-36922	substance	_	
216-18	36923-36926	use	_	
216-19	36927-36935	disorder	_	
216-20	36936-36945	treatment	_	
216-21	36946-36955	retention	_	
216-22	36955-36956	.	_	

#Text=The Neural Signature of Subliminal Visuomotor Priming: Brain Activity and Functional Connectivity Profiles.
217-1	36957-36960	The	_	
217-2	36961-36967	Neural	_	
217-3	36968-36977	Signature	_	
217-4	36978-36980	of	_	
217-5	36981-36991	Subliminal	_	
217-6	36992-37002	Visuomotor	_	
217-7	37003-37010	Priming	_	
217-8	37010-37011	:	_	
217-9	37012-37017	Brain	_	
217-10	37018-37026	Activity	_	
217-11	37027-37030	and	_	
217-12	37031-37041	Functional	_	
217-13	37042-37054	Connectivity	_	
217-14	37055-37063	Profiles	_	
217-15	37063-37064	.	_	

#Text=Threat-related learning relies on distinct dorsal prefrontal cortex network connectivity.
218-1	37066-37080	Threat-related	_	
218-2	37081-37089	learning	_	
218-3	37090-37096	relies	_	
218-4	37097-37099	on	_	
218-5	37100-37108	distinct	_	
218-6	37109-37115	dorsal	_	
218-7	37116-37126	prefrontal	_	
218-8	37127-37133	cortex	_	
218-9	37134-37141	network	_	
218-10	37142-37154	connectivity	_	
218-11	37154-37155	.	_	

#Text=Distress tolerance: Theory, measurement, and relations to psychopathology.
219-1	37156-37164	Distress	_	
219-2	37165-37174	tolerance	_	
219-3	37174-37175	:	_	
219-4	37176-37182	Theory	_	
219-5	37182-37183	,	_	
219-6	37184-37195	measurement	_	
219-7	37195-37196	,	_	
219-8	37197-37200	and	_	
219-9	37201-37210	relations	_	
219-10	37211-37213	to	_	
219-11	37214-37229	psychopathology	_	
219-12	37229-37230	.	_	

#Text=Task design for the Paced Auditory Serial Addition Task distress tolerance task for fMRI (PASAT-M).
220-1	37231-37235	Task	_	
220-2	37236-37242	design	_	
220-3	37243-37246	for	_	
220-4	37247-37250	the	_	
220-5	37251-37256	Paced	_	
220-6	37257-37265	Auditory	_	
220-7	37266-37272	Serial	_	
220-8	37273-37281	Addition	_	
220-9	37282-37286	Task	_	
220-10	37287-37295	distress	_	
220-11	37296-37305	tolerance	_	
220-12	37306-37310	task	_	
220-13	37311-37314	for	_	
220-14	37315-37319	fMRI	_	
220-15	37320-37321	(	_	
220-16	37321-37328	PASAT-M	_	
220-17	37328-37329	)	_	
220-18	37329-37330	.	_	

#Text=Moderation of the effect of a prior ROI response to distress on distress tolerance (DT) by group.
221-1	37331-37341	Moderation	_	
221-2	37342-37344	of	_	
221-3	37345-37348	the	_	
221-4	37349-37355	effect	_	
221-5	37356-37358	of	_	
221-6	37359-37360	a	_	
221-7	37361-37366	prior	_	
221-8	37367-37370	ROI	_	
221-9	37371-37379	response	_	
221-10	37380-37382	to	_	
221-11	37383-37391	distress	_	
221-12	37392-37394	on	_	
221-13	37395-37403	distress	_	
221-14	37404-37413	tolerance	_	
221-15	37414-37415	(	_	
221-16	37415-37417	DT	_	
221-17	37417-37418	)	_	
221-18	37419-37421	by	_	
221-19	37422-37427	group	_	
221-20	37427-37428	.	_	

#Text=Points on graph reflect point estimate of conditional effect of ROI on DT (Mean ± 1 SD).
222-1	37429-37435	Points	_	
222-2	37436-37438	on	_	
222-3	37439-37444	graph	_	
222-4	37445-37452	reflect	_	
222-5	37453-37458	point	_	
222-6	37459-37467	estimate	_	
222-7	37468-37470	of	_	
222-8	37471-37482	conditional	_	
222-9	37483-37489	effect	_	
222-10	37490-37492	of	_	
222-11	37493-37496	ROI	_	
222-12	37497-37499	on	_	
222-13	37500-37502	DT	_	
222-14	37503-37504	(	_	
222-15	37504-37508	Mean	_	
222-16	37509-37510	±	_	
222-17	37511-37512	1	_	
222-18	37513-37515	SD	_	
222-19	37515-37516	)	_	
222-20	37516-37517	.	_	

#Text=Distress tolerance=persistence in seconds during the DT phase of the PASAT-M. r=right; l=left; ACC=anterior cingulate cortex; MFG=middle frontal gyrus; IFG=inferior frontal gyrus; FMC=frontal medial cortex.
223-1	37518-37526	Distress	_	
223-2	37527-37536	tolerance	_	
223-3	37536-37537	=	_	
223-4	37537-37548	persistence	_	
223-5	37549-37551	in	_	
223-6	37552-37559	seconds	_	
223-7	37560-37566	during	_	
223-8	37567-37570	the	_	
223-9	37571-37573	DT	_	
223-10	37574-37579	phase	_	
223-11	37580-37582	of	_	
223-12	37583-37586	the	_	
223-13	37587-37594	PASAT-M	_	
223-14	37594-37595	.	_	
223-15	37596-37597	r	_	
223-16	37597-37598	=	_	
223-17	37598-37603	right	_	
223-18	37603-37604	;	_	
223-19	37605-37606	l	_	
223-20	37606-37607	=	_	
223-21	37607-37611	left	_	
223-22	37611-37612	;	_	
223-23	37613-37616	ACC	_	
223-24	37616-37617	=	_	
223-25	37617-37625	anterior	_	
223-26	37626-37635	cingulate	_	
223-27	37636-37642	cortex	_	
223-28	37642-37643	;	_	
223-29	37644-37647	MFG	_	
223-30	37647-37648	=	_	
223-31	37648-37654	middle	_	
223-32	37655-37662	frontal	_	
223-33	37663-37668	gyrus	_	
223-34	37668-37669	;	_	
223-35	37670-37673	IFG	_	
223-36	37673-37674	=	_	
223-37	37674-37682	inferior	_	
223-38	37683-37690	frontal	_	
223-39	37691-37696	gyrus	_	
223-40	37696-37697	;	_	
223-41	37698-37701	FMC	_	
223-42	37701-37702	=	_	
223-43	37702-37709	frontal	_	
223-44	37710-37716	medial	_	
223-45	37717-37723	cortex	_	
223-46	37723-37724	.	_	

#Text=PASAT-M response to distress [(Distress-Rest) – (Easy-Rest)] among (a) healthy controls, (b) substance users, and (c) the contrast of substance users < healthy controls.
224-1	37725-37732	PASAT-M	_	
224-2	37733-37741	response	_	
224-3	37742-37744	to	_	
224-4	37745-37753	distress	_	
224-5	37754-37755	[	_	
224-6	37755-37756	(	_	
224-7	37756-37769	Distress-Rest	_	
224-8	37769-37770	)	_	
224-9	37771-37772	–	_	
224-10	37773-37774	(	_	
224-11	37774-37783	Easy-Rest	_	
224-12	37783-37784	)	_	
224-13	37784-37785	]	_	
224-14	37786-37791	among	_	
224-15	37792-37793	(	_	
224-16	37793-37794	a	_	
224-17	37794-37795	)	_	
224-18	37796-37803	healthy	_	
224-19	37804-37812	controls	_	
224-20	37812-37813	,	_	
224-21	37814-37815	(	_	
224-22	37815-37816	b	_	
224-23	37816-37817	)	_	
224-24	37818-37827	substance	_	
224-25	37828-37833	users	_	
224-26	37833-37834	,	_	
224-27	37835-37838	and	_	
224-28	37839-37840	(	_	
224-29	37840-37841	c	_	
224-30	37841-37842	)	_	
224-31	37843-37846	the	_	
224-32	37847-37855	contrast	_	
224-33	37856-37858	of	_	
224-34	37859-37868	substance	_	
224-35	37869-37874	users	_	
224-36	37875-37876	<	_	
224-37	37877-37884	healthy	_	
224-38	37885-37893	controls	_	
224-39	37893-37894	.	_	

#Text=Z (Gaussianised T/F) statistic images were thresholded using clusters determined by Z>3.0 and a (corrected) cluster significance threshold of p=0.05.
225-1	37895-37896	Z	_	
225-2	37897-37898	(	_	
225-3	37898-37910	Gaussianised	_	
225-4	37911-37912	T	_	
225-5	37912-37913	/	_	
225-6	37913-37914	F	_	
225-7	37914-37915	)	_	
225-8	37916-37925	statistic	_	
225-9	37926-37932	images	_	
225-10	37933-37937	were	_	
225-11	37938-37949	thresholded	_	
225-12	37950-37955	using	_	
225-13	37956-37964	clusters	_	
225-14	37965-37975	determined	_	
225-15	37976-37978	by	_	
225-16	37979-37980	Z	_	
225-17	37980-37981	>	_	
225-18	37981-37984	3.0	_	
225-19	37985-37988	and	_	
225-20	37989-37990	a	_	
225-21	37991-37992	(	_	
225-22	37992-38001	corrected	_	
225-23	38001-38002	)	_	
225-24	38003-38010	cluster	_	
225-25	38011-38023	significance	_	
225-26	38024-38033	threshold	_	
225-27	38034-38036	of	_	
225-28	38037-38038	p	_	
225-29	38038-38039	=	_	
225-30	38039-38043	0.05	_	
225-31	38043-38044	.	_	

#Text=PPI Analysis.
226-1	38045-38048	PPI	_	
226-2	38049-38057	Analysis	_	
226-3	38057-38058	.	_	

#Text=Interaction between Group and DT during PASAT-M distress [(Distress-Rest) – (Easy-Rest)] with the r MFG as the seed region.
227-1	38059-38070	Interaction	_	
227-2	38071-38078	between	_	
227-3	38079-38084	Group	_	
227-4	38085-38088	and	_	
227-5	38089-38091	DT	_	
227-6	38092-38098	during	_	
227-7	38099-38106	PASAT-M	_	
227-8	38107-38115	distress	_	
227-9	38116-38117	[	_	
227-10	38117-38118	(	_	
227-11	38118-38131	Distress-Rest	_	
227-12	38131-38132	)	_	
227-13	38133-38134	–	_	
227-14	38135-38136	(	_	
227-15	38136-38145	Easy-Rest	_	
227-16	38145-38146	)	_	
227-17	38146-38147	]	_	
227-18	38148-38152	with	_	
227-19	38153-38156	the	_	
227-20	38157-38158	r	_	
227-21	38159-38162	MFG	_	
227-22	38163-38165	as	_	
227-23	38166-38169	the	_	
227-24	38170-38174	seed	_	
227-25	38175-38181	region	_	
227-26	38181-38182	.	_	

#Text=There was a significant negative interaction between the r MFG and a bilateral vmPFC/sgACC cluster and SFG.
228-1	38183-38188	There	_	
228-2	38189-38192	was	_	
228-3	38193-38194	a	_	
228-4	38195-38206	significant	_	
228-5	38207-38215	negative	_	
228-6	38216-38227	interaction	_	
228-7	38228-38235	between	_	
228-8	38236-38239	the	_	
228-9	38240-38241	r	_	
228-10	38242-38245	MFG	_	
228-11	38246-38249	and	_	
228-12	38250-38251	a	_	
228-13	38252-38261	bilateral	_	
228-14	38262-38267	vmPFC	_	
228-15	38267-38268	/	_	
228-16	38268-38273	sgACC	_	
228-17	38274-38281	cluster	_	
228-18	38282-38285	and	_	
228-19	38286-38289	SFG	_	
228-20	38289-38290	.	_	

#Text=Z (Gaussianised T/F) statistic images were thresholded using clusters determined by Z>2.6 and a (corrected) cluster significance threshold of p=0.05. r=right; l=left; sgACC=subgenual anterior cingulate cortex; MFG=middle frontal gyrus; SFG=superior frontal gyrus.
229-1	38291-38292	Z	_	
229-2	38293-38294	(	_	
229-3	38294-38306	Gaussianised	_	
229-4	38307-38308	T	_	
229-5	38308-38309	/	_	
229-6	38309-38310	F	_	
229-7	38310-38311	)	_	
229-8	38312-38321	statistic	_	
229-9	38322-38328	images	_	
229-10	38329-38333	were	_	
229-11	38334-38345	thresholded	_	
229-12	38346-38351	using	_	
229-13	38352-38360	clusters	_	
229-14	38361-38371	determined	_	
229-15	38372-38374	by	_	
229-16	38375-38376	Z	_	
229-17	38376-38377	>	_	
229-18	38377-38380	2.6	_	
229-19	38381-38384	and	_	
229-20	38385-38386	a	_	
229-21	38387-38388	(	_	
229-22	38388-38397	corrected	_	
229-23	38397-38398	)	_	
229-24	38399-38406	cluster	_	
229-25	38407-38419	significance	_	
229-26	38420-38429	threshold	_	
229-27	38430-38432	of	_	
229-28	38433-38434	p	_	
229-29	38434-38435	=	_	
229-30	38435-38439	0.05	_	
229-31	38439-38440	.	_	
229-32	38441-38442	r	_	
229-33	38442-38443	=	_	
229-34	38443-38448	right	_	
229-35	38448-38449	;	_	
229-36	38450-38451	l	_	
229-37	38451-38452	=	_	
229-38	38452-38456	left	_	
229-39	38456-38457	;	_	
229-40	38458-38463	sgACC	_	
229-41	38463-38464	=	_	
229-42	38464-38473	subgenual	_	
229-43	38474-38482	anterior	_	
229-44	38483-38492	cingulate	_	
229-45	38493-38499	cortex	_	
229-46	38499-38500	;	_	
229-47	38501-38504	MFG	_	
229-48	38504-38505	=	_	
229-49	38505-38511	middle	_	
229-50	38512-38519	frontal	_	
229-51	38520-38525	gyrus	_	
229-52	38525-38526	;	_	
229-53	38527-38530	SFG	_	
229-54	38530-38531	=	_	
229-55	38531-38539	superior	_	
229-56	38540-38547	frontal	_	
229-57	38548-38553	gyrus	_	
229-58	38553-38554	.	_	

#Text=The effect of the vmPFC/sgACC cluster functional connectivity with rMFG on distress tolerance (DT) by group.
230-1	38555-38558	The	_	
230-2	38559-38565	effect	_	
230-3	38566-38568	of	_	
230-4	38569-38572	the	_	
230-5	38573-38578	vmPFC	_	
230-6	38578-38579	/	_	
230-7	38579-38584	sgACC	_	
230-8	38585-38592	cluster	_	
230-9	38593-38603	functional	_	
230-10	38604-38616	connectivity	_	
230-11	38617-38621	with	_	
230-12	38622-38626	rMFG	_	
230-13	38627-38629	on	_	
230-14	38630-38638	distress	_	
230-15	38639-38648	tolerance	_	
230-16	38649-38650	(	_	
230-17	38650-38652	DT	_	
230-18	38652-38653	)	_	
230-19	38654-38656	by	_	
230-20	38657-38662	group	_	
230-21	38662-38663	.	_	

#Text=Points on graph reflect point estimate of conditional effect of connectivity on DT (Mean ± 1 SD).
231-1	38664-38670	Points	_	
231-2	38671-38673	on	_	
231-3	38674-38679	graph	_	
231-4	38680-38687	reflect	_	
231-5	38688-38693	point	_	
231-6	38694-38702	estimate	_	
231-7	38703-38705	of	_	
231-8	38706-38717	conditional	_	
231-9	38718-38724	effect	_	
231-10	38725-38727	of	_	
231-11	38728-38740	connectivity	_	
231-12	38741-38743	on	_	
231-13	38744-38746	DT	_	
231-14	38747-38748	(	_	
231-15	38748-38752	Mean	_	
231-16	38753-38754	±	_	
231-17	38755-38756	1	_	
231-18	38757-38759	SD	_	
231-19	38759-38760	)	_	
231-20	38760-38761	.	_	

#Text=Distress tolerance=persistence in seconds during the DT phase of the PASAT-M. vmPFC/sgACC functional connectivity with r MFG= the average rMFG-vmPFC/sgACC PPI beta coefficient during distress on the PASAT-M; r=right; l=left; vmPFC=ventromedial prefrontal cortex; sgACC=subgenual anterior cingulate cortex; MFG=middle frontal gyrus; ***p<.001.
232-1	38762-38770	Distress	_	
232-2	38771-38780	tolerance	_	
232-3	38780-38781	=	_	
232-4	38781-38792	persistence	_	
232-5	38793-38795	in	_	
232-6	38796-38803	seconds	_	
232-7	38804-38810	during	_	
232-8	38811-38814	the	_	
232-9	38815-38817	DT	_	
232-10	38818-38823	phase	_	
232-11	38824-38826	of	_	
232-12	38827-38830	the	_	
232-13	38831-38838	PASAT-M	_	
232-14	38838-38839	.	_	
232-15	38840-38845	vmPFC	_	
232-16	38845-38846	/	_	
232-17	38846-38851	sgACC	_	
232-18	38852-38862	functional	_	
232-19	38863-38875	connectivity	_	
232-20	38876-38880	with	_	
232-21	38881-38882	r	_	
232-22	38883-38886	MFG	_	
232-23	38886-38887	=	_	
232-24	38888-38891	the	_	
232-25	38892-38899	average	_	
232-26	38900-38910	rMFG-vmPFC	_	
232-27	38910-38911	/	_	
232-28	38911-38916	sgACC	_	
232-29	38917-38920	PPI	_	
232-30	38921-38925	beta	_	
232-31	38926-38937	coefficient	_	
232-32	38938-38944	during	_	
232-33	38945-38953	distress	_	
232-34	38954-38956	on	_	
232-35	38957-38960	the	_	
232-36	38961-38968	PASAT-M	_	
232-37	38968-38969	;	_	
232-38	38970-38971	r	_	
232-39	38971-38972	=	_	
232-40	38972-38977	right	_	
232-41	38977-38978	;	_	
232-42	38979-38980	l	_	
232-43	38980-38981	=	_	
232-44	38981-38985	left	_	
232-45	38985-38986	;	_	
232-46	38987-38992	vmPFC	_	
232-47	38992-38993	=	_	
232-48	38993-39005	ventromedial	_	
232-49	39006-39016	prefrontal	_	
232-50	39017-39023	cortex	_	
232-51	39023-39024	;	_	
232-52	39025-39030	sgACC	_	
232-53	39030-39031	=	_	
232-54	39031-39040	subgenual	_	
232-55	39041-39049	anterior	_	
232-56	39050-39059	cingulate	_	
232-57	39060-39066	cortex	_	
232-58	39066-39067	;	_	
232-59	39068-39071	MFG	_	
232-60	39071-39072	=	_	
232-61	39072-39078	middle	_	
232-62	39079-39086	frontal	_	
232-63	39087-39092	gyrus	_	
232-64	39092-39093	;	_	
232-65	39094-39095	*	_	
232-66	39095-39096	*	_	
232-67	39096-39097	*	_	
232-68	39097-39098	p	_	
232-69	39098-39099	<	_	
232-70	39099-39103	.001	_	
232-71	39103-39104	.	_	

#Text=Group characteristics and self-report, behavioral, and physiological response to the PASAT-M.
233-1	39105-39110	Group	_	
233-2	39111-39126	characteristics	_	
233-3	39127-39130	and	_	
233-4	39131-39142	self-report	_	
233-5	39142-39143	,	_	
233-6	39144-39154	behavioral	_	
233-7	39154-39155	,	_	
233-8	39156-39159	and	_	
233-9	39160-39173	physiological	_	
233-10	39174-39182	response	_	
233-11	39183-39185	to	_	
233-12	39186-39189	the	_	
233-13	39190-39197	PASAT-M	_	
233-14	39197-39198	.	_	

#Text=Substance Users (n=21)\tHealthy Controls (n=25)\tStatistic\t \tAge\t\t41.95 (6.95)\t40.08 (8.03)\tF(2, 45)=0.42\t \tIQ\t\t102.8 (12.5)\t108.0 (13.2)\tF(2, 45)=2.15\t \tGender (% male)\t\t90.5\t64.0\tχ2(1)=4.40*\t \tRace (% Black/African American)\t\t85.7\t80.0\tχ2(1)=0.26\t \tDistress Tolerance (seconds)\t\t389.9 (232.9)\t487.6 (180.7)\tF(1, 45)=3.9*†\t \tPerformance (% Correct)\t\t21.47 (9.05)\t19.27 (10.21)\tF(1,45)=.77\t \tMotivation to Perform Well (1-10)\t\t8.15 (1.89)\t8.16 (1.88)\tF(1,45)=.01\t \tSelf-Report Distress Rating\tPre-Easy Phase\t22.93 (29.56)\t10.16 (19.44)\taF(3,132)=13.62***\t \t\tPost-Easy Phase\t23.20 (27.86)\t11.21 (19.01)\tbF(1,42)=2.30\t \t\tPost-Latency Phase\t29.86 (29.72)\t22.94 (22.84)\tcF(3,126)=1.05\t \t\tPost-Distress Phase\t32.19 (30.82)\t24.68 (27.22)\t\t \tSkin Conductance Response (μmho)\tEasy Phase\t6.71 (1.78)\t5.54 (1.48)\taF(1,42)=6.18*\t \t\tDistress Phase\t7.08 (1.69)\t5.59 (1.56)\tbF(1,42)=7.66**\t \t\t\t\t\tcF(1,42)=3.91\t \tHeart Rate (bpm)\tEasy Phase\t70.71 (13.53)\t91.19 (20.43)\taF(1,42)=4.21*\t \t\tDistress Phase\t73.74 (12.74)\t97.81 (25.29)\tbF(1,42)=15.01***\t \t\t\t\t\tcF(1,42)=0.03\t \t
#Text=Note:
#Text=Main effect of time from pre-post task
#Text=Main effect of group
#Text=Group × Time interaction
#Text=Statistic based on log transformed values
#Text=p<.05
#Text=p < .01
#Text=p<.001.
234-1	39201-39210	Substance	_	
234-2	39211-39216	Users	_	
234-3	39217-39218	(	_	
234-4	39218-39219	n	_	
234-5	39219-39220	=	_	
234-6	39220-39222	21	_	
234-7	39222-39223	)	_	
234-8	39224-39231	Healthy	_	
234-9	39232-39240	Controls	_	
234-10	39241-39242	(	_	
234-11	39242-39243	n	_	
234-12	39243-39244	=	_	
234-13	39244-39246	25	_	
234-14	39246-39247	)	_	
234-15	39248-39257	Statistic	_	
234-16	39260-39263	Age	_	
234-17	39265-39270	41.95	_	
234-18	39271-39272	(	_	
234-19	39272-39276	6.95	_	
234-20	39276-39277	)	_	
234-21	39278-39283	40.08	_	
234-22	39284-39285	(	_	
234-23	39285-39289	8.03	_	
234-24	39289-39290	)	_	
234-25	39291-39292	F	_	
234-26	39292-39293	(	_	
234-27	39293-39294	2	_	
234-28	39294-39295	,	_	
234-29	39296-39298	45	_	
234-30	39298-39299	)	_	
234-31	39299-39300	=	_	
234-32	39300-39304	0.42	_	
234-33	39307-39309	IQ	_	
234-34	39311-39316	102.8	_	
234-35	39317-39318	(	_	
234-36	39318-39322	12.5	_	
234-37	39322-39323	)	_	
234-38	39324-39329	108.0	_	
234-39	39330-39331	(	_	
234-40	39331-39335	13.2	_	
234-41	39335-39336	)	_	
234-42	39337-39338	F	_	
234-43	39338-39339	(	_	
234-44	39339-39340	2	_	
234-45	39340-39341	,	_	
234-46	39342-39344	45	_	
234-47	39344-39345	)	_	
234-48	39345-39346	=	_	
234-49	39346-39350	2.15	_	
234-50	39353-39359	Gender	_	
234-51	39360-39361	(	_	
234-52	39361-39362	%	_	
234-53	39363-39367	male	_	
234-54	39367-39368	)	_	
234-55	39370-39374	90.5	_	
234-56	39375-39379	64.0	_	
234-57	39380-39382	χ2	_	
234-58	39382-39383	(	_	
234-59	39383-39384	1	_	
234-60	39384-39385	)	_	
234-61	39385-39386	=	_	
234-62	39386-39390	4.40	_	
234-63	39390-39391	*	_	
234-64	39394-39398	Race	_	
234-65	39399-39400	(	_	
234-66	39400-39401	%	_	
234-67	39402-39407	Black	_	
234-68	39407-39408	/	_	
234-69	39408-39415	African	_	
234-70	39416-39424	American	_	
234-71	39424-39425	)	_	
234-72	39427-39431	85.7	_	
234-73	39432-39436	80.0	_	
234-74	39437-39439	χ2	_	
234-75	39439-39440	(	_	
234-76	39440-39441	1	_	
234-77	39441-39442	)	_	
234-78	39442-39443	=	_	
234-79	39443-39447	0.26	_	
234-80	39450-39458	Distress	_	
234-81	39459-39468	Tolerance	_	
234-82	39469-39470	(	_	
234-83	39470-39477	seconds	_	
234-84	39477-39478	)	_	
234-85	39480-39485	389.9	_	
234-86	39486-39487	(	_	
234-87	39487-39492	232.9	_	
234-88	39492-39493	)	_	
234-89	39494-39499	487.6	_	
234-90	39500-39501	(	_	
234-91	39501-39506	180.7	_	
234-92	39506-39507	)	_	
234-93	39508-39509	F	_	
234-94	39509-39510	(	_	
234-95	39510-39511	1	_	
234-96	39511-39512	,	_	
234-97	39513-39515	45	_	
234-98	39515-39516	)	_	
234-99	39516-39517	=	_	
234-100	39517-39520	3.9	_	
234-101	39520-39521	*	_	
234-102	39521-39522	†	_	
234-103	39525-39536	Performance	_	
234-104	39537-39538	(	_	
234-105	39538-39539	%	_	
234-106	39540-39547	Correct	_	
234-107	39547-39548	)	_	
234-108	39550-39555	21.47	_	
234-109	39556-39557	(	_	
234-110	39557-39561	9.05	_	
234-111	39561-39562	)	_	
234-112	39563-39568	19.27	_	
234-113	39569-39570	(	_	
234-114	39570-39575	10.21	_	
234-115	39575-39576	)	_	
234-116	39577-39578	F	_	
234-117	39578-39579	(	_	
234-118	39579-39583	1,45	_	
234-119	39583-39584	)	_	
234-120	39584-39585	=	_	
234-121	39585-39588	.77	_	
234-122	39591-39601	Motivation	_	
234-123	39602-39604	to	_	
234-124	39605-39612	Perform	_	
234-125	39613-39617	Well	_	
234-126	39618-39619	(	_	
234-127	39619-39620	1	_	
234-128	39620-39621	-	_	
234-129	39621-39623	10	_	
234-130	39623-39624	)	_	
234-131	39626-39630	8.15	_	
234-132	39631-39632	(	_	
234-133	39632-39636	1.89	_	
234-134	39636-39637	)	_	
234-135	39638-39642	8.16	_	
234-136	39643-39644	(	_	
234-137	39644-39648	1.88	_	
234-138	39648-39649	)	_	
234-139	39650-39651	F	_	
234-140	39651-39652	(	_	
234-141	39652-39656	1,45	_	
234-142	39656-39657	)	_	
234-143	39657-39658	=	_	
234-144	39658-39661	.01	_	
234-145	39664-39675	Self-Report	_	
234-146	39676-39684	Distress	_	
234-147	39685-39691	Rating	_	
234-148	39692-39700	Pre-Easy	_	
234-149	39701-39706	Phase	_	
234-150	39707-39712	22.93	_	
234-151	39713-39714	(	_	
234-152	39714-39719	29.56	_	
234-153	39719-39720	)	_	
234-154	39721-39726	10.16	_	
234-155	39727-39728	(	_	
234-156	39728-39733	19.44	_	
234-157	39733-39734	)	_	
234-158	39735-39737	aF	_	
234-159	39737-39738	(	_	
234-160	39738-39743	3,132	_	
234-161	39743-39744	)	_	
234-162	39744-39745	=	_	
234-163	39745-39750	13.62	_	
234-164	39750-39751	*	_	
234-165	39751-39752	*	_	
234-166	39752-39753	*	_	
234-167	39757-39766	Post-Easy	_	
234-168	39767-39772	Phase	_	
234-169	39773-39778	23.20	_	
234-170	39779-39780	(	_	
234-171	39780-39785	27.86	_	
234-172	39785-39786	)	_	
234-173	39787-39792	11.21	_	
234-174	39793-39794	(	_	
234-175	39794-39799	19.01	_	
234-176	39799-39800	)	_	
234-177	39801-39803	bF	_	
234-178	39803-39804	(	_	
234-179	39804-39808	1,42	_	
234-180	39808-39809	)	_	
234-181	39809-39810	=	_	
234-182	39810-39814	2.30	_	
234-183	39818-39830	Post-Latency	_	
234-184	39831-39836	Phase	_	
234-185	39837-39842	29.86	_	
234-186	39843-39844	(	_	
234-187	39844-39849	29.72	_	
234-188	39849-39850	)	_	
234-189	39851-39856	22.94	_	
234-190	39857-39858	(	_	
234-191	39858-39863	22.84	_	
234-192	39863-39864	)	_	
234-193	39865-39867	cF	_	
234-194	39867-39868	(	_	
234-195	39868-39873	3,126	_	
234-196	39873-39874	)	_	
234-197	39874-39875	=	_	
234-198	39875-39879	1.05	_	
234-199	39883-39896	Post-Distress	_	
234-200	39897-39902	Phase	_	
234-201	39903-39908	32.19	_	
234-202	39909-39910	(	_	
234-203	39910-39915	30.82	_	
234-204	39915-39916	)	_	
234-205	39917-39922	24.68	_	
234-206	39923-39924	(	_	
234-207	39924-39929	27.22	_	
234-208	39929-39930	)	_	
234-209	39934-39938	Skin	_	
234-210	39939-39950	Conductance	_	
234-211	39951-39959	Response	_	
234-212	39960-39961	(	_	
234-213	39961-39965	μmho	_	
234-214	39965-39966	)	_	
234-215	39967-39971	Easy	_	
234-216	39972-39977	Phase	_	
234-217	39978-39982	6.71	_	
234-218	39983-39984	(	_	
234-219	39984-39988	1.78	_	
234-220	39988-39989	)	_	
234-221	39990-39994	5.54	_	
234-222	39995-39996	(	_	
234-223	39996-40000	1.48	_	
234-224	40000-40001	)	_	
234-225	40002-40004	aF	_	
234-226	40004-40005	(	_	
234-227	40005-40009	1,42	_	
234-228	40009-40010	)	_	
234-229	40010-40011	=	_	
234-230	40011-40015	6.18	_	
234-231	40015-40016	*	_	
234-232	40020-40028	Distress	_	
234-233	40029-40034	Phase	_	
234-234	40035-40039	7.08	_	
234-235	40040-40041	(	_	
234-236	40041-40045	1.69	_	
234-237	40045-40046	)	_	
234-238	40047-40051	5.59	_	
234-239	40052-40053	(	_	
234-240	40053-40057	1.56	_	
234-241	40057-40058	)	_	
234-242	40059-40061	bF	_	
234-243	40061-40062	(	_	
234-244	40062-40066	1,42	_	
234-245	40066-40067	)	_	
234-246	40067-40068	=	_	
234-247	40068-40072	7.66	_	
234-248	40072-40073	*	_	
234-249	40073-40074	*	_	
234-250	40081-40083	cF	_	
234-251	40083-40084	(	_	
234-252	40084-40088	1,42	_	
234-253	40088-40089	)	_	
234-254	40089-40090	=	_	
234-255	40090-40094	3.91	_	
234-256	40097-40102	Heart	_	
234-257	40103-40107	Rate	_	
234-258	40108-40109	(	_	
234-259	40109-40112	bpm	_	
234-260	40112-40113	)	_	
234-261	40114-40118	Easy	_	
234-262	40119-40124	Phase	_	
234-263	40125-40130	70.71	_	
234-264	40131-40132	(	_	
234-265	40132-40137	13.53	_	
234-266	40137-40138	)	_	
234-267	40139-40144	91.19	_	
234-268	40145-40146	(	_	
234-269	40146-40151	20.43	_	
234-270	40151-40152	)	_	
234-271	40153-40155	aF	_	
234-272	40155-40156	(	_	
234-273	40156-40160	1,42	_	
234-274	40160-40161	)	_	
234-275	40161-40162	=	_	
234-276	40162-40166	4.21	_	
234-277	40166-40167	*	_	
234-278	40171-40179	Distress	_	
234-279	40180-40185	Phase	_	
234-280	40186-40191	73.74	_	
234-281	40192-40193	(	_	
234-282	40193-40198	12.74	_	
234-283	40198-40199	)	_	
234-284	40200-40205	97.81	_	
234-285	40206-40207	(	_	
234-286	40207-40212	25.29	_	
234-287	40212-40213	)	_	
234-288	40214-40216	bF	_	
234-289	40216-40217	(	_	
234-290	40217-40221	1,42	_	
234-291	40221-40222	)	_	
234-292	40222-40223	=	_	
234-293	40223-40228	15.01	_	
234-294	40228-40229	*	_	
234-295	40229-40230	*	_	
234-296	40230-40231	*	_	
234-297	40238-40240	cF	_	
234-298	40240-40241	(	_	
234-299	40241-40245	1,42	_	
234-300	40245-40246	)	_	
234-301	40246-40247	=	_	
234-302	40247-40251	0.03	_	
234-303	40255-40259	Note	_	
234-304	40259-40260	:	_	
234-305	40261-40265	Main	_	
234-306	40266-40272	effect	_	
234-307	40273-40275	of	_	
234-308	40276-40280	time	_	
234-309	40281-40285	from	_	
234-310	40286-40294	pre-post	_	
234-311	40295-40299	task	_	
234-312	40300-40304	Main	_	
234-313	40305-40311	effect	_	
234-314	40312-40314	of	_	
234-315	40315-40320	group	_	
234-316	40321-40326	Group	_	
234-317	40327-40328	×	_	
234-318	40329-40333	Time	_	
234-319	40334-40345	interaction	_	
234-320	40346-40355	Statistic	_	
234-321	40356-40361	based	_	
234-322	40362-40364	on	_	
234-323	40365-40368	log	_	
234-324	40369-40380	transformed	_	
234-325	40381-40387	values	_	
234-326	40388-40389	p	_	
234-327	40389-40390	<	_	
234-328	40390-40393	.05	_	
234-329	40394-40395	p	_	
234-330	40396-40397	<	_	
234-331	40398-40401	.01	_	
234-332	40402-40403	p	_	
234-333	40403-40404	<	_	
234-334	40404-40408	.001	_	
234-335	40408-40409	.	_	

#Text=Group means for percent signal change among a priori regions of interest.
235-1	40410-40415	Group	_	
235-2	40416-40421	means	_	
235-3	40422-40425	for	_	
235-4	40426-40433	percent	_	
235-5	40434-40440	signal	_	
235-6	40441-40447	change	_	
235-7	40448-40453	among	_	
235-8	40454-40455	a	_	
235-9	40456-40462	priori	_	
235-10	40463-40470	regions	_	
235-11	40471-40473	of	_	
235-12	40474-40482	interest	_	
235-13	40482-40483	.	_	

#Text=Substance Users (n=21)\tHealthy Controls (n=25)\tF Statistic\t \tr Insula\t−0.145±0.363\t0.069±0.506\t2.70\t \tr Amygdala\t−0.195±0.814\t0.124±0.933\t2.07\t \tl Amygdala\t−0.363±0.880\t0.109±1.269\t1.54\t \tACC\t−0.162±0.289\t−0.019±0.372\t2.10\t \tr MFG\t−0.439±0.555\t−0.044±0.369\t8.30***\t \tl MFG\t−0.443±0.546\t−0.129±0.341\t5.65*\t \tr IFG\t−0.246±0.399\t0.049±0.524\t4.59*\t \tl IFG\t−0.596±0.799\t−0.230±0.527\t3.47\t \tr vmPFC\t−0.176±0.997\t−0.114±0.969\t0.04\t \tl vmPFC\t−0.131±0.880\t−0.126±0.686\t0.00\t \t
#Text=r=right; l=left; ACC=anterior cingulate cortex; MFG=middle frontal gyrus; IFG=inferior frontal gyrus; vmPFC=ventromedial prefrontal cortex.
236-1	40485-40494	Substance	_	
236-2	40495-40500	Users	_	
236-3	40501-40502	(	_	
236-4	40502-40503	n	_	
236-5	40503-40504	=	_	
236-6	40504-40506	21	_	
236-7	40506-40507	)	_	
236-8	40508-40515	Healthy	_	
236-9	40516-40524	Controls	_	
236-10	40525-40526	(	_	
236-11	40526-40527	n	_	
236-12	40527-40528	=	_	
236-13	40528-40530	25	_	
236-14	40530-40531	)	_	
236-15	40532-40533	F	_	
236-16	40534-40543	Statistic	_	
236-17	40546-40547	r	_	
236-18	40548-40554	Insula	_	
236-19	40555-40556	−	_	
236-20	40556-40561	0.145	_	
236-21	40561-40562	±	_	
236-22	40562-40567	0.363	_	
236-23	40568-40573	0.069	_	
236-24	40573-40574	±	_	
236-25	40574-40579	0.506	_	
236-26	40580-40584	2.70	_	
236-27	40587-40588	r	_	
236-28	40589-40597	Amygdala	_	
236-29	40598-40599	−	_	
236-30	40599-40604	0.195	_	
236-31	40604-40605	±	_	
236-32	40605-40610	0.814	_	
236-33	40611-40616	0.124	_	
236-34	40616-40617	±	_	
236-35	40617-40622	0.933	_	
236-36	40623-40627	2.07	_	
236-37	40630-40631	l	_	
236-38	40632-40640	Amygdala	_	
236-39	40641-40642	−	_	
236-40	40642-40647	0.363	_	
236-41	40647-40648	±	_	
236-42	40648-40653	0.880	_	
236-43	40654-40659	0.109	_	
236-44	40659-40660	±	_	
236-45	40660-40665	1.269	_	
236-46	40666-40670	1.54	_	
236-47	40673-40676	ACC	_	
236-48	40677-40678	−	_	
236-49	40678-40683	0.162	_	
236-50	40683-40684	±	_	
236-51	40684-40689	0.289	_	
236-52	40690-40691	−	_	
236-53	40691-40696	0.019	_	
236-54	40696-40697	±	_	
236-55	40697-40702	0.372	_	
236-56	40703-40707	2.10	_	
236-57	40710-40711	r	_	
236-58	40712-40715	MFG	_	
236-59	40716-40717	−	_	
236-60	40717-40722	0.439	_	
236-61	40722-40723	±	_	
236-62	40723-40728	0.555	_	
236-63	40729-40730	−	_	
236-64	40730-40735	0.044	_	
236-65	40735-40736	±	_	
236-66	40736-40741	0.369	_	
236-67	40742-40746	8.30	_	
236-68	40746-40747	*	_	
236-69	40747-40748	*	_	
236-70	40748-40749	*	_	
236-71	40752-40753	l	_	
236-72	40754-40757	MFG	_	
236-73	40758-40759	−	_	
236-74	40759-40764	0.443	_	
236-75	40764-40765	±	_	
236-76	40765-40770	0.546	_	
236-77	40771-40772	−	_	
236-78	40772-40777	0.129	_	
236-79	40777-40778	±	_	
236-80	40778-40783	0.341	_	
236-81	40784-40788	5.65	_	
236-82	40788-40789	*	_	
236-83	40792-40793	r	_	
236-84	40794-40797	IFG	_	
236-85	40798-40799	−	_	
236-86	40799-40804	0.246	_	
236-87	40804-40805	±	_	
236-88	40805-40810	0.399	_	
236-89	40811-40816	0.049	_	
236-90	40816-40817	±	_	
236-91	40817-40822	0.524	_	
236-92	40823-40827	4.59	_	
236-93	40827-40828	*	_	
236-94	40831-40832	l	_	
236-95	40833-40836	IFG	_	
236-96	40837-40838	−	_	
236-97	40838-40843	0.596	_	
236-98	40843-40844	±	_	
236-99	40844-40849	0.799	_	
236-100	40850-40851	−	_	
236-101	40851-40856	0.230	_	
236-102	40856-40857	±	_	
236-103	40857-40862	0.527	_	
236-104	40863-40867	3.47	_	
236-105	40870-40871	r	_	
236-106	40872-40877	vmPFC	_	
236-107	40878-40879	−	_	
236-108	40879-40884	0.176	_	
236-109	40884-40885	±	_	
236-110	40885-40890	0.997	_	
236-111	40891-40892	−	_	
236-112	40892-40897	0.114	_	
236-113	40897-40898	±	_	
236-114	40898-40903	0.969	_	
236-115	40904-40908	0.04	_	
236-116	40911-40912	l	_	
236-117	40913-40918	vmPFC	_	
236-118	40919-40920	−	_	
236-119	40920-40925	0.131	_	
236-120	40925-40926	±	_	
236-121	40926-40931	0.880	_	
236-122	40932-40933	−	_	
236-123	40933-40938	0.126	_	
236-124	40938-40939	±	_	
236-125	40939-40944	0.686	_	
236-126	40945-40949	0.00	_	
236-127	40953-40954	r	_	
236-128	40954-40955	=	_	
236-129	40955-40960	right	_	
236-130	40960-40961	;	_	
236-131	40962-40963	l	_	
236-132	40963-40964	=	_	
236-133	40964-40968	left	_	
236-134	40968-40969	;	_	
236-135	40970-40973	ACC	_	
236-136	40973-40974	=	_	
236-137	40974-40982	anterior	_	
236-138	40983-40992	cingulate	_	
236-139	40993-40999	cortex	_	
236-140	40999-41000	;	_	
236-141	41001-41004	MFG	_	
236-142	41004-41005	=	_	
236-143	41005-41011	middle	_	
236-144	41012-41019	frontal	_	
236-145	41020-41025	gyrus	_	
236-146	41025-41026	;	_	
236-147	41027-41030	IFG	_	
236-148	41030-41031	=	_	
236-149	41031-41039	inferior	_	
236-150	41040-41047	frontal	_	
236-151	41048-41053	gyrus	_	
236-152	41053-41054	;	_	
236-153	41055-41060	vmPFC	_	
236-154	41060-41061	=	_	
236-155	41061-41073	ventromedial	_	
236-156	41074-41084	prefrontal	_	
236-157	41085-41091	cortex	_	
236-158	41091-41092	.	_	

#Text=Note:
#Text=p<.05
#Text=**p < .01
#Text=p<.001.
237-1	41093-41097	Note	_	
237-2	41097-41098	:	_	
237-3	41099-41100	p	_	
237-4	41100-41101	<	_	
237-5	41101-41104	.05	_	
237-6	41105-41106	*	_	
237-7	41106-41107	*	_	
237-8	41107-41108	p	_	
237-9	41109-41110	<	_	
237-10	41111-41114	.01	_	
237-11	41115-41116	p	_	
237-12	41116-41117	<	_	
237-13	41117-41121	.001	_	
237-14	41121-41122	.	_	

#Text=Clusters and max Z-values in response to distress [(Distress-Rest)-(Easy-Rest)] for the contrast of Substance Users < Healthy Controls.
238-1	41123-41131	Clusters	_	
238-2	41132-41135	and	_	
238-3	41136-41139	max	_	
238-4	41140-41148	Z-values	_	
238-5	41149-41151	in	_	
238-6	41152-41160	response	_	
238-7	41161-41163	to	_	
238-8	41164-41172	distress	_	
238-9	41173-41174	[	_	
238-10	41174-41175	(	_	
238-11	41175-41188	Distress-Rest	_	
238-12	41188-41189	)	_	
238-13	41189-41190	-	_	
238-14	41190-41191	(	_	
238-15	41191-41200	Easy-Rest	_	
238-16	41200-41201	)	_	
238-17	41201-41202	]	_	
238-18	41203-41206	for	_	
238-19	41207-41210	the	_	
238-20	41211-41219	contrast	_	
238-21	41220-41222	of	_	
238-22	41223-41232	Substance	_	
238-23	41233-41238	Users	_	
238-24	41239-41240	<	_	
238-25	41241-41248	Healthy	_	
238-26	41249-41257	Controls	_	
238-27	41257-41258	.	_	

#Text=Deactivations\tVoxels\tp\tZ-Max X (mm)\tZ-Max Y (mm)\tZ-Max Z (mm)\t \tR.
239-1	41259-41272	Deactivations	_	
239-2	41273-41279	Voxels	_	
239-3	41280-41281	p	_	
239-4	41282-41287	Z-Max	_	
239-5	41288-41289	X	_	
239-6	41290-41291	(	_	
239-7	41291-41293	mm	_	
239-8	41293-41294	)	_	
239-9	41295-41300	Z-Max	_	
239-10	41301-41302	Y	_	
239-11	41303-41304	(	_	
239-12	41304-41306	mm	_	
239-13	41306-41307	)	_	
239-14	41308-41313	Z-Max	_	
239-15	41314-41315	Z	_	
239-16	41316-41317	(	_	
239-17	41317-41319	mm	_	
239-18	41319-41320	)	_	
239-19	41323-41324	R	_	
239-20	41324-41325	.	_	

#Text=Superior frontal gyrus\t466\t2.71×10−5\t12\t14\t70\t \t    -Juxtapositional lobule cortexa\t\t\t\t\t\t \t    -Bilateral precentral gyrusa\t\t\t\t\t\t \tL.
240-1	41326-41334	Superior	_	
240-2	41335-41342	frontal	_	
240-3	41343-41348	gyrus	_	
240-4	41349-41352	466	_	
240-5	41353-41357	2.71	_	
240-6	41357-41358	×	_	
240-7	41358-41360	10	_	
240-8	41360-41361	−	_	
240-9	41361-41362	5	_	
240-10	41363-41365	12	_	
240-11	41366-41368	14	_	
240-12	41369-41371	70	_	
240-13	41374-41378	    	_	
240-14	41378-41379	-	_	
240-15	41379-41394	Juxtapositional	_	
240-16	41395-41401	lobule	_	
240-17	41402-41409	cortexa	_	
240-18	41417-41421	    	_	
240-19	41421-41422	-	_	
240-20	41422-41431	Bilateral	_	
240-21	41432-41442	precentral	_	
240-22	41443-41449	gyrusa	_	
240-23	41457-41458	L	_	
240-24	41458-41459	.	_	

#Text=Lateral occipital cortex\t301\t0.0008\t−22\t−70\t40\t \t    -L.
241-1	41460-41467	Lateral	_	
241-2	41468-41477	occipital	_	
241-3	41478-41484	cortex	_	
241-4	41485-41488	301	_	
241-5	41489-41495	0.0008	_	
241-6	41496-41497	−	_	
241-7	41497-41499	22	_	
241-8	41500-41501	−	_	
241-9	41501-41503	70	_	
241-10	41504-41506	40	_	
241-11	41509-41513	    	_	
241-12	41513-41514	-	_	
241-13	41514-41515	L	_	
241-14	41515-41516	.	_	

#Text=Precuneusa\t\t\t\t\t\t \tL.
242-1	41517-41527	Precuneusa	_	
242-2	41535-41536	L	_	
242-3	41536-41537	.	_	

#Text=Occipital fusiform gyrus\t292\t0.0011\t−34\t−78\t−16\t \tR.
243-1	41538-41547	Occipital	_	
243-2	41548-41556	fusiform	_	
243-3	41557-41562	gyrus	_	
243-4	41563-41566	292	_	
243-5	41567-41573	0.0011	_	
243-6	41574-41575	−	_	
243-7	41575-41577	34	_	
243-8	41578-41579	−	_	
243-9	41579-41581	78	_	
243-10	41582-41583	−	_	
243-11	41583-41585	16	_	
243-12	41588-41589	R	_	
243-13	41589-41590	.	_	

#Text=Middle frontal gyrus\t187\t0.0143\t30\t8\t60\t \t    -R.
244-1	41591-41597	Middle	_	
244-2	41598-41605	frontal	_	
244-3	41606-41611	gyrus	_	
244-4	41612-41615	187	_	
244-5	41616-41622	0.0143	_	
244-6	41623-41625	30	_	
244-7	41626-41627	8	_	
244-8	41628-41630	60	_	
244-9	41633-41637	    	_	
244-10	41637-41638	-	_	
244-11	41638-41639	R	_	
244-12	41639-41640	.	_	

#Text=Superior frontal gyrusa\t\t\t\t\t\t \tR.
245-1	41641-41649	Superior	_	
245-2	41650-41657	frontal	_	
245-3	41658-41664	gyrusa	_	
245-4	41672-41673	R	_	
245-5	41673-41674	.	_	

#Text=Lateral occipital cortex\t147\t0.0472\t28\t−64\t58\t \t    -R.
246-1	41675-41682	Lateral	_	
246-2	41683-41692	occipital	_	
246-3	41693-41699	cortex	_	
246-4	41700-41703	147	_	
246-5	41704-41710	0.0472	_	
246-6	41711-41713	28	_	
246-7	41714-41715	−	_	
246-8	41715-41717	64	_	
246-9	41718-41720	58	_	
246-10	41723-41727	    	_	
246-11	41727-41728	-	_	
246-12	41728-41729	R	_	
246-13	41729-41730	.	_	

#Text=Precuneusa\t\t\t\t\t\t \t
#Text=Note:
#Text=Regions that also showed activation in the clusters.
247-1	41731-41741	Precuneusa	_	
247-2	41750-41754	Note	_	
247-3	41754-41755	:	_	
247-4	41756-41763	Regions	_	
247-5	41764-41768	that	_	
247-6	41769-41773	also	_	
247-7	41774-41780	showed	_	
247-8	41781-41791	activation	_	
247-9	41792-41794	in	_	
247-10	41795-41798	the	_	
247-11	41799-41807	clusters	_	
247-12	41807-41808	.	_	
